Hologic (HOLX) 10-K 26 Nov 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Sep. 28, 2013	Nov. 18, 2013	Mar. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	28-Sep-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'Hologic Inc.	'	'
Entity Central Index Key	'0000859737	'	'
Current Fiscal Year End Date	'--09-28	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	273,128,747	'
Entity Public Float	'	'	$6,049,671,259

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Revenues:	'	'	'
Product sales	$2,100,891	$1,657,728	$1,478,340
Service and other revenues	391,388	344,924	311,009
Total revenues	2,492,279	2,002,652	1,789,349
Costs and expenses:	'	'	'
Cost of product sales	818,160	616,839	521,189
Cost of product sales - amortization of intangible assets	307,895	201,864	177,456
Cost of product sales - impairment of intangible assets	1,714	'	'
Cost of service and other revenues	203,122	189,512	167,523
Research and development	197,646	130,962	116,696
Selling and marketing	342,137	322,314	286,730
General and administrative	227,680	220,494	159,563
Amortization of intangible assets	112,597	72,036	58,334
Contingent consideration - compensation expense	80,010	81,031	20,002
Contingent consideration - fair value adjustments	11,310	38,466	-8,016
Impairment of goodwill	1,117,369	5,826	'
Gain on sale of intellectual property	-53,884	-12,424	-84,502
Acquired in-process research and development	'	4,500	'
Restructuring and divestiture charges	32,805	17,515	-71
Costs and expenses, total	3,398,561	1,888,935	1,414,904
(Loss) income from operations	-906,282	113,717	374,445
Interest income	1,302	2,340	1,860
Interest expense	-281,075	-140,287	-114,846
Debt extinguishment loss	-9,209	-42,347	-29,891
Other income (expense), net	2,303	4,916	-4,182
(Loss) income before income taxes	-1,192,961	-61,661	227,386
(Benefit) provision for income taxes	-20,123	11,973	70,236
Net (loss) income	($1,172,838)	($73,634)	$157,150
Basic net (loss) income per common share	($4.36)	($0.28)	$0.60
Diluted net (loss) income per common share	($4.36)	($0.28)	$0.59
Weighted average number of common shares outstanding:	'	'	'
Basic	268,704	264,041	261,099
Diluted	268,704	264,041	264,305

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 23, 2012

Mar. 24, 2012

Dec. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

($1,113,902)

[1]

($10,950)

[1]

($51,104)

[1]

$3,118

[1]

($77,767)

[2],[3]

$23,594

[2]

($40,273)

[2]

$20,812

[2]

($1,172,838)

($73,634)

$157,150

Foreign currency translation adjustment

'

'

'

'

'

'

'

'

1,373

6,217

1,088

Adjustment to minimum pension liability, net

'

'

'

'

'

'

'

'

134

-1,484

764

Unrealized gain on available-for-sale security

'

'

'

'

'

'

'

'

12,094

62

'

Other comprehensive income

'

'

'

'

'

'

'

'

13,601

4,795

1,852

Comprehensive (loss) income

'

'

'

'

'

'

'

'

($1,159,237)

($68,839)

$159,002

[1]

Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.

[2]

Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.

[3]

The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract]	'	'	'
Adjustment to minimum pension liability, tax	$58	$636	$327

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$822,490	$560,430
Restricted cash	6,914	5,696
Accounts receivable, less reserves of $8,798 and $6,396 respectively	409,273	409,333
Inventories	289,363	367,191
Deferred income tax assets	'	11,715
Prepaid income taxes	44,745	69,845
Prepaid expenses and other current assets	48,361	44,301
Other current assets - assets held-for-sale	2,997	94,503
Total current assets	1,624,143	1,563,014
Property, plant and equipment:	'	'
Land	51,633	51,430
Buildings and improvements	171,469	156,665
Equipment and software	318,473	296,776
Equipment under customer usage agreements	275,696	249,692
Furniture and fixtures	22,628	21,495
Leasehold improvements	68,159	71,943
Property, plant and equipment, gross	908,058	848,001
Less accumulated depreciation and amortization	-416,530	-340,003
Property, plant and equipment, net	491,528	507,998
Intangible assets, net	3,906,722	4,301,250
Goodwill	2,814,528	3,942,779
Other assets	163,902	162,067
Total assets	9,000,823	10,477,108
Current liabilities:	'	'
Current portion of long-term debt	563,812	64,435
Accounts payable	80,534	87,223
Accrued expenses	271,931	372,381
Deferred revenue	132,319	129,688
Deferred income tax liabilities	39,810	'
Other current liabilities - assets held-for-sale	'	7,622
Total current liabilities	1,088,406	661,349
Long-term debt, net of current portion	4,242,098	4,971,179
Deferred income tax liabilities	1,535,306	1,771,585
Deferred service obligations - long-term	25,456	13,714
Other long-term liabilities	168,044	98,250
Commitments and contingencies (Notes 12 and 13)	'	'
Stockholders' equity	'	'
Preferred stock, $0.01 par value - 1,623 shares authorized; 0 shares issued	'	'
Common stock, $0.01 par value - 750,000 shares authorized; 272,036 and 265,635 shares issued, respectively	2,720	2,656
Additional paid-in-capital	5,536,312	5,396,657
Accumulated deficit	-3,616,392	-2,443,554
Accumulated other comprehensive income	20,391	6,790
Treasury stock, at cost - 219 shares	-1,518	-1,518
Total stockholders' equity	1,941,513	2,961,031
Total liabilities and stockholders' equity	$9,000,823	$10,477,108

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, reserves	$8,798	$6,396
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,623	1,623
Preferred stock, shares issued	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	750,000	750,000
Common stock, shares issued	272,036	265,635
Treasury stock, shares	219	219

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Treasury Stock [Member]
In Thousands
Balance at Sep. 25, 2010	$2,698,549	$2,595	$5,224,399	($2,527,070)	$143	($1,518)
Balance, shares at Sep. 25, 2010	'	259,488	'	'	'	219
Exercise of stock options	23,894	18	23,876	'	'	'
Exercise of stock options, shares	'	1,779	'	'	'	'
Issuance of common stock to employees upon vesting of restricted stock units, net of shares withheld for employee taxes	-10,399	11	-10,410	'	'	'
Issuance of common stock to employees upon vesting of restricted stock units, net of shares withheld for employee taxes, shares	'	1,104	'	'	'	'
Issuance of common shares under the employee stock purchase plan	1,510	1	1,509	'	'	'
Issuance of common shares under the employee stock purchase plan, shares	'	88	'	'	'	'
Stock-based compensation expense	35,472	'	35,472	'	'	'
Reduction in excess tax benefit from employee equity awards	-5,832	'	-5,832	'	'	'
Allocation of equity component related to convertible notes exchange, net of taxes	34,699	'	34,699	'	'	'
Net income (loss)	157,150	'	'	157,150	'	'
Foreign currency translation adjustment	1,088	'	'	'	1,088	'
Adjustment to minimum pension liability, net	764	'	'	'	764	'
Balance at Sep. 24, 2011	2,936,895	2,625	5,303,713	-2,369,920	1,995	-1,518
Balance, shares at Sep. 24, 2011	'	262,459	'	'	'	219
Exercise of stock options	27,687	24	27,663	'	'	'
Exercise of stock options, shares	'	2,457	'	'	'	'
Issuance of common stock to employees upon vesting of restricted stock units, net of shares withheld for employee taxes	-5,710	7	-5,717	'	'	'
Issuance of common stock to employees upon vesting of restricted stock units, net of shares withheld for employee taxes, shares	'	673	'	'	'	'
Issuance of common shares under the employee stock purchase plan	907	'	907	'	'	'
Issuance of common shares under the employee stock purchase plan, shares	'	46	'	'	'	'
Stock-based compensation expense	40,011	'	40,011	'	'	'
Excess tax benefit from employee equity awards	4,413	'	4,413	'	'	'
Fair value of options exchanged in a business combination	2,655	'	2,655	'	'	'
Allocation of equity component related to convertible notes exchange, net of taxes	23,012	'	23,012	'	'	'
Net income (loss)	-73,634	'	'	-73,634	'	'
Foreign currency translation adjustment	6,217	'	'	'	6,217	'
Adjustment to minimum pension liability, net	-1,484	'	'	'	-1,484	'
Unrealized gain on marketable security	62	'	'	'	62	'
Balance at Sep. 29, 2012	2,961,031	2,656	5,396,657	-2,443,554	6,790	-1,518
Balance, shares at Sep. 29, 2012	'	265,635	'	'	'	219
Exercise of stock options	65,605	48	65,557	'	'	'
Exercise of stock options, shares	4,786	4,786	'	'	'	'
Issuance of common stock to employees upon vesting of restricted stock units, net of shares withheld for employee taxes	-12,256	11	-12,267	'	'	'
Issuance of common stock to employees upon vesting of restricted stock units, net of shares withheld for employee taxes, shares	'	1,117	'	'	'	'
Issuance of common shares under the employee stock purchase plan	7,984	5	7,979	'	'	'
Issuance of common shares under the employee stock purchase plan, shares	'	498	'	'	'	'
Stock-based compensation expense	52,443	'	52,443	'	'	'
Excess tax benefit from employee equity awards	5,898	'	5,898	'	'	'
Allocation of equity component related to convertible notes exchange, net of taxes	20,045	'	20,045	'	'	'
Net income (loss)	-1,172,838	'	'	-1,172,838	'	'
Foreign currency translation adjustment	1,373	'	'	'	1,373	'
Adjustment to minimum pension liability, net	134	'	'	'	134	'
Unrealized gain on marketable security	12,094	'	'	'	12,094	'
Balance at Sep. 28, 2013	$1,941,513	$2,720	$5,536,312	($3,616,392)	$20,391	($1,518)
Balance, shares at Sep. 28, 2013	'	272,036	'	'	'	219

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Operating activities	'	'	'
Net (loss) income	($1,172,838)	($73,634)	$157,150
Adjustments to reconcile net (loss) income to net cash provided by operating activities:	'	'	'
Depreciation	95,518	71,851	68,946
Amortization	420,492	273,900	235,790
Non-cash interest expense	81,177	74,974	76,814
Stock-based compensation expense	52,307	40,572	35,472
Excess tax benefit related to equity awards	-7,439	-6,206	-3,652
Deferred income taxes	-197,983	-155,192	-48,107
Gain on sale of intellectual property	-53,884	-12,424	-84,502
Debt extinguishment loss	9,209	42,347	29,891
Fair value adjustments to contingent consideration	11,310	38,466	-8,016
Fair value write-up of inventory sold	52,397	19,918	3,298
Impairment of goodwill	1,117,369	5,826	'
Impairment of intangible assets	1,714	'	'
Asset impairment charges	7,667	16,901	'
Acquired in-process research and development	'	4,500	'
Cost method equity investment impairment	6,438	'	2,445
Gain on sale of cost-method equity investment	-1,972	'	'
Loss on disposal of property and equipment	4,925	3,809	2,639
Other	2,923	-3,568	1,093
Changes in operating assets and liabilities, excluding the effect of acquisitions:	'	'	'
Accounts receivable	4,102	-11,005	-17,131
Inventories	25,165	-12,174	-32,158
Prepaid income taxes	25,100	6,071	-6,154
Prepaid expenses and other assets	871	69,806	-471
Accounts payable	-6,406	3,768	2,589
Accrued expenses and other liabilities	2,335	-41,017	40,569
Deferred revenue	13,325	12,733	-481
Net cash provided by operating activities	493,822	370,222	456,024
Investing activities	'	'	'
Acquisition of businesses, net of cash acquired	-6,273	-3,762,403	-198,744
Payment of additional acquisition consideration	-16,808	-9,784	-19,660
Proceeds from sale of business, net of cash transferred	85,134	'	2,267
Proceeds from sale of intellectual property	60,000	12,500	13,250
Purchase of property and equipment	-48,954	-33,149	-27,785
Increase in equipment under customer usage agreements	-41,176	-45,624	-27,878
Purchase of licensed technology and other intangible assets	'	'	-3,021
Purchase of insurance contracts	-4,000	'	-5,322
Acquisition of in-process research and development assets	'	-4,500	'
Sale of cost method investment	2,104	'	'
Purchases of cost method investments	-3,725	-250	-99
(Increase) decrease in other assets	-7,548	-7,574	405
Net cash provided by (used in) investing activities	18,754	-3,850,784	-266,587
Financing activities	'	'	'
Proceeds from long-term debt	'	3,476,320	'
Repayment of long-term debt and notes payable	-265,000	'	-1,362
Payment of debt issuance costs	-9,440	-81,408	-5,327
Payment of contingent consideration	-42,958	-51,680	-4,294
Payment of deferred acquisition consideration	-1,655	-44,223	'
Net proceeds from issuance of common stock pursuant to employee stock plans	75,100	28,594	25,404
Excess tax benefit related to equity awards	7,439	6,206	3,652
Payment of employee restricted stock minimum tax withholdings	-12,256	-5,710	-10,399
Net cash (used in) provided by financing activities	-248,770	3,328,099	7,674
Effect of exchange rate changes on cash and cash equivalents	-1,746	561	-404
Net increase (decrease) in cash and cash equivalents	262,060	-151,902	196,707
Cash and cash equivalents, beginning of period	560,430	712,332	515,625
Cash and cash equivalents, end of period	$822,490	$560,430	$712,332

Operations

Operations	12 Months Ended
	Sep. 28, 2013
Accounting Policies [Abstract]	'
Operations	'
	1	Operations
	Hologic, Inc. (the “Company” or “Hologic”) develops, manufactures and distributes premium diagnostics products, medical imaging systems and surgical products with an emphasis on serving the healthcare needs of women. The Company’s core business units are focused on Diagnostics, Breast Health, GYN surgical and Skeletal Health.
	On August 1, 2012, the Company completed the acquisition of Gen-Probe Incorporated (“Gen-Probe”), which resulted in the Company significantly expanding its suite of molecular diagnostic products. Gen-Probe develops, manufactures and markets rapid, accurate and cost effective molecular diagnostics products and services that are used primarily to diagnose human diseases and screen donated blood. Gen-Probe’s results of operations are reported within the Company’s Diagnostics reportable segment. The Company’s acquisition of Gen-Probe is more fully described in Note 3. In connection with the acquisition, the Company borrowed $3.5 billion in aggregate principal to fund a portion of the purchase price, which is described in Note 5.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 28, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on the last Saturday in September. Fiscal 2013, 2012 and 2011 ended on September 28, 2013, September 29, 2012 and September 24, 2011, respectively. Fiscal 2013 and 2011 were 52 week fiscal periods and fiscal 2012 was a 53 week fiscal period.
	Management’s Estimates and Uncertainties
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple element arrangements, allowance for doubtful accounts, the net realizable value of inventory, estimated fair value of cost-method equity investments, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, stock-based compensation, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company’s net deferred tax assets and related valuation allowance.
	Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
	The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill), competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment, limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government regulations, future sales or issuances of its common stock, management of international activities, protection of proprietary rights, patent and other litigation and dependence on key individuals.
	Cash Equivalents
	Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities of three months or less at the time of acquisition. At September 28, 2013 and September 29, 2012, the Company’s cash equivalents consisted of money market accounts.
	Marketable Securities
	The Company’s marketable securities are comprised of an equity security and mutual funds. The equity security is an investment in the common stock of a publicly traded company, and the mutual funds are used to fund the deferred compensation plan the Company assumed in its Gen-Probe acquisition. The equity security is classified as available-for-sale and is recorded at fair value with the unrealized gains or losses, net of tax, within accumulated other comprehensive income (loss), which is a component of stockholders’ equity. The mutual funds are classified as trading and are recorded at fair value with unrealized gains and losses recorded in other income (expense), net in the Consolidated Statements of Operations.
	The Company periodically reviews its marketable equity securities classified as available-for-sale for other-than-temporary declines in fair value below cost basis, or whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The determination that a decline is other-than-temporary is, in part, subjective and influenced by many factors. When assessing marketable equity securities for other-than-temporary declines in value, the Company considers factors including: the significance of the decline in value compared to the cost basis; the underlying factors contributing to a decline in the prices of the security; how long the market value of the investment has been less than its cost basis; any market conditions that impact liquidity; the views of external investment analysts; the financial condition and near-term prospects of the investee; any news or financial information that has been released specific to the investee; and the outlook for the overall industry in which the investee operates. No such other-than-temporary impairment appeared to exist at September 28, 2013.
	The Company has one investment in a publicly traded security and the following reconciles its cost basis to its fair market value as of September 28, 2013 and September 29, 2012. There were no marketable securities at September 24, 2011.
			Cost			Gross Unrealized			Gross Unrealized			Fair Value
						Gains			Losses
	Equity security as of September 28, 2013		$	5,931		$	12,156		$	—		$	18,087
	Equity security as of September 29, 2012		$	5,931		$	98		$	—		$	6,029
	Concentrations of Credit Risk
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, cost-method equity investments, and trade accounts receivable. The Company invests its cash and cash equivalents with high credit quality financial institutions.
	The Company’s customers are principally located in the United States, Europe and Asia. The Company performs ongoing credit evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is directly affected by the overall financial condition of the healthcare industry, as well as global economic conditions, management does not believe significant credit risk exists as of September 28, 2013. The Company generally has not experienced any material losses related to receivables from individual customers or groups of customers in the healthcare industry. The Company maintains an allowance for doubtful accounts based on accounts past due and historical collection experience.
	There were no customers with balances greater than 10% of accounts receivable as of September 28, 2013 and September 29, 2012, or any customers that represented greater than 10% of consolidated revenues for fiscal years 2013, 2012 and 2011.
	Supplemental Cash Flow Statement Information
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Cash paid during the period for income taxes		$	79,893		$	166,565		$	118,850
	Cash paid during the period for interest		$	192,794		$	55,045		$	36,268
	Non-Cash Investing Activities:
	Fair value of stock options assumed in the Gen-Probe acquisition		$	—		$	2,655		$	—
	Additional acquisition contingent consideration accrued		$	—		$	—		$	18,924
	Non-Cash Financing Activities:
	Fair value of contingent consideration at acquisition		$	525		$	—		$	86,600
	Deferred payments for acquisitions		$	—		$	1,655		$	47,258
	Inventories
	Inventories are valued at the lower of cost or market on a first in, first out basis. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates of forecasted sales, usage levels and expiration dates as applicable for disposable products. A significant change in the timing or level of demand for the Company’s products as compared to forecasted amounts may result in recording additional provisions for excess and obsolete inventory in the future. The Company records provisions for excess and obsolete inventory as cost of product sales.
	Inventories consisted of the following:
			September 28,			September 29,
			2013			2012
	Raw materials		$	115,575		$	134,983
	Work-in-process			51,171			93,218
	Finished goods			122,617			138,990
			$	289,363		$	367,191
	Property, Plant and Equipment
	Property, plant and equipment is recorded at cost less allowances for depreciation. The straight-line method of depreciation is used for all property and equipment. Repair and maintenance costs are expensed as incurred. Property, plant and equipment are depreciated over the following estimated useful lives:
	Asset Classification		Estimated Useful Life
	Building and improvements		35–40 years
	Equipment and software		3–10 years
	Equipment under customer usage agreements		3–8 years
	Furniture and fixtures		5–7 years
	Leasehold improvements		Shorter of the Original Term of Lease
			or Estimated Useful Life
	Equipment under customer usage agreements primarily consists of diagnostic instrumentation and medical imaging equipment located at customer sites but owned by the Company. Generally, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables. The depreciation costs associated with equipment under customer usage agreements are charged to cost of product sales over the estimated useful life of the equipment. The costs to maintain the equipment in the field are charged to cost of product sales as incurred.
	Long-Lived Assets
	The Company reviews its long-lived assets, which includes property and equipment and identifiable intangible assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets (ASC 360). Recoverability of these assets is evaluated by comparing the carrying value of the assets to the undiscounted cash flows estimated to be generated by those assets over their remaining economic life. If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are considered impaired. The impairment loss is measured by comparing the fair value of the assets to their carrying value. Fair value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique. At the end of the fourth quarter of fiscal 2013, the Company decided to transition certain of its placed equipment at customer sites to its Panther instrument, and as a result, the Company recorded a charge of $6.3 million to cost of product sales of which $3.7 million related to recording certain equipment at its fair value. At the end of the second quarter of fiscal 2012, the Company decided to cease manufacturing, marketing and selling its Adiana system, which was a product line within the Company’s GYN Surgical reporting segment, determining that the product was not financially viable and would not become so in the foreseeable future. As a result, in fiscal 2012, the Company recorded charges of $19.5 million of which $6.5 million was recorded within cost of product sales to write down certain manufacturing equipment and equipment placed at customer sites to its fair value that had no further utility. There were no significant impairment charges related to property and equipment in fiscal 2011.
	Business Combinations and Acquisition of Intangible Assets
	The Company records tangible and intangible assets acquired in business combinations under the purchase method of accounting. The Company accounts for acquisitions in accordance with ASC 805, Business Combinations (ASC 805). Amounts paid for each acquisition are allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. The Company allocates the purchase price in excess of the fair value of the net tangible assets acquired to identifiable intangible assets, including purchased research and development, based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The use of alternative valuation assumptions, including estimated cash flows and discount rates, and alternative useful life assumptions could result in different purchase price allocations and intangible asset amortization expense in current and future periods.
	The valuation of purchased in-process research and development (“IPR&D”) as part of a business combination represents the estimated fair value at the dates of acquisition related to in-process projects. The Company’s IPR&D represents the value of in-process projects that have not yet reached technological feasibility and have no alternative future uses as of the date of acquisition. As required by ASC 805, the Company capitalizes the value attributable to these in-process projects at the time of the acquisition. Subsequent to acquisition, IPR&D assets are evaluated as an indefinite-lived intangible asset, consistent with the accounting treatment of goodwill. No additional amounts are capitalized and once the project is completed the asset is amortized over its estimated useful life. If the projects are not successful or completed in a timely manner, the Company may not realize the financial benefits expected for these projects or for the acquisitions as a whole and impairments may result.
	The Company uses the income approach to determine the fair value of its developed technology and IPR&D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. Regarding the value of the in-process projects, the Company considers, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of core technologies and other acquired assets, the expected introduction date and the estimated useful life of the technology. The Company bases the discount rate used to arrive at a present value as of the date of acquisition on the time value of money and medical technology investment risk factors. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets.
	The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.
	Intangible Assets and Goodwill
	Intangible Assets
	Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. The Company amortizes its intangible assets that have finite lives using either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. Amortization is recorded over the estimated useful lives ranging from 2 to 30 years. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements.
	Indefinite lived intangible assets, such as IPR&D assets, are required to be tested for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test date is as of the first day of its fourth quarter. The Company tested its IPR&D assets utilizing the DCF model and determined they were not impaired.
During the fourth quarter of fiscal 2013, as a result of the Company’s conclusion that its Molecular Diagnostics reporting unit was impaired (as discussed below), the Company performed an impairment test of this reporting unit’s long-lived assets as of the first day of the fourth quarter. The impairment evaluation was based on expectations of future undiscounted cash flows compared to the carrying value of the long-lived assets. The Company’s cash flow estimates were based upon future projected net cash flows derived from the Company-wide annual planning process, which were used for the annual goodwill impairment test discussed below. Based on this analysis, the Molecular Diagnostics long-lived assets were deemed to not be impaired. The Company believes its procedures for estimating future cash flows were reasonable and consistent with market conditions at the time of estimation.
During the third quarter of fiscal 2013, the Company determined that a certain developed technology asset was impaired and recorded a $1.7 million charge to cost of product sales to record the asset at its estimated fair value.
During the fourth quarter of fiscal 2012 in connection with the company-wide annual budgeting and strategic planning process, the Company determined that indicators of impairment existed in its MammoSite reporting unit, which is included in the Breast Health reportable segment. The impairment indicators were due to a reduction in the Company’s revenue projections and long-term growth rates as a result of the continuing deterioration of the brachytherapy market and competition from existing technologies. The Company’s cash flow estimates were based upon future projected net cash flows derived from the company-wide annual planning process. The analysis indicated that MammoSite’s long-lived assets were recoverable based on the undiscounted cash flows over the remaining life of the predominant long-lived asset. The Company believes that its procedures for estimating future cash flows were reasonable and consistent with market conditions at the measurement date.
During the fourth quarter of fiscal 2012, the Company acquired certain in-process research and development assets that were not part of a business acquisition. Since these assets had no alternative future use, the Company recorded in-process research and development charges of $4.5 million in fiscal 2012.
Intangible assets consist of the following:
		September 28, 2013						September 29, 2012
Description		Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Value						Value
Developed technology		$	4,008,947		$	1,094,435		$	3,784,689		$	788,274
In-process research and development			24,000			—			227,000			—
Customer relationships and contracts			1,101,870			296,481			1,097,842			205,612
Trade names			238,103			81,844			240,092			60,318
Patents			13,026			8,495			11,417			7,906
Business licenses			2,647			616			2,577			344
Non-compete agreements			296			296			310			223
		$	5,388,889		$	1,482,167		$	5,363,927		$	1,062,677
In fiscal 2012, as a result of its acquisition of Gen-Probe, the Company recorded $1.57 billion of developed technology assets and $227.0 million of IPR&D assets related to six projects. In fiscal 2013, management revised its valuation analysis for a correction of projected revenues expected from certain of the development projects which increased the value of the developed technology assets to $1.7 billion and reduced the IPR&D assets to $117.0 million. The Company recorded this adjustment in fiscal 2013 and determined it was immaterial to its financial statements.
Subsequent to the acquisition and through September 2013, the Company has received FDA approval for three projects with an aggregate value of $93.0 million. Amortization of these assets begins once FDA approval is received. The other projects are expected to be completed over the next four years with a total cost of approximately $49.0 million to complete such projects. Given the uncertainties inherent with product development and commercial introduction, there can be no assurance that any of the Company’s product development efforts will be successful, completed on a timely basis or within budget, if at all.
During 2012, the in-process research and development project from the Healthcome acquisition was completed and transferred to developed technology.
Amortization expense related to developed technology and patents is classified as a component of cost of product sales—amortization of intangible assets in the Consolidated Statements of Operations. Amortization expense related to customer relationships and contracts, trade names, business licenses and non-competes is classified as a component of amortization of intangible assets in the Consolidated Statements of Operations.
The estimated amortization expense at September 28, 2013 for each of the five succeeding fiscal years is as follows:
Fiscal 2014		$	417,053
Fiscal 2015			402,177
Fiscal 2016			388,370
Fiscal 2017			379,260
Fiscal 2018			368,505
Goodwill
In accordance with ASC 350, Intangibles—Goodwill and Other (ASC 350), the Company tests goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator.
In performing the impairment test, the Company utilizes the two-step approach prescribed under ASC 350. The first step requires a comparison of the carrying value of each reporting unit to its estimated fair value. To estimate the fair value of its reporting units for Step 1, the Company primarily utilizes the income approach. The income approach is based on a discounted cash flow analysis (“DCF”) and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to a present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company’s most recent budget and for years beyond the budget, the Company’s estimates are based on assumed growth rates. The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates, which are intended to reflect the risks inherent in future cash flow projections, used in the DCF are based on estimates of the weighted-average cost of capital (“WACC”) of market participants relative to each respective reporting unit. The market approach considers comparable market data based on multiples of revenue or earnings before interest, taxes, depreciation and amortization (“EBITDA”) and is primarily used as a corroborative analysis to the results of the DCF. The Company believes its assumptions used to determine the fair value of its respective reporting units are reasonable. If different assumptions were used, particularly with respect to forecasted cash flows, terminal values, WACCs, or market multiples, different estimates of fair value may result and there could be the potential that an impairment charge could result. Actual operating results and the related cash flows of the reporting units could differ from the estimated operating results and related cash flows.
If the carrying value of a reporting unit exceeds its estimated fair value, the Company is required to perform the second step of the goodwill impairment test to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of a reporting unit’s goodwill to its carrying value. The implied fair value of goodwill is derived by performing a hypothetical purchase price allocation for each reporting unit as of the measurement date and allocating the reporting unit’s estimated fair value to its assets and liabilities. The residual amount from performing this allocation represents the implied fair value of goodwill. To the extent this amount is below the carrying value of goodwill, an impairment charge is recorded.
The Company conducted its fiscal 2013 annual impairment test on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 30, 2013, and ultimately used the fair value determined by the DCF in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, market multiples and discount rates as of the measurement date. As a result of completing Step 1, all of the Company’s reporting units, except for its Molecular Diagnostics reporting unit, which is within the Company’s Diagnostics segment, had fair values exceeding their carrying values, and as such, Step 2 of the impairment test was not required for those reporting units. For illustrative purposes, had the fair value of each of the reporting units that passed Step 1 been lower by 10%, all of the remaining reporting units would have still passed Step 1 of the goodwill impairment test. Since the fair value of the reporting units was determined by use of the DCF, and the key assumptions that drive the fair value in this model are the WACC, terminal values, growth rates, and the amount and timing of expected future cash flows, significant judgment is applied in determining fair value. If the current economic environment were to deteriorate, this would likely result in a higher WACC because market participants would require a higher rate of return. In the DCF as the WACC increases, the fair value decreases. The other significant factor in the DCF is the Company’s projected financial information (i.e., amount and timing of expected future cash flows and growth rates) and if these assumptions were to be adversely impacted; this could result in a reduction of the fair values of these reporting units.
In connection with its company-wide annual budgeting and strategic planning process performed in the fourth quarter of fiscal 2013, the Company performed a full re-evaluation of its existing product development efforts and cost structure. As a result, the Company reduced its short term and long term revenue forecasts and determined that indicators of impairment existed in its Molecular Diagnostics reporting unit. The Molecular Diagnostics reporting unit is primarily comprised of the Company’s Aptima business acquired in the Gen-Probe acquisition and the molecular diagnostics business acquired in the Third Wave acquisition. The updated forecast, which reflects recent pricing pressures, is now lower, and the current projections for revenue and profitability are lower than those expected at the time of the Gen-Probe acquisition. As a result, the fair value of this reporting unit was below its carrying value. The Company performed Step 2 of the impairment test, consistent with the procedures described above, and recorded a goodwill impairment charge of $1.1 billion. The basis of fair value for Molecular Diagnostics assumed the reporting unit would be purchased or sold in a taxable transaction, and the discount rate of 10% applied to the after-tax cash flows was relatively consistent with that used in the Company’s purchase accounting for the Gen-Probe acquisition. For illustrative purposes, had the fair value of Molecular Diagnostics been lower by 10%, the Company would have recorded an additional impairment charge of $195.4 million.
At September 28, 2013, the Company believes that its other reporting units, with goodwill aggregating $2.5 billion were not at risk of failing Step 1 of the goodwill impairment test based on the current forecasts.
The Company conducted its fiscal 2012 annual impairment test on the first day of the fourth quarter. The Company utilized DCF and market approaches to estimate the fair value of its reporting units as of June 24, 2012, and ultimately used the fair value determined by the DCF in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, market multiples and discount rates as of the measurement date. As a result of completing Step 1, all of the Company’s reporting units, except MammoSite, which is within the Company’s Breast Health segment, had fair values exceeding their carrying values, and as such, Step 2 of the impairment test was not required. MammoSite’s fair value declined from fiscal 2011 primarily due to a reduction in the Company’s revenue projections and long-term growth rates. The changes in MammoSite’s financial projections were a result of the continuing deterioration of the brachytherapy market, and competition from existing technologies. The Company performed the Step 2 analysis for MammoSite, consistent with the procedures described above, and recorded a $5.8 million goodwill impairment charge, resulting in no remaining goodwill for this reporting unit. For the Company’s other reporting units, if their respective fair values had been lower by 10%, each reporting unit would have still passed Step 1 of the goodwill impairment test.
The Company previously had ongoing litigation with Conceptus regarding potential patent infringement of a Conceptus patent by the Company’s Adiana system. In the first quarter of fiscal 2012, the jury returned a verdict in favor of Conceptus and awarded Conceptus $18.8 million in damages. Post-trial motions were filed, and Conceptus sought to enjoin the Company from further sales of the Adiana system. At the time, the Company was appealing the jury verdict. The jury verdict in the first quarter of fiscal 2012 and related subsequent litigation status was an indicator of impairment for the Company’s GYN Surgical reporting unit, and a reduction in the anticipated future cash flows of the GYN Surgical reporting unit could result in a material impairment charge. Accordingly, the Company performed an interim goodwill impairment analysis of the GYN Surgical reporting unit as of December 24, 2011, updating its cash flow projections and related assumptions from its fiscal 2011 annual impairment test, including the WACC, under various potential scenarios. The Company applied the weighted average probability approach to these scenarios to estimate the fair value of the GYN Surgical reporting unit. As a result of completing Step 1, GYN Surgical’s fair value exceeded its carrying value. Therefore, Step 2 of the impairment test was not required as of December 24, 2011. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, probabilities of cash flow scenarios, and market multiples as of that measurement date.
In connection with the Company’s decision to discontinue the Adiana product line in the second quarter of fiscal 2012 and the Company’s updated lower forecast for the GYN Surgical reporting unit, the Company concluded that potential goodwill impairment indicators existed as of March 24, 2012. As such, the Company performed another interim goodwill impairment test of the GYN Surgical reporting unit as of March 24, 2012, updating its cash flow projections and related assumptions from the analysis performed as of December 24, 2011. As a result of completing Step 1, GYN Surgical’s fair value exceeded its carrying value. Therefore, Step 2 of the impairment test was not required as of March 24, 2012. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, probabilities of cash flow scenarios, and market multiples as of that measurement date.
The Company conducted its fiscal 2011 annual impairment test on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 26, 2011, and ultimately used the fair value determined by the DCF in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows and market multiples as of the measurement date. As a result of completing Step 1, all of the Company’s reporting units had fair values exceeding their carrying values, and as such, Step 2 of the impairment test was not required. For illustrative purposes, had the fair value of each reporting unit been lower by 10%, each reporting unit would have still passed Step 1 of the goodwill impairment test.
The Company believes that the procedures performed and the estimates and assumptions used in the Step 1 and Step 2 analyses for each reporting unit are reasonable and in accordance with U.S. generally accepted accounting principles. The estimate of fair value requires significant judgment. The impairment testing process is subjective and requires judgment at many points throughout the analysis. If these estimates or their related assumptions change in the future, the Company may be required to record impairment charges for these assets not previously recorded.
A rollforward of goodwill activity by reportable segment from September 29, 2012 to September 28, 2013 is as follows:
		Breast Health			Diagnostics			GYN Surgical			Skeletal Health			Total
Balance at September 29, 2012		$	635,741		$	2,283,447		$	1,015,466		$	8,125		$	3,942,779
Impairment charge			—			(1,117,369	)		—			—			(1,117,369	)
Disposition of portion of a reporting unit			—			(1,257	)		—			—			(1,257	)
Gen-Probe acquisition adjustments			—			4,226			—			—			4,226
Gen-Probe valuation revision adjustment			—			(15,750	)		—			—			(15,750	)
Chindex acquisition			1,798			—			—			—			1,798
SenoRx acquisition			692			—			—			—			692
Tax adjustments			—			(868	)		12			—			(856	)
Foreign currency			(1,866	)		1,125			978			28			265
Balance at September 28, 2013		$	636,365		$	1,153,554		$	1,016,456		$	8,153		$	2,814,528
A rollforward of accumulated goodwill impairment losses by reportable segment from September 29, 2012 to September 28, 2013 is as follows:
		Breast Health			Diagnostics			GYN Surgical			Total
Balance at September 29, 2012		$	348,419		$	908,349		$	1,165,804		$	2,422,572
Impairment charge			—			1,117,369			—			1,117,369
Balance at September 28, 2013		$	348,419		$	2,025,718		$	1,165,804		$	3,539,941
Other Assets
Other assets consist of the following:
		September 28,			September 29,
		2013			2012
Other Assets
Deferred financing costs		$	60,620		$	82,760
Life insurance contracts			33,864			25,978
Mutual funds			6,861			6,995
Marketable security			18,087			6,029
Manufacturing access fees			15,971			18,323
Cost-method equity investments			12,558			15,976
Other			15,941			6,006
		$	163,902		$	162,067
Deferred financing costs are related to the Company’s convertible notes, Credit Agreement and Senior Notes (see Note 5 for further discussion). The Company amortizes amounts related to each debt issuance using the effective interest rate method over the period of earliest redemption or the term of such debt. Life insurance contracts were purchased in connection with the Company’s Nonqualified Deferred Compensation Plan (“DCP”) and are recorded at their cash surrender value (see Note 11 for further discussion). The marketable security represents a publicly traded equity security, and the mutual funds are the underlying investments related to the deferred compensation liabilities the Company assumed in connection with the Gen-Probe acquisition. The manufacturing access fees are related to a manufacturing supply and purchase agreement for our HPV products acquired in the Gen-Probe acquisition, and these fees are being amortized over the term of the agreement.
The Company’s cost-method equity investments are generally carried at cost as the Company owns less than 20% of the voting equity and does not have the ability to exercise significant influence over these companies. The Company regularly evaluates the carrying value of its cost-method equity investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income (expense), net in the Consolidated Statements of Operations. During fiscal 2013 and 2011, the Company recorded other-than-temporary impairment charges of $6.4 million and $2.4 million, respectively, related to certain of its cost-method equity investments to adjust their carrying amounts to fair value. No such charges were recorded in fiscal 2012. In the third quarter of fiscal 2013, the Company sold one of its investments and recorded a gain of $2.0 million.
Research and Software Development Costs
Costs incurred for the research and development of the Company’s products are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future by the Company for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. If the Company’s expectations change such that it does not expect it will need the goods to be delivered or the services to be rendered, capitalized nonrefundable advance payments are recorded to expense in that period.
The Company accounts for the development costs of software embedded in the Company’s products in accordance with ASC 985, Software. Costs incurred in the research, design and development of software embedded in products to be sold to customers are charged to expense until technological feasibility of the ultimate product to be sold is established. The Company’s policy is that technological feasibility is achieved when a working model, with the key features and functions of the product, is available for customer testing. Software development costs incurred after the establishment of technological feasibility and until the product is available for general release are capitalized, provided recoverability is reasonably assured. Software development costs eligible for capitalization have not been significant to date.
Foreign Currency Translation
The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, Foreign Currency Matters. The reporting currency for the Company is the U.S. dollar. With the exception of its Costa Rica subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in other income (expense), net in the Consolidated Statement of Operations. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in other income (expense), net in the Consolidated Statements of Operations and to date have not been material.
Accumulated Other Comprehensive Income
Other comprehensive income (loss) includes certain transactions that have generally been reported in the statement of stockholders’ equity. The components of accumulated other comprehensive income consisted of the following:
		September 28,			September 29,
		2013			2012
Foreign currency translation adjustment		$	8,584		$	7,211
Unrealized gains on available-for-sale securities			12,156			62
Minimum pension liability, net of tax of $150 and $207, respectively			(349	)		(483	)
		$	20,391		$	6,790
Revenue Recognition
The Company generates revenue from the sale of its products, primarily medical imaging systems and diagnostic and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems.
The Company recognizes product revenue upon shipment provided that there is persuasive evidence of an arrangement, there are no uncertainties regarding acceptance, the sales price is fixed or determinable, no right of return exists and collection of the resulting receivable is reasonably assured. Generally, the Company’s product arrangements for capital equipment sales, primarily in its Breast Health and Skeletal Health reporting segments, are multiple-element arrangements, including services, such as installation and training, and multiple products. Based on the terms and conditions of the product arrangements, the Company believes that these services and undelivered products can be accounted for separately from the delivered product element as the Company’s delivered products have value to its customers on a stand-alone basis. Accordingly, revenue for services not yet performed at the time of product shipment are deferred and recognized as such services are performed. The relative selling price of any undelivered products is also deferred at the time of shipment and recognized as revenue when these products are delivered. There is no customer right of return in the Company’s sales agreements.
Service revenues primarily consist of amounts recorded under service and maintenance contracts and repairs not covered under warranty, installation and training, and shipping and handling costs billed to customers. Service and maintenance contract revenues are recognized ratably over the term of the contract. Other service revenues are recognized as the services are performed.
For revenue arrangements with multiple deliverables, the Company records revenue as separate units of accounting if the delivered items have value to the customer on a stand-alone basis, and if the arrangement includes a general right of return relative to the delivered items, the delivery or performance of the undelivered items is considered probable and substantially within the Company’s control. Some of the Company’s products have both software and non-software components that function together to deliver the product’s essential functionality. The Company determined that except for its computer-aided detection (“CAD”) products and C-View product, the software element in its other products is incidental in accordance with the software revenue recognition rules and are not within the scope of the software revenue recognition rules, ASC 985-605, Software—Revenue Recognition. The Company determined that given the significance of the software component’s functionality to its CAD and C-View systems, which are sold by its Breast Health segment, these products are within the scope of the software revenue recognition rules. The Company evaluated the appropriate revenue recognition treatment of its other hardware products, including its Dimensions digital mammography systems, which have both software and non-software components that function together to deliver the products’ essential functionality (i.e., it is a tangible product), and determined they are not within the scope of ASC 985-605.
The Company is required to allocate revenue to its multiple element arrangements based on the relative fair value of each element’s selling price. The Company typically determines the selling price of its products based on its best estimate of selling prices (“ESP”) and services based on vendor-specific objective evidence of selling price (“VSOE”). The Company determines VSOE based on its normal pricing and discounting practices for the specific product or service when sold on a stand-alone basis. In determining VSOE, the Company’s policy requires a substantial majority of selling prices for a product or service to be within a reasonably narrow range. The Company also considers the class of customer, method of distribution, and the geographies into which its products and services are sold when determining VSOE. If VSOE cannot be established, which may occur in instances when a product or service has not been sold separately, stand-alone sales are too infrequent, or product pricing is not within a narrow range, the Company attempts to establish the selling price based on third-party evidence of selling price (“TPE”). TPE is determined based on competitor prices for similar deliverables when sold separately. When the Company cannot determine VSOE or TPE, it uses ESP in its allocation of arrangement consideration. The objective of ESP is to determine the price at which the Company would typically transact a stand-alone sale of the product or service. ESP is determined by considering a number of factors including Company pricing policies, internal costs and gross margin objectives, method of distribution, information gathered from experience in customer negotiations, market research and information, recent technological trends, competitive landscape and geographies.
For those arrangements accounted for under the software revenue recognition rules, ASC 985-605 generally requires revenue earned on software arrangements involving multiple elements to be allocated to each element based on their relative VSOE of fair value. If VSOE does not exist for a delivered element, the residual method is applied in which the arrangement consideration is allocated to the undelivered elements based on their VSOE with the remaining consideration recognized as revenue for the delivered elements. For multiple-element software arrangements where VSOE of fair value of Post-Contract Customer Support (“PCS”) has been established, the Company recognizes revenue using the residual method at the time all other revenue recognition criteria have been met.
As part of the Diagnostics segment and as a result of the Gen-Probe acquisition, the Company manufactures blood screening products according to demand schedules provided by its collaboration partner, Novartis Vaccines and Diagnostics, Inc. (“Novartis”). The Company’s agreement provides that it shares a portion of Novartis’s revenue from screening blood donations. Upon shipment to Novartis, the Company recognizes blood screening product sales at an agreed upon fixed transfer price, which is not refundable, and records the related cost of products sold. Based on the terms of the Company’s collaboration agreement with Novartis, the Company’s ultimate share of the net revenue from sales to the end user in excess of the transfer price revenues recognized is not known until it is reported to the Company by Novartis. On a monthly basis, Novartis reports net revenue generated during the prior month and remits an additional corresponding net payment to the Company, which is recorded as revenue at that time. This payment combined with the transfer price revenues previously recognized represents the Company’s ultimate share of net revenue under the agreement.
The Company sells its instruments to Novartis for use in blood screening and records these instrument sales upon delivery since Novartis is responsible for the placement, maintenance and repair of the units with its customers. The Company also sells instruments to its clinical diagnostics customers and records sales of these instruments upon delivery and customer acceptance. For certain customers with non-standard payment terms, instrument sales are recorded based upon expected cash collection. Prior to delivery, each instrument is tested to meet the Company’s specifications and the specifications of the United States Food and Drug Administration (“FDA”), and is shipped fully assembled. Customer acceptance of the Company’s clinical diagnostic instrument systems requires installation and training by the Company’s technical service personnel. Installation is a standard process consisting principally of uncrating, calibrating and testing the instrumentation.
Within its Diagnostics business, and to a lesser extent, its GYN Surgical business, the Company provides its instrumentation (for example, the ThinPrep Processor, ThinPrep Imaging System, and the Panther and Tigris systems) and certain other hardware to customers without requiring them to purchase the equipment or enter into a lease. The Company installs the instrumentation or equipment at the customer’s site and recovers the cost of providing the instrumentation or equipment in the amount it charges for its diagnostic tests, assays and other disposables. Customers enter into a customer usage agreement and typically commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is typically between three and five years. Revenue is recognized over the term of the customer usage agreement as tests, assays and other disposable products are shipped, either origin or destination. The depreciation costs associated with the instruments and equipment are charged to cost of product sales on a straight-line basis over the estimated life of the instrument or equipment. The costs to maintain instruments and equipment in the field are charged to cost of product sales as incurred.
Accounts Receivable and Reserves
The Company records reserves for doubtful accounts based upon a specific review of all outstanding invoices, known collection issues and historical experience. The Company regularly evaluates the collectability of its trade accounts receivables and performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and its assessment of the customer’s current credit worthiness.
Accounts receivable reserve activity for fiscal 2013, 2012 and 2011 is as follows:
		Balance at			Charged to			Write-			Balance at
		Beginning			Costs and			offs and			End of
		of Period			Expenses			Payments			Period
Period Ended:
September 28, 2013		$	6,396		$	4,296		$	(1,894	)	$	8,798
September 29, 2012		$	6,516		$	3,270		$	(3,390	)	$	6,396
September 24, 2011		$	7,769		$	1,614		$	(2,867	)	$	6,516
Cost of Service and Other Revenues
Cost of service and other revenues primarily represents payroll and related costs associated with the Company’s professional services’ employees, consultants, infrastructure costs and overhead allocations, including depreciation and rent and materials consumed in providing the service.
Stock-Based Compensation
The Company accounts for share-based payments in accordance with ASC 718, Stock Compensation (ASC 718). As such, all share-based payments to employees, including grants of stock options and restricted stock units and shares issued under the Company’s employee stock purchase plan, are recognized in the Consolidated Statements of Operations based on their fair values on the date of grant.
Net Income (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares and the dilutive effect of potential future issuances of common stock from outstanding stock options, restricted stock units and convertible debt determined by applying the treasury stock method. In accordance with ASC 718, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of in-the-money stock options and restricted stock units. This results in the assumed buyback of additional shares, thereby reducing the dilutive impact of stock options.
The Company applies the provisions of ASC 260, Earnings Per Share, Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it relates to its convertible notes, and due to the type of debt instrument issued and its accounting policy, the Company applies the treasury stock method and not the if-converted method. The dilutive impact of the Company’s convertible notes is based on the difference between the Company’s current period average stock price and the conversion price of the convertible notes, provided there is a premium. Pursuant to this accounting standard, there is no dilution from the accreted principal of the convertible notes.
A reconciliation of basic and diluted share amounts for fiscal 2013, 2012, and 2011 is as follows:
		September 28,			September 29,			September 24,
		2013			2012			2011
Basic weighted average common shares outstanding			268,704			264,041			261,099
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units			—			—			3,206
Diluted weighted average common shares outstanding			268,704			264,041			264,305
Weighted-average anti-dilutive shares related to:
Outstanding stock options			8,445			10,491			7,747
Restricted stock units			1,109			1,378			—
In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock options’ combined exercise price, average unrecognized stock compensation expense and assumed tax benefits upon exercise is greater than the average stock price for the period. In those reporting periods in which the Company has a net loss, anti-dilutive shares are comprised of the impact of those number of shares that would have been dilutive had the Company had net income plus the number of common stock equivalents that would be anti-dilutive had the company had net income.
Product Warranties
The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
Product warranty activity for fiscal 2013 and 2012 is as follows:
		Balance at			Provisions			Acquired			Settlements/			Balance at End
		Beginning of									Adjustments			of Period
		Period
Period ended:
September 28, 2013		$	6,179		$	12,827		$	—		$	(9,748	)	$	9,258
September 29, 2012		$	4,448		$	9,535		$	230		$	(8,034	)	$	6,179
Advertising Costs
Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising costs, which include trade shows and conventions, were approximately $14.1 million, $29.8 million and $29.0 million for fiscal 2013, 2012 and 2011, respectively, and were included in selling and marketing expense in the Consolidated Statements of Operations.
Recently Issued Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist. ASU 2013-11 amends the presentation requirements of ASC 740, Income Taxes, and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The Company is currently evaluating the impact of the adoption of ASU 2013-11 on its consolidated financial statements.
In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. Under ASU 2013-02, an entity is required to provide information about the amounts reclassified out of Accumulated Other Comprehensive Income (AOCI) by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. The ASU is effective prospectively for reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 is not expected to have a significant impact on the Company’s results of operations or financial position.
In December 2011, the FASB issued ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 amended ASC 210, Balance Sheet, to converge the presentation of offsetting assets and liabilities between U.S. GAAP and IFRS. ASU 2011-11 requires that entities disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. ASU 2011-11 is effective for fiscal years, and interim periods within those years, beginning after January 1, 2013, which is the Company’s fiscal year 2014. The Company is currently evaluating the impact of the adoption of ASU 2011-11 on its consolidated financial statements.

Business_Combinations

Business Combinations	12 Months Ended
	Sep. 28, 2013
Business Combinations [Abstract]	'
Business Combinations	'
	3	Business Combinations
	Fiscal 2013 Acquisitions:
	Chindex Medical Limited
	On December 31, 2012, the Company acquired certain assets from Chindex Medical Limited (“Chindex”) for a net purchase price of $4.4 million, including contingent consideration. Chindex was a distributor of certain of the Company’s Breast Health products in China. The Company accounted for this transaction as the acquisition of a business pursuant to ASC 805 and allocated the majority of the purchase price to customer relationships.
	SenoRx, Inc.
	On May 31, 2013, through the settlement of litigation, the Company acquired certain assets related to SenoRx, Inc.’s (“SenoRx”) Contura brachytherapy device for a net purchase price of $2.4 million. The Company accounted for this transaction as the acquisition of a business pursuant to ASC 805 and allocated the majority of the purchase price to developed technology.
	Fiscal 2012 Acquisition:
	Gen-Probe, Incorporated
	On August 1, 2012, the Company completed its acquisition of Gen-Probe and acquired all of the outstanding shares of Gen-Probe. Pursuant to the merger agreement, each share of common stock outstanding immediately prior to the effective time of the acquisition was cancelled and converted into the right to receive $82.75 in cash. In addition, all outstanding restricted shares, restricted stock units, performance shares, and those stock options granted prior to February 8, 2012 were cancelled and converted into the right to receive $82.75 per share in cash less the exercise price, as applicable. Stock options granted after February 8, 2012 were converted into stock options to acquire shares of Hologic common stock determined by a conversion formula defined in the merger agreement. The Company paid $3.8 billion to the shareholders of Gen-Probe and $169.0 million to equity award holders. The Company funded the acquisition using available cash and financing consisting of senior secured credit facilities and Senior Notes (see Note 5 for further discussion) resulting in aggregate proceeds of $3.48 billion, excluding financing fees to the underwriters. The Company incurred approximately $34.3 million of direct transaction costs, which were recorded within general and administrative expenses in fiscal 2012.
	Gen-Probe, headquartered in San Diego, California, is a leader in molecular diagnostics products and services that are used primarily to diagnose human diseases and screen donated human blood. The Company expected this acquisition to enhance its molecular diagnostics franchise and to complement its existing portfolio of diagnostics products. Gen-Probe’s results of operations are reported within the Company’s Diagnostics reportable segment from the date of acquisition.
	The purchase price consideration was as follows:
	Cash paid		$	3,967,866
	Deferred payment			1,655
	Fair value of stock options exchanged			2,655
	Total purchase price		$	3,972,176
	The fair value of stock options exchanged, that were recorded as purchase price, represented the fair value of Gen-Probe options converted into the Company’s stock options attributable to pre-combination services pursuant to ASC 805. The remainder of the fair value of these stock options of $23.2 million is being recognized as stock-based compensation expense ratably over the remaining vesting period, which was approximately 3.5 years at the date of acquisition. The Company estimated the fair value of the stock options using a binomial valuation model with the following weighted average assumptions: risk free interest rate of 0.41%, expected volatility of 39.9%, expected life of 3.6 years and dividend yield of 0.0%. The weighted average fair value of stock options granted was $7.07 per share.
	The allocation of the purchase price presented below is based on estimates of the fair value of assets acquired and liabilities assumed as of August 1, 2012. The final, adjusted components of the purchase price allocation are as follows:
	Cash		$	205,463
	Accounts receivable			81,444
	Inventory			153,416
	Property, plant and equipment			274,095
	Other assets			191,971
	Assets held-for-sale, net			87,465
	Accounts payable			(19,671	)
	Accrued expenses			(131,623	)
	Other liabilities			(22,939	)
	Identifiable intangible assets:
	Developed technology			1,700,000
	In-process research and development			117,000
	Customer contract			585,000
	Trade names			95,000
	Deferred income taxes, net			(985,465	)
	Goodwill			1,641,020
	Purchase Price		$	3,972,176
	The purchase price has been allocated to the acquired assets and liabilities based on management’s estimate of their fair values. During fiscal 2013, the Company revised its valuation analysis for a correction to projected revenues expected from certain development projects which increased developed technology assets by $135.0 million, reduced IPR&D assets by $110.0 million and lowered trade names by $2.0 million with an offsetting net decrease to goodwill after the impact to deferred tax liabilities. In addition, certain tax related adjustments have been recorded. The Company concluded that these adjustments recorded in fiscal 2013 were immaterial to its financials statements.
	Certain of Gen-Probe’s assets were designated as assets held-for-sale and recorded at fair value less the estimated cost to sell such assets. These represented non-core assets to the Company’s business plan and were expected to be sold within one year of the acquisition. Assets and liabilities held-for-sale are reflected separately in the Company’s Consolidated Balance Sheet. The following represents the components of the asset groups classified as held-for-sale as of September 29, 2012:
	Assets:
	Cash		$	2,563
	Accounts receivable			8,520
	Inventory			15,680
	Property, plant and equipment			13,259
	Other assets			3,083
	Intangible assets and goodwill			51,398
	Total assets held-for-sale		$	94,503
	Liabilities:
	Accrued liabilities			(7,622	)
	Net assets held-for-sale		$	86,881
	On January 3, 2013, the Company entered into a definitive agreement to sell its LIFECODES business to Immucor, Inc. for $85.0 million in cash, subject to adjustment, plus a contingent payment of an additional $10.0 million if certain future revenue results are achieved. This transaction closed on March 22, 2013, and the Company recorded a gain on the sale of $0.9 million in the second quarter of fiscal 2013. LIFECODES sells molecular and antibody-based assays in the markets of transplant diagnostics, specialty coagulation and transfusion medicine. In the first and third quarters of fiscal 2013, the Company completed the sale of the other asset groups classified as held-for-sale for an aggregate of $2.8 million.
	As part of the purchase price allocation, the Company determined that the identifiable intangible assets were developed technology, IPR&D, a customer contract, and trade names. The fair value of the intangible assets was estimated using the income approach and the cash flow projections were discounted using rates ranging from 10% to 12%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital.
	The developed technology assets are comprised of know-how, patents and technologies embedded in Gen-Probe’s products and relate to currently marketed products and related instrument automation. In valuing the developed technology assets, consideration was only given to products that have received regulatory approval. The developed technology assets primarily comprise the significant product families used in diagnostic testing, and the majority of fair value relates to the Aptima family of assays for testing of certain sexually transmitted diseases and microbial infectious diseases and the Procleix family of assays for blood screening. The Company applied the Excess Earnings Method under the income approach to determine the fair value of the developed technology assets excluding the Procleix technology asset, for which the Company applied the Relief-from-Royalty Method to determine its fair value.
	IPR&D projects relate to in-process projects that have not reached technological feasibility as of the acquisition date and have no alternative future use. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product, which primarily pertains to receiving approval to perform certain diagnostic testing on Gen-Probe’s instrumentation, such as the Panther and Tigris systems. The Company recorded $117.0 million of IPR&D assets related to six projects. Subsequent to the acquisition and through September 2013, the Company has received FDA approval for three projects with an aggregate value of $93.0 million. Amortization of these assets begins once FDA approval is received. The other projects are expected to be completed over the next four years with a total cost of approximately $49.0 million to complete such projects. Given the uncertainties inherent with product development and commercial introduction, there can be no assurance that any of the Company’s product development efforts will be successful, completed on a timely basis or within budget, if at all. All of the IPR&D assets were valued using the Multiple-Period Excess Earnings Method approach using a discount rate of 12.0%.
	The customer contract intangible asset pertains to Gen-Probe’s relationship with Novartis Vaccines and Diagnostics, Inc., and the Company used the Excess Earnings Method to estimate the fair value of this asset. Trade names relate to the Gen-Probe corporate name and the primary product names, and the Company used the Relief-from-Royalty Method to estimate the fair value of these assets.
	Developed technology, customer contract and trade names are being amortized on a straight-line basis over a weighted average period of 13.4 years, 13.0 years and 11.0 years, respectively.
	The Company estimated the fair value of property, plant and equipment using a combination of the cost and market approaches, depending on the component. The Company applied the cost approach as the primary method in estimating the fair value of land and buildings. In total, the fair value adjustment to increase the carrying amount of property, plant and equipment was $107.9 million, of which $70.6 million related to land and buildings.
	The excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the amount of goodwill were based on several strategic and synergistic benefits that are expected to be realized from the Gen-Probe acquisition. These benefits include the expectation that the combination of the combined company’s complementary products in the molecular diagnostics market with Gen-Probe’s fully automated product franchise will significantly broaden the Company’s offering in women’s health and diagnostics. The combined company is expected to benefit from a broader global presence and with Hologic’s direct sales force and marketing in Europe and its investment in China distribution, the growth prospects of Gen-Probe’s products are expected to be enhanced significantly. The combined company anticipates significant cross-selling opportunities within the diagnostics market through Hologic’s larger channel coverage and physician sales team. None of the goodwill is expected to be deductible for income tax purposes.
	Gen-Probe’s revenue and pre-tax loss for the period from the acquisition date to September 29, 2012 were $89.5 million and $47.7 million, respectively. The following unaudited pro forma information presents the combined financial results for the Company and Gen-Probe as if the acquisition of Gen-Probe had been completed at the beginning of fiscal 2011:
			Year Ended			Year Ended
			September 29, 2012			September 24, 2011
	Revenue		$	2,526,336		$	2,310,384
	Net loss		$	(164,539	)	$	(127,240	)
	Basic and diluted net loss per common share		$	(0.62	)	$	(0.49	)
	The unaudited pro forma information for fiscal 2012 and 2011 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. Fiscal 2012 unaudited pro forma net loss was adjusted to exclude acquisition-related transaction costs and restructuring costs solely related to the consolidation of the Diagnostics business. These expenses have been added to fiscal 2011 unaudited pro forma net loss. In addition, the fiscal year 2012 unaudited pro forma net loss was adjusted to exclude nonrecurring expenses related to the fair value adjustments associated with the acquisition of Gen-Probe that were recorded by the Company. The fiscal year 2011 pro forma net loss was adjusted to include these acquisition-related transaction costs and expenses related to the fair value adjustments. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments to reflect pro forma results of operations as if the acquisition occurred on September 26, 2010, such as fair value adjustment to inventory, accounts receivable, and property, plant and equipment, increased expenses for restructuring charges and retention costs, increased interest expense on debt obtained to finance the transaction, lower investment income and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs, other than restructuring and retention, or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.
	Fiscal 2011 Acquisitions:
TCT International Co., Ltd.
On June 1, 2011, the Company completed the acquisition of 100% of the equity interest in TCT International Co., Ltd. (“TCT”) and subsidiaries, a privately-held distributor of medical products, including the Company’s ThinPrep Pap Test, related instruments and other diagnostic and surgical products. TCT’s operating subsidiaries are located in Beijing, China. The Company’s acquisition of TCT has enabled it to obtain an established nationwide sales organization and customer support infrastructure in China, which is consistent with the Company’s international expansion strategy. TCT has been integrated within the Company’s international operations, and its results are primarily reported within the Company’s Diagnostics reporting segment and to a lesser extent within the Company’s GYN Surgical reporting segment from the date of acquisition. The Company concluded that the acquisition of TCT did not represent a material business combination, and therefore, no pro forma financial information has been provided herein.
The purchase price of $148.4 million was comprised of $135.0 million in cash, of which $100.0 million was paid up-front and $35.0 million plus a working capital adjustment of $13.2 million, was deferred for one year. In addition, $0.9 million was paid in the first quarter of fiscal 2012 for additional assets acquired. The deferred payment was recorded on a present value basis of $47.5 million in purchase accounting to reflect fair value, and such payment was accreted through interest expense over the one year deferral period. The $35.0 million and a portion of the working capital adjustment of $8.5 million were paid in the fourth quarter of fiscal 2012. As agreed to by the parties, the remainder is due after the completion of fiscal 2013. In addition, the majority of the former shareholders of TCT were eligible to receive two annual contingent earn-out payments (subject to adjustment) not to exceed $200.0 million less the deferred payment. The contingent earn-out payments were based on a multiple of incremental revenue growth for the one year periods beginning January 1, 2011 and January 1, 2012 as compared to the respective prior year periods, and were payable after the first and second anniversaries from the date of acquisition, respectively. Since these payments were contingent on future employment, they were recognized as compensation expense ratably over the required service periods. Based on actual and projected revenues for the TCT business, the Company recorded compensation expense of $80.0 million, $75.5 million and $17.6 million in fiscal 2013, 2012 and 2011, respectively. In the third quarter of fiscal 2012, the first measurement period was completed, and the Company paid the earned contingent consideration of $54.0 million in the fourth quarter of fiscal 2012. The second earn-out period was completed in the third quarter of fiscal 2013, and the Company paid $87.4 million in the fourth quarter of fiscal 2013. As of September 28, 2013, the Company had accrued $31.7 million, which the Company paid in November 2013.
The Company did not issue any equity awards in connection with this acquisition, and third-party transaction costs were not significant.
The allocation of the purchase price was based on estimates of the fair value of assets acquired and liabilities assumed as of June 1, 2011. The components of the purchase price allocation consisted of the following:
Cash		$	27,961
Accounts receivable			17,811
Inventory			5,301
Property and equipment			4,710
Other tangible assets			1,082
Accrued taxes			(14,874	)
Accounts payable and accrued expenses			(6,641	)
Customer relationships			45,780
Business licenses			2,500
Trade names			2,110
Deferred taxes, net			(12,473	)
Goodwill			75,161
Purchase Price		$	148,428
In connection with the purchase price allocation, the Company determined that the separately identifiable intangible assets were customer relationships, business licenses, and trade names related to the TCT company name. The fair value of the intangible assets was determined through the application of the income approach, and the cash flow projections were discounted at 12.5%. Customer relationships relate to relationships that TCT’s founders and sales force have developed with obstetricians, gynecologists, hospitals, and clinical laboratories. Customer relationships, business licenses and trade names are being amortized over a weighted average period of 12.7 years, 10 years and 12 years, respectively. The excess of the purchase price over the fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The goodwill recognized is attributable to the established sales and distribution network of TCT and expected synergies that the Company will realize from this acquisition. None of the goodwill is expected to be deductible for income tax purposes.
Interlace Medical, Inc.
On January 6, 2011, the Company consummated the acquisition of 100% of the equity interest in Interlace, a privately-held company located in Framingham, Massachusetts. Interlace is the developer, manufacturer and supplier of the MyoSure hysteroscopic tissue removal system (“MyoSure”). The MyoSure system is a tissue removal device that is designed to provide incision-less removal of fibroids and polyps within the uterus. Interlace’s operations are reported within the Company’s GYN Surgical reporting segment from the date of acquisition. The Company believes that MyoSure is a complementary product to its existing surgical product portfolio. The Company concluded that the acquisition of Interlace did not represent a material business combination, and therefore, no pro forma financial information has been provided herein.
The purchase price was comprised of $126.8 million in cash (“Initial Consideration”), which was net of certain adjustments, plus two annual contingent payments up to a maximum of an additional $225.0 million in cash. In addition to the Initial Consideration, $2.1 million was paid to certain employees upon the completion of three and six months of service from the date of acquisition. Since these payments were contingent on future employment, they were recognized as compensation expense in fiscal 2011. The purchase agreement includes an indemnification provision that provides for the reimbursement of a portion of legal expenses in defense of the Interlace intellectual property. The Company has the right to collect certain amounts set aside in escrow from the Initial Consideration and, as applicable, offset contingent consideration payments with qualifying legal costs.
The contingent payments were based on a multiple of incremental revenue growth during a two-year period following the completion of the acquisition. Pursuant to ASC 805, the Company recorded its estimate of the fair value of the contingent consideration liability based on future revenue projections of the Interlace business under various potential scenarios and weighted probability assumptions of these outcomes. As of the date of acquisition, these cash flow projections were discounted using a rate of 15.6%. The discount rate is based on the weighted-average cost of capital of the acquired business plus a credit risk premium for non-performance risk related to the liability pursuant to ASC 820. This analysis resulted in an initial contingent consideration liability of $86.6 million, which was adjusted periodically as a component of operating expenses based on changes in fair value of the liability due to the accretion of the liability for the time value of money and changes in the assumptions pertaining to the achievement of the defined revenue growth milestones. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820. This fair value measurement is directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or benefits, respectively, as appropriate. The Company recorded charges of $11.3 million and $41.8 million in fiscal 2013 and 2012, respectively, due to an increase in revenue estimates for Interlace and $6.3 million in fiscal 2011 for accretion to record the contingent consideration liability at fair value. The fair value of the contingent consideration for the first and second measurement periods was $93.8 million and $51.8 million, respectively. Payments were disbursed in the second quarter of fiscal 2013 and 2012, respectively, of which $39.0 million and $47.6 million, respectively, is reflected in the Consolidated Statements of Cash Flows as cash used in financing activities, representing the liability recognized at fair value for the first measurement period as of the acquisition date. The remainder, which is related to changes in the fair value of the liability, is reflected within cash provided by operating activities. The second measurement period payment of $86.9 million was paid to the former Interlace stockholders in the second quarter of fiscal 2013. The remainder was withheld for legal indemnification provisions and is being used to pay qualifying legal expenses.
The Company did not issue any equity awards in connection with this acquisition, and third-party transaction costs were not significant.
The purchase price consideration was as follows:
Cash		$	126,798
Contingent consideration			86,600
Total purchase price		$	213,398
The allocation of the purchase price was based on estimates of the fair value of assets acquired and liabilities assumed as of January 6, 2011. The components of the purchase price allocation consisted of the following:
Cash		$	9,070
Inventory, including fair value adjustments			1,795
Other tangible assets			1,291
Accounts payable and accrued expenses			(1,988	)
Developed technology			158,741
Trade names			1,750
Deferred taxes, net			(45,342	)
Goodwill			88,081
Purchase Price		$	213,398
As part of the purchase price allocation, the Company determined that the separately identifiable intangible assets were developed technology and trade names related to the MyoSure product name. The fair value of the intangible assets was determined through the application of the income approach, and the cash flow projections were discounted at 12.7%. Developed technology represented currently marketable Interlace products that the Company will continue to sell and utilize to enhance and incorporate into the Company’s existing products. In determining the fair value of developed technology, consideration was only given to products that had been approved by the FDA. Based on the early stage of other projects and an insignificant allocation of resources to those projects, the Company concluded that there were no in-process projects of a material nature. Developed technology and trade names are being amortized over 15 years and 13 years, respectively. The excess of the purchase price over the fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The goodwill recognized is attributable to expected synergies that the Company will realize from this acquisition. None of the goodwill is expected to be deductible for income tax purposes.
Beijing Healthcome Technology Company, Ltd.
On July 19, 2011, the Company completed its acquisition of 100% of the equity in Beijing Healthcome Technology Company, Ltd. (“Healthcome”), a privately-held manufacturer of medical equipment, including mammography equipment, located in Beijing, China. Healthcome manufactured analog mammography products targeted to lower tier hospital segments in China. Additionally, Healthcome had been collaborating with the Company’s research and development team to integrate its selenium detector technology into the Healthcome mammography platform. On December 21, 2011, the Company received SFDA approval in China for its Serenity digital mammography system. This acquisition provides the Company with manufacturing capability in China and additional access to the Chinese markets. The purchase price was $8.8 million in cash, which is net of a working capital adjustment. The Company concluded that the acquisition of Healthcome did not represent a material business combination, and therefore, no pro forma financial information has been provided herein. The Company was obligated to make future payments to the shareholders, who remain employed, up to an additional $7.1 million over three years. Since these payments were contingent on future employment, they were being recognized as compensation expense ratably over the respective service periods. In the fourth quarter of fiscal 2012, the Company and former shareholders agreed that the former shareholders would terminate their employment. The Company agreed to pay the majority of the contingent consideration in accordance with the original payment terms. As a result, the Company accelerated the unearned compensation in the fourth quarter of fiscal 2012. The Company recorded compensation expense of $5.6 million and $0.3 million in fiscal 2012 and 2011, respectively. Healthcome’s operations are reported within the Company’s Breast Health reporting segment from the date of acquisition.
As part of the purchase price allocation, the Company determined that the separately identifiable intangible assets were developed technology of $3.3 million, in-process research and development of $0.9 million, and trade names of $0.2 million. The in-process research and development project was completed in the first quarter of fiscal 2012. The fair value of the intangible assets was determined through the application of the income approach, and the cash flow projections were discounted using rates ranging from 27% to 30%. Developed technology and trade names are being amortized over their useful lives of 13 and 7 years, respectively. The excess of the purchase price over the fair value of the tangible net assets and intangible assets acquired of $6.4 million was recorded to goodwill. The goodwill recognized is attributable to expected synergies that the Company will realize from this acquisition. None of the goodwill is expected to be deductible for income tax purposes.

Restructuring_and_Divestiture_

Restructuring and Divestiture Charges	12 Months Ended
	Sep. 28, 2013
Restructuring And Related Activities [Abstract]	'
Restructuring and Divestiture Charges	'
	4	Restructuring and Divestiture Charges
	The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. As a result of these assessments, the Company has undertaken various restructuring actions as described below. The following table displays charges taken related to restructuring actions in fiscal 2013 and 2012 and a rollforward of the charges to the accrued balances as of September 28, 2013. Such initiatives were not significant in fiscal 2011.
	Restructuring Charges		Abandonment of			Consolidation of			Closure of			Fiscal 2013			Other			Total
			Adiana Product			Diagnostics			Indianapolis			Actions			Operating
			Line			Operations			Facility						Cost
															Reductions
	Fiscal 2012 charges:
	Non-cash impairment charge		$	16,316		$	585		$	—		$	—		$	—		$	16,901
	Purchase orders and other contractual obligations			3,099			—			—			—			—			3,099
	Workforce reductions			128			14,202			879			—			40			15,249
	Facility closure costs			—			—			—			—			430			430
	Other			—			—			900			—			—			900
	Total fiscal 2012 charges		$	19,543		$	14,787		$	1,779		$	—		$	470		$	36,579
	Recorded to cost of product sales		$	19,064		$	—		$	—		$	—		$	—		$	19,064
	Recorded to restructuring		$	479		$	14,787		$	1,779		$	—		$	470		$	17,515
	Fiscal 2013 charges:
	Workforce reductions		$	—		$	13,950		$	4,805		$	11,332		$	1,127		$	31,214
	Facility closure costs			—			—			173			—			377			550
	Other			—			—			651			42			236			929
	Fiscal 2013 restructuring charges		$	—		$	13,950		$	5,629		$	11,374		$	1,740		$	32,693
	Divestiture net charges			—			—			—			—			—			112
	Fiscal 2013 restructuring and divestiture charges		$	—		$	13,950		$	5,629		$	11,374		$	1,740		$	32,805
	Rollforward of Accrued Restructuring
	Total fiscal 2012 charges		$	19,543		$	14,787		$	1,779		$	—		$	470		$	36,579
	Non-cash impairment charges			(16,316	)		(585	)		—			—			—			(16,901	)
	Stock compensation			—			(3,500	)		—			—			—			(3,500	)
	Severance payments			(128	)		(2,423	)		—			—			(78	)		(2,629	)
	Other payments			(2,572	)		—			—			—			(430	)		(3,002	)
	Acquired			—			83			—			—			—			83
	Foreign exchange and other adjustments			—			22			—			—			91			113
	Balance at September 29, 2012		$	527		$	8,384		$	1,779		$	—		$	53		$	10,743
	Fiscal 2013 restructuring charges		$	—		$	13,950		$	5,629		$	11,374		$	1,740		$	32,693
	Stock compensation			—			(6,322	)		—			(1,595	)		—			(7,917	)
	Non-cash impairment charges			—			—			—			—			(54	)		(54	)
	Severance payments			—			(13,068	)		(3,048	)		(4,425	)		(897	)		(21,438	)
	Other payments			(527	)		—			(566	)		(25	)		(560	)		(1,678	)
	Foreign exchange and other adjustments			—			(2	)		—			(14	)		6			(10	)
	Balance at September 28, 2013		$	—		$	2,942		$	3,794		$	5,315		$	288		$	12,339
	Abandonment of Adiana Product Line
	At the end of the second quarter of fiscal 2012, the Company decided to cease manufacturing, marketing and selling its Adiana system, which was a product line within the Company’s GYN Surgical reporting segment. Management determined that the product was not financially viable and would not become so in the foreseeable future. In addition, the Company settled its intellectual property litigation regarding the Adiana system with Conceptus as discussed in Note 13. As a result, in the second quarter of fiscal 2012, the Company recorded a charge of $18.3 million and recorded additional adjustments in fiscal 2012 resulting in an aggregate charge of $19.5 million. Of the total charge, $19.1 million was recorded within cost of product sales and $0.4 million was recorded in restructuring. The amount recorded in cost of product sales comprised impairment charges of $9.9 million to record inventory at its net realizable value, $6.5 million to write down certain manufacturing equipment and equipment placed at customer sites to its fair value that had no further utility, and $2.7 million for outstanding contractual purchase orders of raw materials and components that will not be utilized and other contractual obligations. In connection with this action, the Company terminated certain manufacturing and other personnel primarily at its Costa Rica location, resulting in severance charges of $0.1 million, and incurred other contractual charges of $0.3 million. All identified employees were terminated and paid as of September 29, 2012.
	Consolidation of Diagnostics Operations
	In connection with its acquisition of Gen-Probe, the Company implemented restructuring actions to consolidate its Diagnostics operations, such as streamlining product development initiatives, reducing overlapping functional areas such as sales, marketing and general and administrative functions, and consolidation of manufacturing resources, field services and support. As a result, the Company terminated certain employees from Gen-Probe and its legacy diagnostics business in research and development, sales, marketing, and general and administrative functions. The Company recorded severance and benefit charges in fiscal 2012 of $13.3 million related to this action pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420). The majority of these employees ceased working in the fourth quarter of fiscal 2012, and their full severance charge was recorded in the fourth quarter of fiscal 2012. In addition, certain of the terminated Gen-Probe employees had unvested stock options, which were accelerated at termination pursuant to the stock options’ original terms. As such, the severance charges in fiscal 2012 include $3.5 million of stock-based compensation expense. For the year ended September 28, 2013, the Company recorded $10.8 million of severance charges, including $6.3 million for stock-based compensation. Included in these charges is $9.7 million recorded in the second quarter of fiscal 2013 related to certain Gen-Probe executives including Carl Hull, Gen-Probe’s former Chairman, President and Chief Executive Officer, who ceased employment. The charge was for the acceleration of certain retention payments and equity awards pursuant to the original terms of the related agreements.
	In addition, the Company is in process of moving its legacy molecular diagnostics operations from Madison, Wisconsin to Gen-Probe’s facilities in San Diego, California. This transfer is expected to be finalized by the end of fiscal 2014 and, as a result, the majority of employees in Madison will be terminated. The Company is recording severance and benefit charges pursuant to ASC 420 and estimates the total severance and benefits charge to be approximately $6.4 million, which is being recorded ratably over the estimated service period of the affected employees. The Company recorded $3.2 million in the year ended September 28, 2013 and $0.9 million in the fourth quarter of fiscal 2012. The Company also recorded non-cash charges of $0.6 million in the fourth quarter of fiscal 2012 as a result of exiting certain research projects. Additional charges, which are not expected to be significant, will be recorded as the manufacturing operation is transferred and the facility is closed down. These charges will be recorded as they are incurred.
	Closure of Indianapolis Facility
	In the fourth quarter of fiscal 2012, the Company finalized its decision to transfer production of the majority of its interventional breast products, which are included within the Breast Health reporting segment, from its Indianapolis facility to its facility in Costa Rica. The transfer is expected to be completed in the first half of fiscal 2014, and the majority of employees at the Indianapolis, Indiana location will be terminated. The Company is recording severance and benefit charges pursuant to ASC 420 and estimates the total severance and benefits charge to be approximately $6.0 million, which is being recorded ratably over the estimated service period of the affected employees. The Company recorded $4.8 million of severance benefits in the year ended September 28, 2013 and $0.9 million in the fourth quarter of fiscal 2012. In addition, the Company recorded charges of $0.8 million in fiscal 2013 for additional miscellaneous items and $0.9 million in the fourth quarter of fiscal 2012 for amounts owed to the state of Indiana for employment credits. Additional charges, which are not expected to be significant, will be recorded as the manufacturing operation is transferred and the facility is closed down. These charges will be recorded as they are incurred.
	Fiscal 2013 Actions
	During the third quarter of fiscal 2013, the Company implemented a cost reduction initiative comprised of reducing headcount and evaluating research projects and operating costs. In connection with this plan, the Company terminated certain employees on a worldwide basis. The Company is primarily recording severance and benefit charges pursuant to ASC 420 and estimates the total severance and benefits charge to be approximately $5.2 million. For those employees who will continue to be employed beyond the minimum retention period, charges are being recorded ratably over the estimated service period of the affected employees. The Company recorded $4.6 million of severance and benefit charges in fiscal 2013.
	During the fourth quarter of fiscal 2013, effective July 18, 2013, Robert A. Cascella resigned as the Company’s President and Chief Executive Officer, and as a member of the Board of Directors of the Company, and effective at the same time, John W. Cumming was appointed as the Company’s President and Chief Executive Officer. In connection with this management change, additional headcount reductions were implemented. As a result of this action, the Company recorded $6.8 million in the fourth quarter of fiscal 2013 for severance and benefits charges. All employees were notified prior to September 28, 2013 and primarily ceased employment in the fourth quarter. The severance and benefit charges were accounted for pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits, for those employess with contractual arrangements and under ASC 420 for the remainder of affected employees. In addition to the acceleration of stock options pursuant to the stock options’ original terms for certain employees, the Company also modified the terms of equity awards to certain employees resulting in aggregate stock compensation charges of $1.4 million.
	In the fourth quarter of fiscal 2013, in connection with the Company’s cost reduction initiatives, it decided to shut-down its Hitec-Imaging organic photoconductor manufacturing line located in Germany. As a result, the Company will terminate certain employees, primarily in manufacturing, in fiscal 2014 and incur severance and benefit charges, which will be recorded pursuant to ASC 420. The Company is currently working with the local Works Council to negotiate severance benefits for the affected employees, which number approximately 100. In connection with this action, the Company recorded a $0.3 million impairment charge in the fourth quarter of fiscal 2013 to record certain equipment at fair value.
	Other Operating Cost Reductions:
	Consolidation of Selenium Panel Coating Production
	During the third quarter of fiscal 2012, the Company finalized its decision to consolidate its Selenium panel coating process and transfer the production line to its Newark, Delaware facility from its Hitec-Imaging German subsidiary. This production line is included within the Breast Health segment. The transfer was completed in the fourth quarter of fiscal 2013. In connection with this consolidation plan, the Company terminated certain employees, primarily manufacturing personnel. Severance charges were recorded pursuant to ASC 420 because the severance benefits qualify as one-time employee termination benefits. The termination communications began in January 2013, and the Company recorded severance charges of $1.1 million in the year ended September 28, 2013. No additional charges will be incurred under this plan.
	Other
	The Company recorded a charge of $0.4 million in fiscal 2013 for a lease obligation charge and the write-off of related leaseholds.
	During the second quarter of fiscal 2012, the Company abandoned certain lease space and recorded charges of $0.4 million to terminate the leases and write-off related leasehold improvements that have no further utility. The obligation to the landlord was paid in the third quarter of fiscal 2012. During the fourth quarter of fiscal 2012, the Company terminated the employment of certain individuals and recorded a severance and benefits charge of $0.1 million, which was partially offset by the reversal of severance charges recorded in fiscal 2011.
	Divestitures
	In the fourth quarter of fiscal 2013, the Company designated the assets of its Elucigene product line, acquired in the Gen-Probe acquisition, as assets held-for-sale, and recorded a charge of $0.7 million to record the assets at fair value. In the first quarter of fiscal 2014, the Company finalized the sale of the assets for $3.0 million. At September 28, 2013, assets held-for-sale consisted of inventory and certain equipment valued at $2.4 million and goodwill of $0.6 million.
	The Company completed the sale of its LIFECODES business and recorded a net gain of $0.9 million in the second quarter of fiscal 2013. For the year ended September 28, 2013, the Company recorded a charge of $0.3 million related to the disposition of certain other assets held-for-sale.
	Fiscal 2011 Charges
	In the fourth quarter of fiscal 2011, the Company terminated the employment of certain individuals and recorded a severance and benefits charge of $0.3 million, all of which was unpaid as of September 24, 2011. In addition, in the fourth quarter of fiscal 2011, the Company sold a minor non-core product line for $1.1 million resulting in a net gain of $0.4 million.
	Subsequent Events—Fiscal 2014 Action
	In the first quarter of fiscal 2014, the Company implemented an additional cost reduction initiative which included headcount reductions. All affected employees were notified and ceased employment in the first quarter of fiscal 2014. The Company expects to record a severance and benefits charge of approximately $4.6 million in the first quarter of fiscal 2014.

Borrowings_and_Credit_Arrangem

Borrowings and Credit Arrangements	12 Months Ended
	Sep. 28, 2013
Debt Disclosure [Abstract]	'
Borrowings and Credit Arrangements	'
	5	Borrowings and Credit Arrangements
	The Company had total debt with a carrying value of $4.8 billion and $5.04 billion at September 28, 2013 and September 29, 2012, respectively. The Company’s borrowings consisted of the following:
			September 28,			September 29,
			2013			2012
	Current debt obligations, net of debt discount:
	Term Loan A		$	49,713		$	49,582
	Term Loan B			113,966			14,853
	Convertible Notes			400,133			—
	Total current debt obligations			563,812			64,435
	Long-term debt obligations, net of debt discount:
	Term Loan A			894,834			942,065
	Term Loan B			1,159,272			1,470,454
	Senior Notes			1,000,000			1,000,000
	Convertible Notes			1,187,992			1,558,660
	Total long-term debt obligations			4,242,098			4,971,179
	Total debt obligations		$	4,805,910		$	5,035,614
	The debt maturity schedule for the Company’s obligations as of September 28, 2013 is as follows:
			2014			2015			2016		2017		2018		2019 and		Total
															Thereafter
	Term Loan A		$	50,000		$	100,000		$	200,000	$	600,000	$	—	$	—	$	950,000
	Term Loan B (1)			115,000			15,000			15,000		15,000		15,000		1,110,000		1,285,000
	Senior Notes			—			—			—		—		—		1,000,000		1,000,000
	Convertible Notes (2)			405,000			—			—		450,000		879,225		—		1,734,225
			$	570,000		$	115,000		$	215,000	$	1,065,000	$	894,225	$	2,110,000	$	4,969,225
	-1	Fiscal 2014 column reflects reclassifying the Company’s early pay-down of $100.0 million of Term Loan B on October 31, 2013 to current.
	-2	Classified based on the earliest date of redemption for each respective issuance and the balance in fiscal 2018 reflects accretion on the 2013 Notes through September 28, 2013 as described below.
	Credit Agreement
	On August 1, 2012, the Company and certain domestic subsidiaries (the “Guarantors”) entered into a credit and guaranty agreement (the “Credit Agreement”) with Goldman Sachs Bank USA, in its capacity as administrative and collateral agent, and the lenders party thereto (collectively, the “Lenders”).
	The credit facilities under the Credit Agreement initially consisted of:
		•		$1.0 billion senior secured tranche A term loan (“Term Loan A”) with a final maturity date of August 1, 2017;
		•		$1.5 billion secured tranche B term loan (“Term Loan B”) with a final maturity date of August 1, 2019; and
		•		$300.0 million secured revolving credit facility (“Revolving Facility”) with a final maturity date of August 1, 2017.
	Pursuant to the terms and conditions of the Credit Agreement, the Lenders committed to provide senior secured financing in an aggregate amount of up to $2.8 billion. As of the closing of the Gen-Probe acquisition, the Company borrowed $2.5 billion aggregate principal under the term loans of the Credit Agreement. Net proceeds to the Company were $2.41 billion, after issuing the term loans at a discount and deducting associated fees and expenses, all of which will be amortized to interest expense over the respective maturity dates of the debt. The proceeds were used to fund a portion of the purchase price for the Gen-Probe acquisition.
	On March 20, 2013, the Company, the Guarantors, Goldman Sachs, and the Lenders entered into Refinancing Amendment No. 1 (the “Credit Agreement Amendment”) to the Credit Agreement.
	The Credit Agreement Amendment (i) refinanced the Company’s original Term Loan A with a new senior secured tranche A term loan facility with the same principal amount, maturity date and amortization schedule but with an applicable margin 1.00% less than the original Term Loan A (at each margin level), (ii) refinanced the Company’s original Revolving Facility with a new senior secured revolving credit facility with the same principal amount and maturity date, but with an applicable margin 1.00% less than the original Revolving Facility (at each margin level), and (iii) amended certain covenants and terms of the Credit Agreement.
	Effective as of the date of the Credit Agreement Amendment and as of September 28, 2013, amounts outstanding under the new Term Loan A and the new Revolving Facility will bear interest, at the Company’s option: (i) at the Base Rate plus 1.00% per annum, or (ii) at the Adjusted Eurodollar Rate (i.e., the Libor rate) plus 2.00% per annum. The applicable margin with respect to the New Term Loan A and the New Revolving Facility are subject to specified changes depending on the Company’s total net leverage ratio, as defined in the Credit Agreement.
	Pursuant to ASC 470, Debt (ASC 470), the accounting for this refinancing is required to be evaluated on a creditor by creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $3.2 million to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to these creditors for the initial borrowings under the Term Loan A facility. For the remainder of the creditors, this transaction has been accounted for as a modification because the present value of the cash flows on a creditor by creditor basis between the two debt instruments was less than 10%. Pursuant to ASC 470, subtopic 50-40, third-party costs incurred directly related to the exchange were expensed as incurred. As such, the Company recorded issuance costs related to the refinancing of $2.4 million to interest expense in the second quarter of fiscal 2013.
	On August 2, 2013, the Company, the Guarantors, Goldman Sachs, and the Lenders entered into Refinancing Amendment No. 2 (the “Credit Agreement Amendment 2”) to the Credit Agreement. The Credit Agreement Amendment 2 (i) refinanced the Company’s original Term Loan B with a new senior secured tranche B term loan facility with the same principal amount (subject to the prepayment referenced below), maturity date and amortization schedule but with an applicable margin 0.75% less than the original Term Loan B, and (ii) amended certain covenants and terms of the Credit Agreement. Effective as of the date of the Credit Agreement Amendment 2, amounts outstanding under the New Term Loan B will bear interest, at the Company’s option: (A) at the Base Rate with a floor of 2.00%, plus 1.75% per annum, or (B) at the Adjusted Eurodollar Rate (i.e., the Libor rate) with a floor of 1.00% plus 2.75% per annum. In connection with this refinancing, the Company voluntarily prepaid $200.0 million of principal of the Term Loan B facility.
	Pursuant to ASC 470, the accounting for this refinancing is consistent with that described above for the Credit Agreement Amendment. As a result, the Company recorded a debt extinguishment loss of $6.0 million to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to the voluntary prepayment of the Term Loan B facility. The Company expensed direct third-party costs of $1.1 million to interest expense in the fourth quarter of fiscal 2013.
	On October 31, 2013, the Company voluntarily prepaid $100.0 million of its Term Loan B facility, which was reflected in current debt obligations, net of debt discount, as of September 28, 2013.
	The Guarantors have guaranteed the Company’s obligations under the credit facilities, and the credit facilities are secured by first-priority liens on, and a first-priority security interest in, substantially all of the assets of the Company and the Guarantors, including all of the capital stock of substantially all of the U.S. subsidiaries owned by the Company and the Guarantors, 65% of the capital stock of certain of the Company’s first-tier foreign subsidiaries and all intercompany debt. The security interests are evidenced by a pledge and security agreement by and among Goldman Sachs Bank USA, as collateral agent, the Company and the Guarantors and other related agreements, including certain intellectual property security agreements and mortgages.
	The Company is required to make scheduled principal payments under Term Loan A in increasing amounts ranging from $12.5 million per three month period beginning October 31, 2012 to $50.0 million per three month period commencing October 31, 2015, and under Term Loan B in equal installments of $3.75 million per three month period beginning on October 31, 2012 and for 27 three month periods thereafter. The remaining balance for each term loan is due at maturity. Any amounts outstanding under the Revolving Facility are due at maturity. Subject to certain limitations, the Company may voluntarily prepay any of the credit facilities without premium or penalty. The Company is required to make principal repayments first, pro rata among the term loan facilities, and second to the Revolving Facility from specified excess cash flows from operations and from the net proceeds of specified types of asset sales, debt issuances, insurance recoveries and equity offerings.
	Interest accruing at the Base Rate generally is payable by the Company on a quarterly basis. Interest accruing at the Eurodollar Rate generally is payable on the last day of selected interest periods (which can be one, two, three and six months and in certain circumstances nine or twelve months) unless the interest period exceeds three months, in which case, interest is due at the end of every three month period. The Company is required to pay a quarterly commitment fee at an annual rate of 0.50% on the undrawn committed amount available under the Revolving Facility (which rate is subject to reduction depending on the total net leverage ratio as defined in the Credit Agreement).
	Borrowings outstanding under the Credit Agreement in fiscal 2013 and 2012 had weighted average interest rates of 3.7% and 4.0%, respectively. The interest rates on the outstanding Term Loan A and Term Loan B borrowings at September 28, 2013 were 2.2% and 3.75%, respectively. Interest expense under the Credit Agreement totaled $107.6 million and $18.4 million for fiscal 2013 and 2012, respectively, which includes non-cash interest expense of $14.5 million and $2.4 million, respectively, related to the amortization of the deferred financing costs and accretion of the debt discount.
	The Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting the ability of the Company and the guarantors, subject to negotiated exceptions, to: incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets; enter into sale-leaseback transactions; pay dividends or make other distributions; voluntarily prepay other indebtedness; enter into transactions with affiliated persons; make investments; and change the nature of their businesses.
	The credit facilities contain total net leverage ratio and interest coverage ratio financial covenants measured as of the last day of each fiscal quarter, effective in our first quarter of fiscal 2013. The maximum net leverage ratio is 7.00:1.00 beginning on our fiscal quarter ended December 29, 2012, and then decreases over time to 4.00:1.00 for the quarter ending September 30, 2017 and each fiscal quarter thereafter. The minimum interest coverage ratio is 3.25:1.00 beginning on our fiscal quarter ended December 29, 2012, and then increases over time to 3.75:1.00 for the fiscal quarter ending September 30, 2017 and each quarter thereafter. The total net leverage ratio is defined as the ratio of our consolidated net debt as of the quarter end to our consolidated adjusted EBITDA for the four-fiscal quarter period ending on the measurement date. The interest coverage ratio is defined as the ratio of our consolidated adjusted EBITDA for the prior four-fiscal quarter period ending on the measurement date to adjusted consolidated cash interest expense for the same measurement period. These terms, and the calculation thereof, are defined in further detail in the Credit Agreement. The Company was in compliance with these financial covenants as of September 28, 2013.
	The Company has evaluated the Credit Agreement for derivatives pursuant to ASC 815, Derivatives and Hedging, and identified embedded derivatives that require bifurcation as the features are not clearly and closely related to the host instrument. The embedded derivatives are a default provision, which could require additional interest payments, and provision requiring contingent payments to compensate the lenders for changes in tax deductions. The Company has determined that the fair value of these embedded derivatives was nominal as of September 28, 2013 and September 29, 2012.
	Senior Notes
	On August 1, 2012, the Company completed a private placement of $1.0 billion aggregate principal amount of its 6.25% senior notes due 2020 (“Senior Notes”) at an offering price of 100% of the aggregate principal amount of the Senior Notes. Net proceeds to the Company were $987.4 million after deducting underwriting fees and offering expenses, which will be amortized to interest expense over the term of the Senior Notes. The Senior Notes were registered under the Securities Act of 1933 in fiscal 2013. The Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by the Guarantors. The proceeds were used to fund a portion of the Gen-Probe acquisition.
	On August 1, 2012, the Company and the Guarantors entered into an indenture with Wells Fargo Bank, National Association, as trustee, relating to the Senior Notes. The Senior Notes mature on August 1, 2020 and bear interest at the rate of 6.25% per year, payable semi-annually on February 1 and August 1 of each year, commencing on February 1, 2013. The Company recorded interest expense of $63.9 million and $10.7 million in fiscal 2013 and 2012, respectively. This includes non-cash interest expense of $1.6 million and $0.3 million in fiscal 2013 and 2012, respectively, related to the amortization of the deferred financing costs.
	The indenture contains customarily applicable affirmative and negative covenants, including covenants restricting the ability of the Company and certain of its subsidiaries’, subject to negotiated exceptions and qualifications to: incur additional indebtedness; pay dividends or repurchase or redeem capital stock; make certain investments; incur liens; enter into certain types of transactions with the Company’s affiliates; and sell assets or consolidate or merge with or into other companies. The Company is not required to maintain any financial covenants with respect to the Senior Notes.
	The Company may redeem up to 35% of the aggregate principal amount of the Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before August 1, 2015, at a redemption price equal to 106.250% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. The Company also has the option to redeem the Senior Notes on or after: August 1, 2015 through July 31, 2016 at 103.125% of par; August 1, 2016 through July 31, 2017 at 102.083% of par; August 1, 2017 through July 31, 2018 at 101.042% of par; and August 1, 2018 and thereafter at 100% of par. In addition, if the Company undergoes a change of control, as provided in the indenture, the Company will be required to make an offer to purchase each holder’s Senior Notes at a price equal to 101% of the aggregate principal amount of the Senior Notes, plus accrued and unpaid interest, if any, to the repurchase date.
	The Company has evaluated the Senior Notes for derivatives pursuant to ASC 815 and did not identify any embedded derivatives that require bifurcation. All features were deemed to be clearly and closely related to the host instrument.
	Convertible Notes
	On December 10, 2007, the Company issued and sold $1.725 billion, at par, of 2.00% Convertible Senior Notes due December 15, 2037 (“2007 Notes”). Net proceeds from the offering were $1.69 billion, after deducting offering expenses. On November 18, 2010, the Company entered into separate, privately-negotiated exchange agreements under which it retired $450.0 million in aggregate principal of its 2007 Notes for $450.0 million in aggregate principal of new 2.00% Convertible Exchange Senior Notes due December 15, 2037 (“2010 Notes”). In connection with this exchange transaction, the Company recorded a debt extinguishment loss of $29.9 million in its Consolidated Statements of Operations in the first quarter of fiscal 2011. On February 29, 2012, the Company entered into separate, privately-negotiated exchange agreements under which it retired $500.0 million in aggregate principal of the 2007 Notes for $500.0 million in aggregate principal of new 2.00% Convertible Senior Notes due March 1, 2042 (“2012 Notes”). In connection with this exchange transaction, the Company recorded a debt extinguishment loss of $42.3 million in the second quarter of fiscal 2012. On February 14, 2013, the Company entered into separate, privately-negotiated exchange agreements under which it retired $370.0 million in aggregate principal of the 2007 Notes for $370.0 million in aggregate principal of new 2.00% Convertible Senior Notes due 2043 (“2013 Notes”). This exchange transaction was accounted for as a modification and no debt extinguishment loss or gain was recorded. The 2007 Notes, the 2010 Notes, the 2012 Notes and the 2013 Notes are collectively referred to herein as the “Convertible Notes.”
	Holders may require the Company to repurchase the Convertible Notes prior to maturity on the dates set forth below:
		•		the 2007 Notes on December 13, 2013, and each of December 15, 2017, 2022, 2027 and 2032;
		•		the 2010 Notes on each of December 15, 2016, 2020 and 2025, December 13, 2030 and December 14, 2035;
		•		the 2012 Notes on each of March 1, 2018, 2022, 2027 and 2032 and March 2, 2037; and
		•		the 2013 Notes on each of December 15, 2017, 2022, 2027, 2032 and 2037.
	Holders may also require the Company to repurchase the Convertible Notes upon a fundamental change, as defined in each of the applicable indentures. The Company may redeem all or a portion of the 2007 Notes at any time on or after December 18, 2013, all or a portion of the 2010 Notes at any time on or after December 19, 2016, all or a portion of the 2012 Notes at any time on or after March 6, 2018 and all or a portion of the 2013 Notes at any time on or after December 15, 2017. If, prior to maturity, a holder requires the Company to repurchase the Convertible Notes or the Company elects to redeem the Convertible Notes, the repurchase or redemption price of each Convertible Note will equal 100% of its principal amount, plus accrued and unpaid interest to, but excluding, the redemption or repurchase date, as applicable. On November 14, 2013, the Company announced that it would repurchase, on December 13, 2013, all of the outstanding 2007 Notes at a repurchase price payable in cash equal to 100% of the original principal amount of the 2007 Notes validly surrendered for repurchase and not withdrawn plus accrued and unpaid interest to, but not including, December 13, 2013, at the option of the holders of the 2007 Notes.
	The 2007 Notes bear interest at a rate of 2.00% per year on the principal amount, payable semi-annually in arrears in cash on June 15 and December 15 of each year, ending on December 15, 2013. The 2007 Notes will accrete principal from December 15, 2013 at a rate that provides holders with an aggregate annual yield to maturity of 2.00% per year. Beginning with the six month interest period commencing December 15, 2013, the Company will pay contingent interest during any six month interest period to the holders of 2007 Notes if the “trading price”, as defined, of the 2007 Notes for each of the five trading days ending on the second trading day immediately preceding the first day of the applicable six month interest period equals or exceeds 120% of the accreted principal amount of the 2007 Notes. The holders of the 2007 Notes may convert the notes into shares of the Company’s common stock at a conversion price of approximately $38.59 per share, subject to adjustment, prior to the close of business on September 15, 2037 under any of the following circumstances: (1) during any calendar quarter if the last reported sale price of the Company’s common stock exceeds 130% of the conversion price for at least 20 trading days in the 30 consecutive trading days ending on the last trading day of the preceding calendar quarter; (2) during the five business day period after any five consecutive trading day period in which the trading price per note for each day of such period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; (3) if the notes have been called for redemption; or (4) upon the occurrence of specified corporate events. None of these triggering events had occurred as of September 28, 2013.
	The 2010 Notes bear interest at a rate of 2.00% per year on the principal amount, payable semi-annually in arrears in cash on June 15 and December 15 of each year ending on December 15, 2016 and will accrete principal from December 15, 2016 at a rate that provides holders with an aggregate annual yield to maturity of 2.00% per year. Beginning with the six month interest period commencing December 15, 2016, the Company will pay contingent interest during any six month interest period to the holders of 2010 Notes if the “trading price”, as defined, of the 2010 Notes for each of the five trading days ending on the second trading day immediately preceding the first day of the applicable six month interest period equals or exceeds 120% of the accreted principal amount of the 2010 Notes. The holders of the 2010 Notes may convert the 2010 Notes into shares of the Company’s common stock at a conversion price of approximately $23.03 per share, subject to adjustment, prior to the close of business on September 15, 2037 under any of the following circumstances: (1) during any calendar quarter if the last reported sale price of the Company’s common stock exceeds 130% of the conversion price for at least 20 trading days in the 30 consecutive trading days ending on the last trading day of the preceding calendar quarter; (2) during the five business day period after any five consecutive trading day period in which the trading price per note for each day of such period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; (3) if the 2010 Notes have been called for redemption; or (4) upon the occurrence of specified corporate events. None of these triggering events had occurred as of September 28, 2013.
The 2012 Notes bear interest at a rate of 2.00% per year on the principal amount, payable semi-annually in arrears in cash on March 1 and September 1 of each year, beginning September 1, 2012 and ending on March 1, 2018 and will accrete principal from March 1, 2018 at a rate that provides holders with an aggregate annual yield to maturity of 2.00% per year. Beginning with the six month interest period commencing March 1, 2018, the Company will pay contingent interest during any six month interest period to the holders of 2012 Notes if the “trading price”, as defined, of the 2012 Notes for each of the five trading days ending on the second trading day immediately preceding the first day of the applicable six month interest period equals or exceeds 120% of the accreted principal amount of the 2012 Notes. The holders of the 2012 Notes may convert the 2012 Notes into shares of the Company’s common stock at a conversion price of $31.175 per share, subject to adjustment, prior to the close of business on March 1, 2042, subject to prior redemption or repurchase of the 2012 Notes, under any of the following circumstances: (1) during any calendar quarter if the last reported sale price of the Company’s common stock exceeds 130% of the conversion price for at least 20 trading days in the 30 consecutive trading days ending on the last trading day of the preceding calendar quarter; (2) during the five business day period after any five consecutive trading day period in which the trading price per note for each day of such period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; (3) if the 2012 Notes have been called for redemption; or (4) upon the occurrence of specified corporate events. None of these triggering events had occurred as of September 28, 2013.
The 2013 Notes bear interest at a rate of 2.00% per year on the original principal amount, payable semi-annually in arrears in cash on June 15 and December 15 of each year, ending on December 15, 2013. The 2013 Notes accrete principal from their date of issuance at a rate of 4.00% per year until and including December 15, 2017, and 2.00% per year thereafter. Beginning with the six month interest period commencing December 15, 2017, the Company will pay contingent interest to the holders of 2013 Notes during any six month interest period if the “trading price,” as defined, of the 2013 Notes for each of the five trading days ending on the second trading day immediately preceding the first day of the applicable six month interest period equals or exceeds 120% of the accreted principal amount of the 2013 Notes. The holders of the 2013 Notes may convert the notes into shares of the Company’s common stock at a conversion price of approximately $38.59 per share, subject to adjustment, prior to the close of business on September 15, 2043 under any of the following circumstances: (1) during any calendar quarter if the last reported sale price of the Company’s common stock exceeds 130% of the conversion price for at least 20 trading days in the 30 consecutive trading days ending on the last trading day of the preceding calendar quarter; (2) during the five business day period after any five consecutive trading day period in which the trading price per note for each day of such period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; (3) if the notes have been called for redemption; or (4) upon the occurrence of specified corporate events. At the option of the holder, regardless of the foregoing circumstances, holders may convert their respective 2013 Notes at any time on or after September 15, 2043 through the close of business on the second scheduled trading day immediately preceding the maturity date. The conversion rate will not be adjusted for accrued interest or accreted principal in excess of the original $1,000 principal amount, as accrued interest and accreted principal will not be convertible into common stock. None of these triggering events had occurred as of September 28, 2013.
In lieu of delivery of shares of the Company’s common stock in satisfaction of the Company’s obligation upon conversion of the Convertible Notes, the Company may elect to deliver cash or a combination of cash and shares of its common stock. If the Company elects to satisfy its conversion obligation in a combination of cash and shares of the Company’s common stock, the Company is required to deliver up to a specified dollar amount of cash per $1,000 original principal amount of Convertible Notes, and will settle the remainder of its conversion obligation in shares of its common stock, in each case based on the daily conversion value calculated as provided in the respective indentures for the Convertible Notes. This net share settlement election is in the Company’s sole discretion and does not require the consent of holders of the Convertible Notes. It is the Company’s current intent and policy to settle any conversion of the Convertible Notes as if the Company had elected to make the net share settlement election.
The Convertible Notes are the Company’s senior unsecured obligations and rank equally with all of its existing and future senior unsecured debt and prior to all future subordinated debt. The Convertible Notes are effectively subordinated to any future secured indebtedness to the extent of the collateral securing such indebtedness, and structurally subordinated to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries.
Accounting for the Convertible Notes
The Convertible Notes have been recorded pursuant to FASB Staff Position (“FSP”) APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (FSP APB 14-1) (codified within ASC 470) since they can be settled in cash, or partially in cash, upon conversion. FSP APB 14-1 requires the liability and equity components of the convertible debt instrument to be separately accounted for in a manner that reflects the entity’s nonconvertible debt borrowing rate when interest expense is subsequently recognized. The excess of the debt’s principal amount over the amount allocated to the liability component is recognized as the value of the embedded conversion feature (“equity component”) within additional-paid-in capital in stockholders’ equity and amortized to interest expense using the effective interest method. The liability component is initially recorded at its fair value, which is calculated using a discounted cash flow technique. Key inputs used to estimate the fair value of the liability component included the Company’s estimated nonconvertible debt borrowing rate as of the measurement date (i.e. the date the Convertible Notes are issued), the amount and timing of cash flows, and the expected life of the Convertible Notes. In addition, third-party transaction costs are required to be allocated to the liability and equity components based on their relative values.
On September 27, 2009 (the first day of fiscal 2010), as required, the Company adopted this accounting standard, which was applicable to the original issuance of its Convertible Notes at which time there was one issue, the 2007 Notes. The Company estimated the fair value of the 2007 Notes without the conversion feature as of the date of issuance (“liability component”). The estimated fair value of the liability component of $1.256 billion was determined using a discounted cash flow technique. Key inputs used to estimate the fair value of the liability component included the Company’s estimated nonconvertible debt borrowing rate as of December 10, 2007 (the date the 2007 Notes were issued), the amount and timing of cash flows, and the expected life of the 2007 Notes. The estimated effective interest rate of 7.62% was estimated by comparing other companies’ debt issuances that had features similar to the Company’s debt excluding the conversion feature and who had similar credit ratings during the same annual period as the Company.
The excess of the gross proceeds received over the estimated fair value of the liability component totaling $468.9 million was allocated to the conversion feature (“equity component”) as an increase to additional paid-in-capital with a corresponding offset recognized as a discount to reduce the net carrying value of the 2007 Notes. The discount, after adjustment for the exchange of convertible notes as discussed below, is being amortized to interest expense over a six-year period ending December 18, 2013 (the expected life of the liability component) using the effective interest method. In addition, a portion of the deferred financing costs were allocated to the equity component and recorded as a reduction to additional paid-in-capital.
The Company accounted for the 2007 Notes retirements in fiscal 2012 and 2011, discussed above, under the derecognition provisions of subtopic ASC 470-20-40, which requires the allocation of the fair value of the consideration transferred (i.e., the 2010 Notes and 2012 Notes, respectively) between the liability and equity components of the original instrument to determine the gain or loss on the transaction. In connection with the 2010 Notes and 2012 Notes transactions, the Company recorded a debt extinguishment loss of $29.9 million and $42.3 million in fiscal 2011 and 2012, respectively. The 2010 Notes exchange loss is comprised of the loss on the debt itself of $26.0 million and the write-off of the pro-rata amount of debt issuance costs of $3.9 million allocated to the notes retired. The 2012 Notes exchange loss is comprised of the loss on the debt itself of $39.7 million and the write-off of the pro-rata amount of debt issuance costs of $2.6 million allocated to the notes retired. The loss on the debt itself is calculated as the difference between the fair value of the liability component of the 2007 Notes amount retired immediately before the respective exchanges and its related carrying value immediately before the exchanges. The fair value of the liability component in each transaction was calculated similar to the description above for initially recording the 2007 Notes under FSP APB 14-1, and the Company used an effective interest rate of 5.46% and 2.89% for the 2010 Notes and 2012 Notes, respectively, representing the estimated nonconvertible debt borrowing rate with a maturity as of the measurement date consistent with the 2007 Notes first put date of December 2013. In addition, under this accounting standard, a portion of the fair value of the consideration transferred is allocated to the reacquisition of the equity component, which is the difference between the fair value of the consideration transferred and the fair value of the liability component immediately before the exchange. As a result, on a gross basis in the 2010 Notes and 2012 Notes transactions, $39.9 million and $41.6 million, respectively, was allocated to the reacquisition of the equity component of the original instrument, which was recorded net of deferred taxes within capital in excess of par value.
Since the 2010 Notes and 2012 Notes have the same characteristics as the 2007 Notes and can be settled in cash or a combination of cash and shares of common stock (i.e., partial settlement), the Company is required to account for the liability and equity components of its 2010 Notes and 2012 Notes separately to reflect its nonconvertible debt borrowing rate. The Company estimated the fair value of the liability component of 2010 Notes and 2012 Notes to be $349.0 million and $454.2 million, respectively, using a discounted cash flow technique with an estimated effective interest rate of 6.52% and 3.72%, respectively. The rates represent the estimated nonconvertible debt borrowing rate with a maturity as of the measurement date consistent with the 2010 Notes and 2012 Notes first put dates of December 2017 and March 2018, respectively.
The excess of the fair value of the consideration transferred, which was estimated using a binomial lattice model, over the estimated fair value of the liability component of $97.3 million and $79.7 million for the 2010 Notes and 2012 Notes, respectively, was allocated to the embedded conversion feature as an increase to additional paid-in-capital with a corresponding offset recognized as a discount to reduce the net carrying value of the respective notes. As a result of the fair value of the 2010 Notes being lower than the 2010 Notes principal value, there was an additional discount on the 2010 Notes of $3.7 million at the measurement date. The total discount on the 2010 Notes is being amortized to interest expense over a six-year period ending December 15, 2016 (the expected life of the liability component) using the effective interest method. The net debt discount of the 2012 Notes is being amortized to interest expense over a six-year period ending March 1, 2018 (the expected life of the liability component) using the effective interest method. In addition, third-party transaction costs in each transaction have been allocated to the liability and equity components based on the relative values of these components.
The 2013 Notes exchange transaction was accounted for as a modification pursuant to ASC 470-50 and not an extinguishment because the terms of the two debt instruments were not substantially different. This determination was based on the fact that the present value of the cash flows on a creditor by creditor basis between the two debt instruments was less than 10% and the change in the fair value of the conversion option before and after the exchange transaction was less than 10%. As a result, there is no gain or loss from this exchange. As required, the Company recorded the increase in the fair value of the conversion option of $32.5 million from this exchange to additional paid-in-capital, net of deferred taxes. The Company determined the fair value of the conversion option for each debt instrument on the date of modification by calculating the fair value of each debt instrument using the binomial model and subtracting the fair value of the respective debt instrument’s liability component. The fair value of the liability component for each debt instrument was determined by using a discounted cash flow technique with an effective interest rate of 3.25% and 5.42% for the 2007 Notes and 2013 Notes, respectively. These rates represent the estimated nonconvertible borrowing rate with a maturity as of the measurement date consistent with the first put dates of each debt instrument. The difference between the debt’s fair value and the fair value of its liability component represents the value allocated to the debt’s conversion option. In addition, direct costs incurred for this exchange of $4.1 million were expensed as incurred within interest expense.
As of September 28, 2013 and September 29, 2012, the Convertible Notes and related equity components (recorded in additional paid-in-capital, net of deferred taxes) consisted of the following:
		2013			2012
2007 Notes principal amount		$	405,000		$	775,000
Unamortized discount			(4,867	)		(50,591	)
Net carrying amount		$	400,133		$	724,409
Equity component, net of taxes		$	121,496		$	233,353
2010 Notes principal amount		$	450,000		$	450,000
Unamortized discount			(58,310	)		(74,062	)
Net carrying amount		$	391,690		$	375,938
Equity component, net of taxes		$	60,054		$	60,054
2012 Notes principal amount		$	500,000		$	500,000
Unamortized discount			(34,630	)		(41,687	)
Net carrying amount		$	465,370		$	458,313
Equity component, net of taxes		$	49,195		$	49,195
2013 Notes principal amount		$	370,000		$	—
Principal accretion			9,225			—
Unamortized discount			(48,293	)		—
Net carrying amount		$	330,932		$	—
Equity component, net of taxes		$	131,451		$	—
Interest expense under the Convertible Notes is as follows:
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
Amortization of debt discount		$	52,732		$	68,532		$	72,908
Amortization of deferred financing costs			3,048			3,828			3,906
Principal accretion			9,225			—			—
Non-cash interest expense			65,005			72,360			76,814
2.00% accrued interest			34,376			34,898			34,427
		$	99,381		$	107,258		$	111,241
If the Company fails to comply with the reporting obligations contained in the Convertible Notes agreements, the sole remedy of the holders of the Convertible Notes for the first 90 days following such event of default consists exclusively of the right to receive an extension fee in an amount equal to 0.25% of the accreted principal amount of the Convertible Notes. Based on the its evaluation of the Convertible Notes in accordance with ASC 815, the Company determined that the Convertible Notes contain a single embedded derivative, comprising both the contingent interest feature and the filing failure penalty payment, requiring bifurcation as the features are not clearly and closely related to the host instrument. The Company has determined that the value of this embedded derivative was nominal as of September 28, 2013 and September 29, 2012.
As of September 28, 2013, upon conversion, including the potential premium that could be payable on a fundamental change (as defined), the Company would issue a maximum of approximately 75.6 million common shares to the Convertible Note holders.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Sep. 28, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	6	Fair Value Measurements
	The Company applies the provisions of ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value each reporting period and its nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability.
	Fair Value Hierarchy
	ASC 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
		•		Level 1—Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
		•		Level 2—Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
		•		Level 3—Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
	The Company has an equity investment in a publicly-traded company and mutual funds, both of which are valued using quoted market prices, representing Level 1 assets. The Company has a payment obligation to the participants under its DCP and the deferred compensation plan assumed in the Gen-Probe acquisition. This aggregate liability is recorded at fair value based on the underlying value of certain hypothetical investments under the DCP and actual investments under the plan assumed from Gen-Probe as designated by each participant for their benefit. Since the value of the DCP obligation is based on market prices, the liability is classified within Level 1. In addition, the Company had contingent consideration liabilities related to its acquisitions that were recorded at fair value and were based on Level 3 inputs (see Note 3). As of September 29, 2012, the Company also had $0.3 million in money market funds that were classified as cash and cash equivalents. Money market funds were classified within Level 1 of the fair value hierarchy and were valued using quoted market prices for identical assets.
	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following:
						Fair Value Measurements at September 28, 2013
			Carrying Value			Quoted Prices in			Significant			Significant
						Active Market for			Other			Unobservable
						Identical Assets			Observable			Inputs (Level 3)
						(Level 1)			Inputs (Level 2)
	Assets:
	Marketable securities:
	Equity security		$	18,087		$	18,087		$	—		$	—
	Mutual funds			6,861			6,861			—			—
	Total		$	24,948		$	24,948		$	—		$	—
	Liabilities:
	Deferred compensation liabilities		$	38,611		$	38,611		$	—		$	—
	Contingent consideration			3,780			—			—			3,780
	Total		$	42,391		$	38,611		$	—		$	3,780
						Fair Value Measurements at September 29, 2012
			Carrying Value			Quoted Prices in			Significant			Significant
						Active Market for			Other			Unobservable
						Identical Assets			Observable			Inputs (Level 3)
						(Level 1)			Inputs (Level 2)
	Assets:
	Money market funds		$	315		$	315		$	—		$	—
	Marketable securities:
	Equity security			6,029			6,029			—			—
	Mutual funds			6,995			6,995			—			—
	Total		$	13,339		$	13,339		$	—		$	—
	Liabilities:
	Deferred compensation liabilities		$	32,082		$	32,082		$	—		$	—
	Contingent consideration			86,368			—			—			86,368
	Total		$	118,450		$	32,082		$	—		$	86,368
	Changes in the fair value of recurring fair value measurements, which solely consisted of contingent consideration liabilities, using significant unobservable inputs (Level 3) during the years ended September 28, 2013 and September 29, 2012 were as follows:
			2013			2012			2011
	Beginning balance		$	86,368		$	103,790		$	29,500
	Contingent consideration liabilities recorded at fair value at acquisition			525			—			86,600
	Fair value adjustments			11,310			38,466			(8,016	)
	Payments made			(94,423	)		(55,888	)		(4,294	)
	Ending balance		$	3,780		$	86,368		$	103,790
	Refer to Note 3 for a description of the valuation of contingent consideration and related sensitivities of the estimates.
	The contingent consideration liability at September 28, 2013 is related to Interlace, representing the remaining amounts withheld from payments made to the former shareholders of Interlace for legal indemnification provisions. As of the end of the second quarter of fiscal 2013, the Interlace contingent liability was no longer being remeasured as the final measurement period lapsed. The withheld amount is being used to pay qualifying legal charges.
	Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
	The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of cost-method equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. During fiscal 2013 and 2012, the Company recorded goodwill impairment charges of $1.1 billion and $5.8 million, respectively, related to its Molecular Diagnostics and MammoSite reporting units, respectively. These adjustments fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The fair value measurements using a discounted cash flow technique, and the amount and timing of future cash flows within the analysis were based on the Company’s most recent operational budgets, long-range strategic plans and other estimates at the time such remeasurement was made.
	The Company holds certain cost-method equity investments in non-publicly traded securities aggregating $12.6 million and $16.0 million at September 28, 2013 and September 29, 2012, respectively, which are included in other long-term assets on the Company’s Consolidated Balance Sheets. These investments are generally carried at cost. Since the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, these cost method investments are classified within Level 3 of the fair value hierarchy. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical. During fiscal 2013 and 2011, the Company recorded other-than-temporary impairment charges of $6.4 million and $2.4 million, respectively, related to certain of its cost-method equity investments to adjust their carrying amounts to fair value.
	The following chart depicts the level of inputs within the fair value hierarchy used to estimate the fair value of equipment, intangible assets, goodwill and cost-method equity investments measured on a nonrecurring basis for which the Company recorded impairment charges:
						Fair Value Measurements Using
			Fair Value			Quoted Prices in		Significant	Significant			Total Gains
						Active Market for		Other	Unobservable			(Losses)
						Identical Assets		Observable	Inputs (Level 3)
						(Level 1)		Inputs (Level 2)
	Fiscal 2013:
	Goodwill		$	277,840					$	277,840		$	(1,117,369	)
	Equipment			1,363						1,363			(4,993	)
	Cost-method equity investments			1,483						1,483			(6,438	)
												$	(1,128,800	)
	Fiscal 2012:
Equipment		$	—					$	—		$	(6,452	)
Goodwill			—						—			(5,826	)
											$	(12,278	)
Fiscal 2011:
Cost-method equity investments		$	345					$	345		$	(2,445	)
The above fair value amounts represent only those individual assets remeasured and not the consolidated balances. Refer to Note 5 for disclosure of the nonrecurring fair value measurement related to debt extinguishment losses recorded in fiscal 2013, 2012 and 2011. Refer to Note 4 for disclosure of the nonrecurring fair value measurement related to assets held-for-sale in the fourth quarter of fiscal 2013.
Disclosure of Fair Value of Financial Instruments
The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, marketable securities, cost-method equity investments, insurance contracts, DCP liability, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s marketable securities are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. generally accepted accounting principles, which approximates fair value, and the related DCP liability is recorded at fair value. The Company believes the carrying amounts of its cost-method investments approximate fair value.
Amounts outstanding under our Credit Agreement aggregating $2.24 billion aggregate principal are subject to variable rates of interest based on current market rates, and as such, we believe the carrying amount of these obligations approximates fair value. The Company’s Senior Notes had a fair value of approximately $1.05 billion as of September 28, 2013 based on their trading price, representing a Level 1 measurement. The fair value of the Company’s Convertible Notes is based on the trading prices of the respective notes at the dates noted and represent Level 1 measurements. Refer to Note 5 for the various components of the Company’s debt respective carrying amounts.
The estimated fair values of the Company’s Convertible Notes as of September 28, 2013 and September 29, 2012 are as follows:
		2013			2012
2007 Notes		$	405,000		$	771,600
2010 Notes			510,800			505,600
2012 Notes			518,800			490,700
2013 Notes			385,700			—
		$	1,820,300		$	1,767,900

Sale_of_Makena

Sale of Makena	12 Months Ended
	Sep. 28, 2013
Text Block [Abstract]	'
Sale of Makena	'
	7	Sale of Makena
	On January 16, 2008, the Company entered into an agreement to sell the full world-wide rights of its Makena (formerly Gestiva) pharmaceutical product to K-V Pharmaceutical Company (“KV”) upon FDA approval of the then pending Makena new drug application for $82.0 million. The Company executed certain amendments to this agreement resulting in an increase in the total sales price to $199.5 million and changing the timing of when payments are due to the Company. Gains attributable to payments in the amount of $79.5 million received from KV prior to FDA approval were deferred.
	On February 3, 2011, the Company received FDA approval of Makena, and subject to a security interest and a right of reversion for failure to make future payments, all rights to Makena were transferred to KV. Upon FDA approval, the Company received $12.5 million, and including the $79.5 million previously received, the Company recorded a gain on the sale of intellectual property, net of the write-off of certain assets, of $84.5 million in the second quarter of fiscal 2011. Pursuant to the amended agreement, the Company received $12.5 million in the second quarter of fiscal 2012, which was recorded net of amounts due to the inventor of Makena. The Company was to receive the remaining $95.0 million of the sales price over a period of 18 to 30 months from FDA approval (subject to further deferral elections) depending on which one of two payment options KV selected. KV would also have owed the Company a 5% royalty on sales for certain time periods determined based upon the payment option or deferral elections selected by KV. On August 4, 2012, KV and certain of its subsidiaries filed voluntary petitions for reorganization under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York. The Company had been pursuing its claims against KV in these proceedings for amounts due to the Company under its agreement with KV, and in December 2012, the Company and KV executed a settlement agreement, which became effective on December 28, 2012 upon the Bankruptcy Court entering certain orders. Under the settlement agreement, the Company released KV from all claims in consideration of a $60.0 million payment. The Company recorded this amount in the first quarter of fiscal 2013, net of certain costs, including contingent fees and amounts due to the inventor, resulting in a gain of $53.9 million. The Company will receive no further payments from KV.

Income_Taxes

Income Taxes	12 Months Ended
	Sep. 28, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	8	Income Taxes
	The Company’s (loss) income before income taxes consisted of the following:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Domestic		$	(1,184,603	)	$	(46,018	)	$	235,204
	Foreign			(8,358	)		(15,643	)		(7,818	)
			$	(1,192,961	)	$	(61,661	)	$	227,386
	The (benefit) provision for income taxes contains the following components:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Federal:
	Current		$	154,900		$	146,164		$	97,834
	Deferred			(182,739	)		(143,582	)		(33,808	)
				(27,839	)		2,582			64,026
	State:
	Current			15,305			15,348			15,739
	Deferred			(16,709	)		(10,186	)		(5,909	)
				(1,404	)		5,162			9,830
	Foreign:
	Current			7,655			5,653			4,770
	Deferred			1,465			(1,424	)		(8,390	)
				9,120			4,229			(3,620	)
			$	(20,123	)	$	11,973		$	70,236
	The income tax (benefit) provision differs from the tax provision computed at the U.S. federal statutory rate due to the following:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Income tax provision at federal statutory rate			(35.0	)%		(35.0	)%		35	%
	Increase (decrease) in tax resulting from:
	Goodwill impairment			32.8			3.3			—
	Domestic production activities deduction			(1.2	)		(20.3	)		(4.1	)
	State income taxes, net of federal benefit			(0.2	)		5.3			3.6
	Research and investment tax credits			(1.2	)		(1.6	)		(3.2	)
	Unrecognized tax benefits			0.3			13.5			(3.3	)
	Contingent consideration			2.6			59.8			1.5
	Nondeductible transaction expenses			—			7.5			—
	Cessation of Adiana			—			(28.6	)		—
	Executive compensation			0.2			2.3			(1.1	)
	Foreign rate differential			0.1			3.1			0.8
	Change in valuation allowance			(0.8	)		5.4			—
	Other			0.7			4.7			1.7
				(1.7	)%		19.4	%		30.9	%
	The Company’s effective tax rate in fiscal 2013 was lower than the statutory rate primarily due to the non-deductible goodwill impairment charge, non-deductible contingent consideration expense related to the TCT and Interlace acquisitions, and unbenefited foreign losses, partially offset by the domestic production activities deduction benefit and the release of a $19.9 million valuation allowance related to capital losses which were utilized to offset capital gains generated during the year.
	The Company’s effective tax rate in fiscal 2012 was significantly impacted by non-deductible contingent consideration compensation expense, non-deductible acquisition costs, a non-deductible goodwill impairment charge, and a net increase in income tax reserves and valuation allowances on certain foreign losses. The items’unfavorable tax impact were partially offset by the domestic production activities deduction benefit and a loss claimed on the discontinued Adiana product line. The fiscal 2012 pre-tax loss magnified the permanent items’ impact on the effective tax rate.
	The Company’s effective tax rate for fiscal 2011 was less than the statutory rate primarily due to reversing income tax reserves, the domestic production activities deduction benefit and both U.S. and Canadian research and development tax credits. The $9.1 million income tax reserve reversal was due to the Company favorably settling its U.S. federal income tax audit for fiscal years 2007 through 2009 and statutes of limitations expiring in several state and foreign jurisdictions.
	The Company uses the liability method to account for income taxes in accordance with ASC 740, Income Taxes. Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the period in which these differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the expected realized amounts.
	The Company’s significant deferred tax assets and liabilities are as follows:
			September 28,			September 29,
			2013			2012
	Deferred tax assets
	Net operating loss carryforwards		$	49,277		$	47,472
	Capital losses			23,857			46,750
	Non-deductible accruals			21,527			22,198
	Non-deductible reserves			16,054			10,346
	Stock-based compensation			30,190			31,437
	Research and other credits			10,679			11,392
	Debt issuance costs			—			811
	Nonqualified deferred compensation plan			14,714			12,007
	Other temporary differences			6,960			3,000
				173,258			185,413
	Less: valuation allowance			(43,354	)		(64,337	)
		$	129,904		$	121,076
Deferred tax liabilities
Depreciation and amortization		$	(1,494,068	)	$	(1,635,043	)
Debt discounts and deferrals			(189,298	)		(209,011	)
Debt issuance costs			(10,941	)		—
Fair value adjustments to current assets and liabilities			—			(28,413	)
Investment in subsidiary			(10,713	)		(8,479	)
		$	(1,705,020	)	$	(1,880,946	)
		$	(1,575,116	)	$	(1,759,870	)
Under ASC 740, the Company can only recognize a deferred tax asset for the future benefit to the extent that it is “more likely than not” that these assets will be realized. After considering all available positive and negative evidence, the Company established a valuation allowance against specifically identified deferred tax assets because it is more-likely-than-not that these will not be realized. In determining these assets realizability, the Company considered numerous factors including historical profitability, the character and estimated future taxable income, prudent and feasible tax planning strategies, and the industry in which it operates. The valuation allowance decreased $21.0 million in fiscal 2013 from fiscal 2012 primarily due to the utilization of reserved capital losses to offset the Company’s capital gains generated during the year.
As of September 28, 2013, the Company had $24.4 million, $41.2 million and $55.2 million in gross federal, state, and foreign net operating losses respectively and $0.9 million, $12.8 million and $1.9 million in federal, state, and foreign credit carryforwards, respectively. These losses and credits expire between 2014 and 2033, except for $55.2 million in losses and $9.0 million in credits that have unlimited carryforward periods. The federal, state, and foreign net operating losses exclude $4.5 million, $69.3 million and $67.5 million, respectively, of net operating losses, which the Company expects will expire unutilized.
The Company had $121.8 million in gross unrecognized tax benefits, excluding interest, as of September 28, 2013 and $53.1 million as of September 29, 2012. The gross unrecognized tax benefits increased $68.7 million from September 29, 2012, of which $58.4 million resulted from uncertain tax positions related to the convertible debt exchange that took place in the second quarter of fiscal 2013. At September 28, 2013, $61.0 million represents the unrecognized tax benefits that, if recognized, would reduce the Company’s effective tax rate. In the next twelve months it is reasonably possible that the Company will reduce its unrecognized tax benefits by $2.0 to $4.0 million due to statutes of limitations expiring and favorably settling with taxing authorities which would reduce the Company’s effective tax rate.
The Company’s unrecognized income tax benefits activity for fiscal 2013 and 2012 are as follows:
		2013			2012
Balance at beginning of fiscal year		$	53,148		$	31,026
Tax positions related to current year:
Additions			64,992			11,673
Reductions			—			—
Tax positions related to prior years:
Additions related to change in estimate			3,317			1,327
Reductions			(363	)		307
Payments			(621	)		(197	)
Lapses in statutes of limitations and settlements			(2,323	)		(4,144	)
Acquired tax positions:
Additions related to reserves acquired from acquisitions			3,676			13,156
Balance as of the end of the fiscal year		$	121,826		$	53,148
The Company’s policy is to include accrued interest and penalties related to unrecognized tax benefits and income tax liabilities, when applicable, in income tax expense. As of September 28, 2013 and September 29, 2012, accrued interest was $3.6 million and $2.6 million, respectively. As of September 28, 2013, no penalties have been accrued.
The Company and its subsidiaries are subject to various federal, state, and foreign income taxes. The Company’s U.S. Federal income tax returns are no longer subject to examination prior to fiscal year 2010. State income tax returns are generally no longer subject to examination prior to fiscal year 2009. The Internal Revenue Service commenced its examination of the Company’s consolidated federal income tax return for fiscal 2011 in July 2013. The Company is also undergoing a tax examination in Germany for fiscal years 2008 through 2010. In November 2013, the IRS notified the Company that Gen Probe’s consolidated federal income tax returns for calendar years 2010 through the 2012 acquisition date were selected for examination. The Company has a tax holiday in Costa Rica that currently does not materially impact its effective tax rate and is scheduled to expire in 2015.
The Company intends to reinvest, indefinitely, approximately $33.4 million in unremitted foreign earnings. It is not practical to estimate the additional taxes that may be payable upon repatriation.

Stockholders_Equity_and_StockB

Stockholders' Equity and Stock-Based Compensation	12 Months Ended
	Sep. 28, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stockholders' Equity and Stock-Based Compensation	'
	9	Stockholders’ Equity and Stock-Based Compensation
	Stockholder Rights Agreement
	On November 20, 2013, the Company’s Board of Directors declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of common stock, par value $0.01 per share, of the Company, to purchase from the Company one ten-thousandth of a share of newly designated Series A Junior Participating Preferred Stock, par value $0.01 per share, of the Company (the “Preferred Stock”) at a price of $107.00 per one ten-thousandth of a share of Preferred Stock, subject to adjustment as provided in the Rights Agreement. The dividend is payable to stockholders of record at the close of business on December 2, 2013 (the “Record Date”). The description and terms of the Rights are set forth in a Rights Agreement, dated as of November 21, 2013, as the same may be amended from time to time (the “Rights Agreement”), between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent.
	The Rights Agreement became effective on November 21, 2013 (the “Effective Date”). Upon and following the Effective Date, Rights will be issued in respect of all outstanding shares of Common Stock on the Record Date, and for all shares of Common Stock issued after the Record Date and, subject to the terms described in the Rights Agreement, prior to the earliest of the Distribution Date (as defined in the Rights Agreement), the redemption of the Rights or the expiration of the Rights.
	The Rights are not exercisable until the Distribution Date. The Rights will expire on November 20, 2014, unless the Rights are earlier redeemed or exchanged by the Company, in each case as defined in the Rights Agreement.
	Stock Repurchase Progam
	On November 11, 2013, the Company announced that its Board of Directors authorized the repurchase of up to $250 million of the Company’s outstanding common stock over the next three years. Under the stock repurchase program, the Company authorized to repurchase, from time-to-time, shares of its outstanding common stock on the open market or in privately negotiated transactions in the United States. The timing and amount of stock repurchases will be determined based upon the Company’s evaluation of market conditions and other factors. The stock repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.
	Stock-Based Compensation
	Equity Compensation Plans
	The Company has one share-based compensation plan pursuant to which awards are currently being made—the 2008 amended and restated Equity Incentive Plan (“2008 Equity Plan”). The Company has four share-based compensation plans pursuant to which outstanding awards have been made, but from which no further awards can or will be made—i) the 1995 Combination Stock Option Plan; ii) the 1997 Employee Equity Incentive Plan; iii) the 1999 Equity Incentive Plan; and iv) the 2000 Acquisition Equity Incentive Plan.
	The purpose of the 2008 Equity Plan is to provide stock options, stock issuances and other equity interests in the Company to employees, officers, directors, consultants and advisors of the Company and its parents and subsidiaries, and any other person who is determined by the Board of Directors to have made (or is expected to make) contributions to the Company. The 2008 Equity Plan is administered by the Board of Directors of the Company, and a total of 31.5 million shares were reserved for issuance under this plan. As of September 28, 2013, the Company had 13.6 million shares available for future grant under the 2008 Equity Plan.
	The Company assumed certain other plans in connection with the Gen-Probe, Cytyc and Third Wave acquisitions, and no shares are available for future grant under these plans.
	The following presents stock-based compensation expense in the Company’s Consolidated Statement of Operations in fiscal 2013, 2012 and 2011:
			2013			2012			2011
	Cost of revenues		$	7,031		$	5,722		$	4,602
	Research and development			7,179			5,328			4,852
	Selling and marketing			8,915			7,355			5,954
	General and administrative			20,153			18,667			20,064
	Restructuring and divestiture			9,029			3,500			—
			$	52,307		$	40,572		$	35,472
	Grant-Date Fair Value
	The Company uses a binomial model to determine the fair value of its stock options. The Company considers a number of factors to determine the fair value of options including the assistance of an outside valuation advisor. Information pertaining to stock options granted during fiscal 2013, 2012 and 2011 and related assumptions are noted in the following table:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Options granted			2,640			2,259			2,249
	Weighted-average exercise price		$	20.29		$	17.21		$	17.15
	Weighted-average grant date fair value		$	7.03		$	6.48		$	6.16
	Assumptions:
	Risk-free interest rates			0.5	%		0.7	%		1	%
	Expected life (in years)			4.4			4.3			4.2
	Expected volatility			44	%		47	%		45	%
	Dividend yield			—			—			—
	The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected life of the stock options. In projecting expected stock price volatility, the Company uses a combination of historical stock price volatility and implied volatility from observable market prices of similar equity instruments. The Company estimated the expected life of stock options based on historical experience using employee exercise and option expiration data.
	The Company also granted approximately 0.1 million market stock units (MSU) in the first quarter of fiscal 2013 to its then Chief Executive Officer and Chief Financial Officer. The MSUs were valued at $18.49 using the Monte Carlo simulation model. Each recipient of the MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s stock price achieves the defined measurement criteria for MSUs. The Company is recognizing compensation expense over the required service period, and since these are market-based awards, the compensation expense will be recognized by the Company regardless of whether the required criteria is met to receive such shares unless the requisite service is not rendered. Due to the resignation of the former Chief Executive Officer in July 2013, his MSUs were forfeited and the related compensation expense previously recognized was reversed.
	Stock-Based Compensation Expense Attribution
	The Company uses the straight-line attribution method to recognize stock-based compensation expense for stock options and restricted stock units (“RSU”). The vesting term of stock options is generally five years with annual vesting of 20% per year on the anniversary of the grant date, and RSUs generally vest over four years with annual vesting at 25% per year on the anniversary of the grant date. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. ASC 718 requires forfeitures to be estimated at the time granted and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on an analysis of historical forfeitures, the Company has determined a specific forfeiture rate for certain employee groups and has applied forfeiture rates ranging from 0% to 6% as of September 28, 2013 depending on the specific employee group. This analysis is re-evaluated annually and the forfeiture rate will be adjusted as necessary. Ultimately, the actual stock-based compensation expense recognized will only be for those stock options and RSUs that vest.
	Stock-based compensation expense related to stock options was $23.7 million, $18.7 million, and $15.2 million in fiscal 2013, 2012 and 2011, respectively. Stock compensation expense related to RSUs was $26.0 million, $21.4 million, and $20.3 million in fiscal 2013, 2012 and 2011, respectively. The related tax benefit recorded in the Consolidated Statements of Operations was $17.2 million, $12.2 million and $14.8 million in fiscal 2013, 2012 and 2011, respectively. Included within stock-based compensation expense in fiscal 2013 and 2012 is $7.9 million and $3.5 million, respectively, related to modification accounting, the acceleration of vesting of certain retention RSUs provided under their original terms upon termination, and the acceleration of vesting for certain options assumed in the Gen-Probe acquisition related to employees who were terminated in connection with the Company’s restructuring action to consolidate its Diagnostics operations. The original terms of the stock options assumed in the Gen-Probe acquisition provided for acceleration upon a change-in-control and termination within 18 months of the change-in-control. At September 28, 2013, there was $30.0 million and $41.6 million of unrecognized compensation expense related to stock options and RSUs, respectively, to be recognized over a weighted average period of 2.7 years and 2.6 years, respectively.
	Share Based Payment Activity
	The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 28, 2013:
			Number			Weighted-			Weighted-			Aggregate
			of Shares			Average			Average			Intrinsic
						Exercise Price			Remaining			Value
									Contractual Life
									in Years
	Options outstanding at September 29, 2012			18,039		$	17.4			4.4		$	78,962
	Granted			2,640			20.29
	Cancelled/forfeited			(1,021	)		20.04
	Exercised			(4,786	)		13.71					$	37,609
	Options outstanding at September 28, 2013			14,872		$	18.92			3.9		$	54,956
	Options exercisable at September 28, 2013			7,472		$	20.28			2.9		$	29,438
	Options vested and expected to vest at September 28, 2013 (1)			13,780		$	19			3.8		$	51,656
	-1	This represents the number of vested stock options as of September 28, 2013 plus the unvested outstanding options at September 28, 2013 expected to vest in the future, adjusted for estimated forfeitures.
	During fiscal 2012 and 2011, the total intrinsic value of options exercised (i.e., the difference between the market price on the date of exercise and the price paid by the employee to exercise the options) was $20.4 million and $12.3 million, respectively.
	A summary of the Company’s RSU activity during the year ended September 28, 2013 is presented below:
	Non-vested Shares		Number of			Weighted-Average
			Shares			Grant-Date  Fair
						Value
	Non-vested at September 29, 2012			3,580		$	16.45
	Granted			1,995			19.94
	Vested			(1,711	)		15.98
	Forfeited			(405	)		18.11
	Non-vested at September 28, 2013			3,459		$	18.51
The number of RSUs vested includes shares withheld on behalf of employees to satisfy minimum statutory tax withholding requirements. The Company pays the minimum statutory tax withholding requirement on behalf of its employees. During fiscal 2013, 2012 and 2011 the total fair value of RSUs vested was $27.3 million, $15.7 million and $43.2 million, respectively.
Employee Stock Purchase Plan
The Company’s 2008 Employee Stock Purchase Plan (the “2008 ESPP”) met the criteria set forth in ASC 718’s definition of a non-compensatory plan and did not give rise to stock-based compensation expense. The ESPP plan period was semi-annual and allowed participants to purchase the Company’s common stock at 95% of the closing price of the stock on the last day of the plan period. A total of 0.4 million shares were authorized for issuance under the 2008 ESPP.
In March 2012, the Company’s stockholders approved the Hologic, Inc. 2012 Employee Stock Purchase Plan (“2012 ESPP”), which provides for the granting of up to 2.5 million shares of the Company’s common stock to eligible employees, and resulted in the termination of the 2008 ESPP. The 2012 ESPP plan period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lower of (i) the market value per share of the common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. The first plan period began on July 1, 2012. Stock-based compensation expense in fiscal 2013 and 2012 was $2.7 million and $0.4 million, respectively.
The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions:
		September 28,			September 29,
		2013			2012
Assumptions:
Risk-free interest rates			0.11	%		0.16	%
Expected life (in years)			0.5			0.5
Expected volatility			32	%		35	%
Dividend yield			—			—

Profit_Sharing_401k_Plan

Profit Sharing 401(k) Plan	12 Months Ended
	Sep. 28, 2013
Text Block [Abstract]	'
Profit Sharing 401(k) Plan	'
	10	Profit Sharing 401(k) Plan
	The Company has a qualified profit sharing plan covering substantially all of its employees. Contributions to the plan are at the discretion of the Company’s Board of Directors. The Company made contributions of $13.4 million, $9.4 million and $6.4 million for fiscal 2013, 2012 and 2011, respectively.

Nonqualified_Deferred_Compensa

Nonqualified Deferred Compensation Plan	12 Months Ended
	Sep. 28, 2013
Text Block [Abstract]	'
Nonqualified Deferred Compensation Plan	'
	11	Nonqualified Deferred Compensation Plan
	Effective March 15, 2006, the Company adopted its DCP to provide non-qualified retirement benefits to a select group of executive officers, senior management and highly compensated employees of the Company. Eligible employees may elect to contribute up to 75% of their annual base salary and 100% of their annual bonus to the DCP and such employee contributions are 100% vested. In addition, the Company may elect to make annual discretionary contributions on behalf of participants in the DCP. Each Company contribution is subject to a three-year vesting schedule, such that each contribution vests one third annually. Employee contributions are recorded within accrued expenses.
	Upon enrollment into the DCP, employees make investment elections for both their voluntary contributions and discretionary contributions, if any, made by the Company. Earnings and losses on contributions based on these investment elections are recorded as a component of compensation expense in the period earned.
	Annually the Compensation Committee of the Board of Directors has approved a discretionary cash contribution to the DCP for each year. Discretionary contributions by the Company to the DCP are held in a Rabbi Trust. The Company is recording compensation expense for the DCP discretionary contributions ratably over the three-year vesting period of each annual contribution, and totaled $2.7 million, $2.6 million and $2.6 million in fiscal 2013, 2012 and 2011, respectively. The full amount of the discretionary contribution, net of forfeitures, along with employee deferrals and the deferred compensation liability assumed from the Gen-Probe acquisition is recorded within accrued expenses and totaled $38.6 million and $32.1 million at September 28, 2013 and September 29, 2012, respectively.
	The Company has purchased Company-owned group life insurance contracts, in which both voluntary and discretionary Company DCP contributions are invested, to partially fund payment of the Company’s obligation to the DCP participants. The total amount invested at September 28, 2013 and September 29, 2012 was $33.9 million and $26.0 million. The values of these life insurance contracts are recorded in other long-term assets. Changes in the cash surrender value of life insurance contracts, which were not significant in fiscal 2013, 2012 and 2011, are recorded within other income (expense), net. In addition, the Company has an additional $6.9 million and $7.0 million of investments in mutual funds to fund the DCP at September 28, 2013 and September 29, 2012, respectively. The mutual funds are classified as trading and the gains and losses in these investments are recorded in other income (expense), net.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 28, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	12	Commitments and Contingencies
	Contingent Earn-Out Payments
	In connection with its acquisitions, the Company has incurred the obligation to make contingent earn-out payments tied to performance criteria, principally revenue growth of the acquired businesses over a specified period. In certain circumstances, such as a change of control, a portion of these obligations may be accelerated. In addition, contractual provisions relating to these contingent earn-out obligations may include covenants to operate the acquired businesses in a manner that may not otherwise be most advantageous to the Company.
	These contingent consideration arrangements are recorded as either additional purchase price or compensation expense if continuing employment is required to receive such payments. Pursuant to ASC 805, contingent consideration that is deemed to be part of the purchase price is recorded as a liability based on the estimated fair value of the consideration the Company expects to pay to the former shareholders of the acquired business as of the acquisition date. This liability is re-measured each reporting period with the changes in fair value recorded through a separate line item within the Company’s Consolidated Statements of Operations. Increases or decreases in the fair value of contingent consideration liabilities can result from accretion of the liability for the passage of time, changes in discount rates, and changes in the timing, probabilities and amount of revenue estimates. Contingent consideration arrangements from acquisitions completed prior to the adoption of ASC 805 (effective in fiscal 2010 for the Company) that are deemed to be part of the purchase price of the acquisition are not subject to the fair value measurement requirements of ASC 805 and are recorded as additional purchase price to goodwill.
	In connection with the acquisition of Adiana, Inc., the Company was obligated to the former Adiana shareholders to make contingent payments tied to the achievement of milestones. The milestone payments included potential contingent payments of up to $155.0 million based on worldwide sales of the Adiana Permanent Contraception System in the first year following FDA approval and on annual incremental sales growth thereafter through December 31, 2012. FDA approval of the Adiana system occurred on July 6, 2009, and the Company began accruing contingent consideration in the fourth quarter of fiscal 2009 based on the defined percentage of worldwide sales of the product. Since this contingent consideration obligation arose from an acquisition prior to the adoption of ASC 805, the amounts accrued were recorded as additional purchase price to goodwill. The purchase agreement included an indemnification provision that provided for the reimbursement of qualifying legal expenses and liabilities associated with legal claims against the Adiana products and intellectual property, and the Company had the right to offset contingent consideration payments to the Adiana shareholders with these qualifying legal costs. The Company made payments of $16.8 million, $8.8 million and $19.7 million in fiscal 2013, 2012 and 2011, respectively, to the former Adiana shareholders, net of amounts withheld for the legal indemnification provision. No additional amounts are due to the former shareholders of Adiana. The Company had been in litigation with Conceptus regarding certain intellectual property matters related to the Adiana system, and to the extent available, the Company has been recording legal fees related to the Conceptus litigation matter as a reduction to the accrued contingent consideration payments. On October 17, 2011, the jury returned a verdict in the Conceptus litigation matter (see below) in favor of Conceptus awarding damages in the amount of $18.8 million. On April 29, 2012, the Company entered into a license and settlement agreement with Conceptus in which Conceptus agreed to forgo the $18.8 million jury award in consideration of the Company agreeing to a permanent injunction against the manufacture, sale and distribution of the Adiana product. As of the end of the second quarter of fiscal 2012, the Company decided to discontinue the manufacture, marketing and sales of the Adiana system.
	The Company also had contingent consideration obligations related to its Sentinelle Medical and Interlace acquisitions. Pursuant to ASC 805, contingent consideration pertaining to Sentinelle Medical and Interlace was required to be recorded as a liability at fair value and all amounts pertaining to these obligations had been paid as of September 28, 2013, excluding certain amounts withheld for legal indemnification provisions. Contingent consideration pertaining to TCT and Healthcome was contingent upon future employment and was being recorded as compensation expense as it is earned. As of September 28, 2013, the Company had accrued $31.7 million and $3.4 million, respectively, for these obligations. For additional information pertaining to the Interlace, TCT and Healthcome acquisitions, contingent consideration terms and the assumptions used to fair value contingent consideration, refer to Note 3.
	A summary of amounts recorded to the Consolidated Statement of Operations is as follows:
	Statement of Operations Line Item – Fiscal 2013		Interlace			TCT		Total
	Contingent consideration—compensation expense		$	—		$	80,010	$	80,010
	Contingent consideration—fair value adjustments			11,310			—		11,310
			$	11,310		$	80,010	$	91,320
	Statement of Operations Line Item – Fiscal 2012		Sentinelle			Interlace		TCT		Healthcome		Total
			Medical
	Contingent consideration—compensation expense		$	—		$	—	$	75,459	$	5,572	$	81,031
	Contingent consideration—fair value adjustments			(3,364	)		41,830		—		—		38,466
			$	(3,364	)	$	41,830	$	75,459	$	5,572	$	119,497
	Statement of Operations Line Item – Fiscal 2011		Sentinelle			Interlace		TCT		Healthcome		Total
			Medical
	Contingent consideration—compensation expense		$	—		$	2,102	$	17,581	$	319	$	20,002
	Contingent consideration—fair value adjustments			(14,328	)		6,312		—		—		(8,016	)
			$	(14,328	)	$	8,414	$	17,581	$	319	$	11,986
	Finance Lease Obligations
	The Company has two non-cancelable lease agreements for buildings that are primarily used for manufacturing. The Company was responsible for a significant portion of the construction costs, and in accordance with ASC 840, Leases, Subsection 40-15-5, the Company was deemed to be the owner of the respective buildings during the construction period. The Company has recorded the fair market value of the buildings and land aggregating $28.3 million within property and equipment on its Consolidated Balance Sheets. At September 28, 2013, the Company has recorded $2.8 million in accrued expenses and $33.5 million in other long-term liabilities related to these obligations. The term of the leases is for a period of approximately 10 and 12 years, respectively, with the option to extend for two consecutive 5-year terms. At the completion of the construction period, the Company reviewed the lease for potential sale-leaseback treatment in accordance with ASC 840, Subsection 40, Sale-Leaseback Transactions. Based on its analysis, the Company determined that the lease did not qualify for sale-leaseback treatment. Therefore, the building, leasehold improvements and associated liabilities remain on the Company’s financial statements throughout the lease term, and the building and leasehold improvements are being depreciated on a straight line basis over their estimated useful lives of 35 years.
	Future minimum lease payments, including principal and interest, under these leases were as follows at September 28, 2013:
	Fiscal 2014		$	2,822
	Fiscal 2015			2,883
	Fiscal 2016			3,054
	Fiscal 2017			3,119
	Fiscal 2018			2,925
	Thereafter			300
	Total minimum payments			15,103
	Less-amount representing interest			(3,607	)
	Total		$	11,496
	Non-cancelable Purchase and Royalty Commitments
	The Company has certain non-cancelable purchase obligations primarily related to inventory purchases and Diagnostics instruments, primarily the Tigris and Panther systems, and to a lesser extent other operating expense commitments. These obligations are not recorded in the Consolidated Balance Sheet. For reasons of quality assurance, sole source availability or cost effectiveness, certain key components and raw materials and instruments are available only from a sole supplier and the Company has certain long-term supply contracts to assure continuity of supply. At September 28, 2013, purchase commitments were as follows:
	Fiscal 2014		$	55,935
	Fiscal 2015			12,684
	Fiscal 2016			3,000
	Fiscal 2017			3,000
	Fiscal 2018			750
	Thereafter			—
	Total		$	75,369
	In addition, as part of its R&D efforts assumed from the Gen-Probe acquisition, the Company has various license agreements with unrelated parties that provide the Company with rights to develop and market products using certain technology and patent rights. Terms of the various license agreements require the Company to pay royalties ranging from less than 1% up to 35% of future sales on products using the specified technology. Such agreements generally provide for a term that commences upon execution and continues until expiration of the last patent covering the licensed technology. Under certain of these agreements, the Company is required to pay minimum annual royalty payments. In addition, the Company has commitments for minimum payments under certain collaboration agreements. At September 28, 2013, minimum commitments for these agreements were as follows:
	Fiscal 2014		$	1,301
	Fiscal 2015			810
	Fiscal 2016			1,426
	Fiscal 2017			745
	Fiscal 2018			560
	Thereafter			4,450
	Total		$	9,292
	Concentration of Suppliers
	The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event.
	Operating Leases
	The Company conducts its operations in leased facilities under operating lease agreements that expire through fiscal 2035. Substantially all of the Company’s lease agreements require the Company to maintain the facilities during the term of the lease and to pay all taxes, insurance, utilities and other costs associated with those facilities. The Company makes customary representations and warranties and agrees to certain financial covenants and indemnities. In the event the Company defaults on a lease, typically the landlord may terminate the lease, accelerate payments and collect liquidated damages. As of September 28, 2013, the Company was not in default of any covenants contained in its lease agreements. Certain of the Company’s lease agreements provide for renewal options. Such renewal options are at rates similar to the current rates under the agreements.
	Future minimum lease payments under all of the Company’s operating leases at September 28, 2013 are as follows:
	Fiscal 2014		$	20,689
	Fiscal 2015			16,192
	Fiscal 2016			13,600
	Fiscal 2017			12,249
	Fiscal 2018			10,830
	Thereafter			32,712
	Total		$	106,272
	Rent expense, net of sublease income, was $19.9 million, $18.3 million, and $19.3 million for fiscal 2013, 2012 and 2011, respectively.
The Company subleases a portion of a building it owns and some of its facilities and has received aggregate rental income of $1.9 million, $3.2 million and $3.5 million in fiscal 2013, 2012 and 2011, respectively, which has been recorded as an offset to rent expense. The future minimum annual rental income payments under these sublease agreements at September 28, 2013 are as follows:
Fiscal 2014		$	1,551
Fiscal 2015			913
Fiscal 2016			20
Fiscal 2017			15
Total		$	2,499
Workforce Subject to Collective Bargaining Agreements
Approximately 164 of Hitec Imaging’s German employees are represented by a Worker’s Council and are subject to collective bargaining agreements. None of the Company’s other employees are subject to a collective bargaining agreement.

Litigation_and_Other_Matters

Litigation and Other Matters	12 Months Ended
	Sep. 28, 2013
Text Block [Abstract]	'
Litigation and Other Matters	'
	13	Litigation and Other Matters
	On June 9, 2010, Smith & Nephew, Inc. (“Smith & Nephew”) filed suit against Interlace, which the Company acquired on January 6, 2011, in the United States District Court for the District of Massachusetts. The complaint alleged that the Interlace MyoSure hysteroscopic tissue removal device infringes U.S. patent 7,226,459. The complaint sought permanent injunctive relief and unspecified damages. A Markman hearing on claim construction was held on November 9, 2010, and a ruling was issued on April 21, 2011. On November 22, 2011, Smith & Nephew filed suit against the Company in the United States District Court for the District of Massachusetts. The complaint alleged that use of the MyoSure hysteroscopic tissue removal system infringed U.S. patent 8,061,359. The complaint sought preliminary and permanent injunctive relief and unspecified damages. On January 17, 2012, at a hearing on Smith & Nephew’s motion for preliminary injunction with respect to the suit filed on November 22, 2011, the judge did not issue an injunction, consolidated the two matters for a single trial and scheduled a trial on the merits for both claims for June 25, 2012. A case management conference held on February 14, 2012 resulted in the trial being rescheduled to begin on August 20, 2012. On March 15, 2012, the Court heard summary judgment arguments related to the ‘459 patent and claim construction arguments related to the ‘359 patent. On June 5, 2012, the Court denied Smith & Nephew’s request for summary judgment of infringement, denied Smith & Nephew’s request for preliminary injunction, and denied the Company’s requests for summary judgment of non-infringement and invalidity. On September 4, 2012, following a two week trial, the jury returned a verdict of infringement of both the ‘459 and ‘359 patents and assessed damages of $4.0 million. A bench trial regarding the Company’s assertion of inequitable conduct on the part of Smith & Nephew with regard to the ‘359 patent was held on December 9, 2012 and oral arguments on the issue of inequitable conduct were presented on February 27, 2013. On June 27, 2013, the Court denied the Company’s motions related to inequitable conduct and allowed Smith & Nephew’s request for injunction, but ordered that enforcement of the injunction be stayed until final resolution, including appeal, of the current re-examinations of both patents at the United States Patent and Trademark Office (“USPTO”). The Court’s decision to stay the injunction is based in part on the fact that the USPTO has taken up a re-examination of both the ‘359 and ‘459 patents. The Court also rejected the jury’s damage award and has ordered the parties to identify a mechanism for resolving the damages issue. On September 12, 2013, a status conference was held and the Court invited the parties to submit briefs on the relevance of recent activity in the re-examinations at the USPTO. A hearing on this topic was held on October 29, 2013, and the parties await the Court’s ruling. The Company intends to file post-trial motions seeking to reverse the jury’s verdict. At this time, based on available information regarding this litigation, the Company believes a loss is not probable and is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses, beyond the pending jury verdict. The purchase and sale agreement associated with the acquisition of Interlace includes an indemnification provision that provides for the reimbursement of a portion of legal expenses in defense of the Interlace intellectual property. The Company has the right to collect certain amounts set aside in escrow and, as applicable, offset contingent consideration payments of qualifying legal costs. The Company is recording legal fees incurred for this suit pursuant to the indemnification provision on a net basis within accrued expenses.
	On February 10, 2012, C.R. Bard (as acquirer of SenoRx, Inc., “SenoRx”) filed suit against the Company in the United States District Court for the District of Delaware. In the complaint, it is alleged that the Company’s MammoSite product infringes SenoRx’s U.S. Patents 8,079,946 and 8,075,469. The complaint seeks permanent injunctive relief and unspecified damages. On September 4, 2012 and October 16, 2012, the USPTO took up a re-examination of the ‘946 and ‘469 patents, respectively. With respect to the ‘469 patent, all previously issued claims were rejected and with respect to the ‘946 patent all but four claims were rejected. Based on the actions of the USPTO, the Company filed a motion seeking to stay all litigation proceedings pending the outcome of the USPTO’s re-examination of both patents in suit. On January 11, 2013, the Court issued an order denying the stay. On February 1, 2013, the Court entered a stay of the proceedings in the case to allow the parties to pursue settlement discussions. On May 31, 2013, the parties settled the litigation and entered into an agreement under which the Company purchased SenoRx’s Contura assets.
	On March 6, 2012, Enzo Life Sciences, Inc. (“Enzo”) filed suit against the Company in the United States District Court for the District of Delaware. In the complaint, it is alleged that certain of the Company’s molecular diagnostics products, including without limitation products based on its proprietary Invader chemistry, such as Cervista HPV HR and Cervista HPV 16/18, infringe Enzo’s U.S. Patent 6,992,180. The complaint seeks permanent injunctive relief and unspecified damages. The Company was formally served with the complaint on July 3, 2012, and a trial is tentatively scheduled for the spring of 2015. In January 2012, Enzo filed suit against Gen-Probe in the United States District Court for the District of Delaware. In that complaint, it is alleged that certain of Gen-Probe’s diagnostics products, including products that incorporate Gen-Probe’s patented HPA technology, such as the Aptima Combo 2 and Aptima HPV assays, infringe Enzo’s U.S. Patent 6,992,180. On September 30, 2013, Enzo amended its list of accused products to include Prodesse, Torch Oligos, PACE and Procleix assays. The complaint seeks permanent injunctive relief and unspecified damages, and a trial is tentatively scheduled for the spring of 2015. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
	Prior to its acquisition by Hologic, Gen-Probe had patent infringement claims against Becton Dickinson (“BD”) seeking monetary damages and injunctive relief. The parties settled this litigation in the first quarter of fiscal 2013. Under the terms of the settlement, BD made a one-time payment and was granted a non-exclusive royalty-bearing license to the asserted intellectual property.
	A number of lawsuits were filed against the Company, Gen-Probe, and Gen-Probe’s board of directors related to the Company’s acquisition of Gen-Probe. These include: (1) Teamsters Local Union No. 727 Pension Fund v. Gen-Probe Incorporated, et al. (Superior Court of the State of California for the County of San Diego); (2) Timothy Coyne v. Gen-Probe Incorporated, et al. (Delaware Court of Chancery); and (3) Douglas R. Klein v. John W. Brown, et al. (Delaware Court of Chancery). The two Delaware actions were consolidated into a single action titled: In re: Gen-Probe Shareholders Litigation. The suits were filed after the announcement of the Company’s acquisition of Gen-Probe on April 30, 2012 as putative stockholder class actions. Each of the actions asserted similar claims alleging that Gen-Probe’s board of directors failed to adequately discharge its fiduciary duties to shareholders by failing to adequately value Gen-Probe’s shares and ensure that Gen-Probe’s shareholders received adequate consideration in the Company’s acquisition of Gen-Probe, that the acquisition was the product of a flawed sales process, and that the Company aided and abetted the alleged breach of fiduciary duty. The plaintiffs sought, among other things, a preliminary and permanent injunction enjoining the Company’s acquisition of Gen-Probe and rescinding the transaction or any part thereof that had been implemented. On May 24, 2012, the plaintiffs in the Delaware action filed an amended complaint, adding allegations that the disclosures in Gen-Probe’s preliminary proxy statement were inadequate. The defendants in the Delaware action answered the complaint on June 4, 2012. On July 18, 2012, the parties in the Delaware action entered into a memorandum of understanding regarding a proposed settlement of the litigation. The proposed settlement was conditioned upon, among other things, the execution of an appropriate stipulation of settlement, consummation of the merger, and final approval of the proposed settlement by the Delaware Court of Chancery. On April 10, 2013, the Delaware Court of Chancery approved the proposed settlement and the consolidated action in Delaware was dismissed with prejudice. On July 9, 2012, the plaintiffs in the California action filed a motion for voluntary dismissal without prejudice. On July 12, 2012, the California Superior Court entered an order dismissing the California complaint without prejudice.
	On October 29, 2013, the Interlace stockholder representatives filed a complaint in the Delaware Court of Chancery alleging breach of contract for issues related to the payment of contingent consideration under the Interlace Merger and Acquisition Agreement, and are seeking $14.7 million in additional payments. The Company believes that Interlace has been paid all amounts due under the Merger Agreement and their claims are without merit. Hologic is currently preparing its answer to the complaint. At this time, the Company is unable to reasonably assess the ultimate outcome of this case.
	The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those described above there are no other proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Novartis_Collaboration_Agreeme

Novartis Collaboration Agreement	12 Months Ended
	Sep. 28, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Novartis Collaboration Agreement	'
	14	Novartis Collaboration Agreement
	The Company, through its Gen-Probe acquisition, has a collaboration agreement with Novartis. In July 2009, Gen-Probe entered into an amended and restated collaboration agreement with Novartis, which sets forth the current terms of the parties’ blood screening collaboration. The term of the collaboration agreement runs through June 30, 2025, unless terminated earlier pursuant to its terms under certain specified conditions. Under the collaboration agreement, the Company manufactures blood screening products, while Novartis is responsible for marketing, sales and service of those products, which Novartis sells under its trademarks.
	Under the amended agreement, the Company is entitled to recover 50% of its manufacturing costs incurred in connection with the collaboration and will receive a percentage of the blood screening assay revenue generated under the collaboration. The Company’s share of revenue from any assay that includes a test for HCV is as follows: 2012-2013, 47%; 2014, 48%; and 2015 through the remainder of the term of the collaboration, 50%. The Company’s share of blood screening assay revenue, from any assay that does not test for HCV is 50%. Novartis is obligated to purchase all of the quantities of assays specified on a 90-day demand forecast, due 90 days prior to the date Novartis intends to take delivery, and certain quantities specified on a rolling 12-month forecast.
	Novartis has also agreed to provide certain funding to customize the Company’s Panther instrument for use in the blood screening market and to pay the Company a milestone payment upon the earlier of certain regulatory approvals or the first commercial sale of the Panther instrument for use in the blood screening field. The parties will share equally in any profit attributable to Novartis’ sale or lease of Panther instruments under the collaboration.
	The Company recognizes product revenue, and collaborative research and license revenue, which is included within services and other revenues, under this collaboration agreement. The Company recognized $197.9 million under this collaboration agreement in fiscal 2013.
	On November 11, 2013, Novartis announced that it is selling its blood screening business to Grifols. Grifols had previously been a customer of the Company’s collaboration with Novartis. As announced, the transaction is subject to customary regulatory approvals and is expected to close in the first half of calendar 2014. Upon the consummation of the acquisition, Grifols will replace Novartis as the Company’s blood screening collaborator.

Business_Segments_and_Geograph

Business Segments and Geographic Information	12 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]	'
Business Segments and Geographic Information	'
	15	Business Segments and Geographic Information
	The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company’s chief operating decision maker is the chief executive officer, and the Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the product are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income (loss) adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset impairment charges, contingent consideration charges, restructuring and divestiture charges, and other one-time or unusual items, and related tax effects.
	Identifiable assets for the four principal operating segments consist of inventories, intangible assets including goodwill, and property and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company presents all other identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal 2013, 2012 and 2011 is as follows:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Total revenues:
	Diagnostics		$	1,189,819		$	718,064		$	571,263
	Breast Health			905,076			875,771			825,551
	GYN Surgical			307,139			313,089			300,538
	Skeletal Health			90,245			95,728			91,997
			$	2,492,279		$	2,002,652		$	1,789,349
	Operating (loss) income:
	Diagnostics		$	(1,149,132	)	$	(32,787	)	$	170,693
	Breast Health			216,049			186,106			187,970
	GYN Surgical			19,664			(51,892	)		3,623
	Skeletal Health			7,137			12,290			12,159
			$	(906,282	)	$	113,717		$	374,445
	Depreciation and amortization:
	Diagnostics		$	369,818		$	197,274		$	165,065
	Breast Health			40,098			42,924			45,165
	GYN Surgical			105,233			103,781			92,587
	Skeletal Health			861			1,772			1,919
			$	516,010		$	345,751		$	304,736
	Capital expenditures:
	Diagnostics		$	51,653		$	44,939		$	23,128
	Breast Health			16,386			9,821			12,069
	GYN Surgical			9,145			12,233			11,467
	Skeletal Health			562			171			2,198
	Corporate			12,384			11,609			6,801
			$	90,130		$	78,773		$	55,663
	Identifiable assets:
	Diagnostics		$	4,667,942		$	6,170,553		$	1,770,107
	Breast Health			932,206			956,134			985,196
	GYN Surgical			1,849,518			1,944,386			2,049,682
	Skeletal Health			33,508			32,778			31,864
	Corporate			1,517,649			1,373,257			1,171,931
			$	9,000,823		$	10,477,108		$	6,008,780
	In fiscal 2013, the Company recorded a goodwill impairment charge of $1.1 billion related to its Molecular Diagnostics reporting unit, which is in its Diagnostics segment. In fiscal 2012, the Company recorded a goodwill impairment charge of $5.8 million related to its MammoSite reporting unit, which is in its Breast Health segment.
	Products sold by the Company internationally are manufactured at domestic and international locations. Transfers between the Company and its subsidiaries are generally recorded at amounts similar to the prices paid by unaffiliated foreign dealers. All intercompany profit is eliminated in consolidation.
	The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location, and internationally totaled $621.7 million, $511.2 million and $414.4 million in fiscal 2013, 2012 and 2011, respectively. The Company’s sales in Europe are predominantly derived from Germany, the United Kingdom and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.
	Revenues by geography as a percentage of total revenues are as follows:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	United States			75	%		74	%		77	%
	Europe			13	%		12	%		14	%
	Asia-Pacific			8	%		8	%		6	%
	All others			4	%		6	%		3	%
				100	%		100	%		100	%
	The Company’s property and equipment, net are geographically located as follows:
			September 28,			September 29,			September 24,
			2013			2012			2011
	United States		$	386,049		$	405,141		$	165,177
	Costa Rica			29,258			30,452			34,107
	Europe			61,472			59,927			29,591
	All other countries			14,749			12,478			9,791
			$	491,528		$	507,998		$	238,666

Accrued_Expenses_and_Other_Lon

Accrued Expenses and Other Long-Term Liabilities	12 Months Ended
	Sep. 28, 2013
Text Block [Abstract]	'
Accrued Expenses and Other Long-Term Liabilities	'
	16	Accrued Expenses and Other Long-Term Liabilities
	Accrued expenses and other long-term liabilities consist of the following:
			September 28,		September 29,
			2013		2012
	Accrued Expenses
	Compensation and employee benefits		$	127,464	$	143,673
	Contingent consideration			38,138		143,881
	Income and other taxes			17,369		12,424
	Interest			23,747		18,422
	Other			65,213		53,981
			$	271,931	$	372,381
			September 28,		September 29,
			2013		2012
	Other Long-Term Liabilities
	Accrued lease obligation—long-term		$	33,494	$	33,256
	Reserve for income tax uncertainties			115,395		38,518
	Pension liabilities			9,691		9,397
	Other			9,464		17,079
			$	168,044	$	98,250

Pension_and_Other_Employee_Ben

Pension and Other Employee Benefits	12 Months Ended
	Sep. 28, 2013
Compensation And Retirement Disclosure [Abstract]	'
Pension and Other Employee Benefits	'
	17	Pension and Other Employee Benefits
	The Company has certain defined benefit pension plans covering the employees of its Hitec Imaging German subsidiary (the “Pension Benefits”). As of September 28, 2013 and September 29, 2012, the Company’s pension liability is $10.1 million and $9.7 million, respectively, which is primarily recorded as a component of long-term liabilities in the Consolidated Balance Sheets. Under German law, there are no rules governing investment or statutory supervision of the pension plan. As such, there is no minimum funding requirement imposed on employers. Pension benefits are safeguarded by the Pension Guaranty Fund, a form of compulsory reinsurance that guarantees an employee will receive vested pension benefits in the event of insolvency.
	The tables below provide a reconciliation of benefit obligations, plan assets, funded status, and related actuarial assumptions of the Company’s German Pension Benefits.
	Change in Benefit Obligation		Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Benefit obligation at beginning of year		$	(9,744	)	$	(8,064	)	$	(9,093	)
	Service cost			—			—			—
	Interest cost			(354	)		(391	)		(389	)
	Plan participants’ contributions			—			—			—
	Actuarial gain (loss)			188			(2,002	)		1,092
	Foreign exchange (loss) gain			(503	)		383			(5	)
	Benefits paid			348			330			331
	Benefit obligation at end of year			(10,065	)		(9,744	)		(8,064	)
	Plan assets			—			—			—
	Funded status		$	(10,065	)	$	(9,744	)	$	(8,064	)
	The tables below outline the components of the net periodic benefit cost and related actuarial assumptions of the Company’s German Pension Benefits plan.
	Components of Net Periodic Benefit Cost		Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Service cost		$	—		$	—		$	—
	Interest cost			354			391			389
	Expected return on plan assets			—			—			—
	Amortization of prior service cost			—			—			—
	Recognized net actuarial gain			—			(38	)		—
	Net periodic benefit cost		$	354		$	353		$	389
	Weighted-Average Net Periodic Benefit Cost Assumptions		2013			2012			2011
	Discount rate			3.6	%		3.52	%		5.2	%
	Expected return on plan assets			0	%		0	%		0	%
	Rate of compensation increase			0	%		0	%		0	%
	The projected benefit obligation for the German Pension Benefits plans with projected benefit obligations in excess of plan assets was $10.1 million and $9.7 million at September 28, 2013 and September 29, 2012, respectively, and the accumulated benefit obligation for the German Pension Benefits plans was $10.1 million and $9.7 million at September 28, 2013 and September 29, 2012, respectively.
	The Company is also obligated to pay long-term service award benefits. The projected benefit obligation for long-term service awards was $0.6 million at September 28, 2013 and September 29, 2012, respectively.
	The table below reflects the total Pension Benefits expected to be paid each fiscal year as of September 28, 2013:
	2014		$	374
	2015			399
	2016			415
	2017			428
	2018			441
	2019 to 2023			2,404
	The Company also maintains additional contractual pension benefits for its top German executive officers in the form of a defined contribution plan. These contributions were insignificant in fiscal 2013, 2012 and 2011.

Quarterly_Statement_of_Operati

Quarterly Statement of Operations Information (Unaudited)	12 Months Ended
	Sep. 28, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Statement of Operations Information (Unaudited)	'
	18	Quarterly Statement of Operations Information (Unaudited)
	The following table presents a summary of quarterly results of operations for fiscal 2013 and 2012:
			2013
			First		Second			Third			Fourth
			Quarter		Quarter			Quarter			Quarter
	Total revenue		$	631,362	$	612,663		$	626,136		$	622,118
	Gross profit			281,673		279,326			309,758			290,631
	Net income (loss) (1)			3,118		(51,104	)		(10,950	)		(1,113,902	)
	Diluted net income (loss) per common share		$	0.01	$	(0.19	)	$	(0.04	)	$	(4.11	)
			2012
			First		Second			Third			Fourth
			Quarter		Quarter			Quarter			Quarter(3)
	Total revenue		$	472,711	$	471,165		$	470,228		$	588,548
	Gross profit			249,370		226,110			244,640			274,317
	Net income (loss) (2)			20,812		(40,273	)		23,594			(77,767	)
	Diluted net income (loss) per common share		$	0.08	$	(0.15	)	$	0.09		$	(0.29	)
	-1	Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.
	-2	Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.
	-3	The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

Supplemental_Guarantor_Condens

Supplemental Guarantor Condensed Consolidating Financials	12 Months Ended
	Sep. 28, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Supplemental Guarantor Condensed Consolidating Financials	'
	19	Supplemental Guarantor Condensed Consolidating Financials
	The Company’s Senior Notes issued in August 2012 are fully and unconditionally and jointly and severally guaranteed by Hologic, Inc. (“Parent/Issuer”) and certain of its domestic subsidiaries, which are 100% owned by Hologic, Inc. The following represents the supplemental condensed financial information of Hologic, Inc. and its guarantor and non-guarantor subsidiaries as of September 28, 2013 and September 29, 2012 and for each of the three years ended September 28, 2013, September 29, 2012 and September 24, 2011.
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Year Ended September 28, 2013
			Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
						Subsidiaries			Subsidiaries
	Revenues:
	Product sales		$	416,871		$	1,569,605		$	477,251		$	(362,836	)	$	2,100,891
	Service and other revenues			326,656			71,718			46,635			(53,621	)		391,388
				743,527			1,641,323			523,886			(416,457	)		2,492,279
	Costs and expenses:
	Cost of product sales			212,899			636,679			331,418			(362,836	)		818,160
	Cost of product sales—amortization of intangible assets			5,346			298,426			4,123			—			307,895
	Cost of product sales—impairment of intangible assets			—			—			1,714			—			1,714
	Cost of service and other revenues			157,391			59,943			39,409			(53,621	)		203,122
	Research and development			29,829			157,846			9,971			—			197,646
	Selling and marketing			77,982			176,041			88,114			—			342,137
	General and administrative			68,883			123,985			34,812			—			227,680
	Amortization of intangible assets			3,013			104,778			4,806			—			112,597
	Contingent consideration—compensation expense			80,010			—			—			—			80,010
	Contingent consideration—fair value adjustments			11,310			—			—			—			11,310
	Impairment of goodwill			—			1,117,369			—			—			1,117,369
	Gain on sale of intellectual property			—			(53,884	)		—			—			(53,884	)
	Restructuring and divestiture charges			4,889			21,647			6,269			—			32,805
				651,552			2,642,830			520,636			(416,457	)		3,398,561
	Income (loss) from operations			91,975			(1,001,507	)		3,250			—			(906,282	)
	Interest income			590			251			461			—			1,302
	Interest expense			(277,771	)		(1,260	)		(2,044	)		—			(281,075	)
	Debt extinguishment loss			(9,209	)		—									(9,209	)
	Other income (expense), net			193,254			(184,564	)		(6,387	)		—			2,303
	Loss before income taxes			(1,161	)		(1,187,080	)		(4,720	)		—			(1,192,961	)
	Provision (benefit) for income taxes			30,794			(59,260	)		8,343			—			(20,123	)
	Equity in earnings (losses) of subsidiaries			(1,140,883	)		13,887			—			1,126,996			—
	Net (loss) income		$	(1,172,838	)	$	(1,113,933	)	$	(13,063	)	$	1,126,996		$	(1,172,838	)
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Year Ended September 29, 2012
			Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
						Subsidiaries			Subsidiaries
	Revenues:
	Product sales		$	420,960		$	1,089,580		$	431,689		$	(284,501	)	$	1,657,728
	Service and other revenues			307,097			63,313			32,555			(58,041	)		344,924
				728,057			1,152,893			464,244			(342,542	)		2,002,652
	Costs and expenses:
	Cost of product sales			211,665			396,747			292,928			(284,501	)		616,839
	Cost of product sales—amortization of intangible assets			5,226			192,377			4,261			—			201,864
	Cost of service and other revenues			155,555			61,285			30,713			(58,041	)		189,512
	Research and development			28,065			91,199			11,698			—			130,962
	Selling and marketing			67,874			170,422			84,018			—			322,314
	General and administrative			52,568			136,243			31,683			—			220,494
	Amortization of intangible assets			2,709			64,357			4,970			—			72,036
	Contingent consideration—compensation expense			81,031			—			—			—			81,031
	Contingent consideration—fair value adjustments			38,466			—			—			—			38,466
	Impairment of goodwill			—			5,826			—			—			5,826
	Gain on sale of intellectual property			—			(12,424	)		—			—			(12,424	)
	Acquired in-process research and development			—			4,500			—			—			4,500
	Restructuring and divestiture charges			49			16,185			1,281			—			17,515
				643,208			1,126,717			461,552			(342,542	)		1,888,935
	Income from operations			84,849			26,176			2,692			—			113,717
	Interest income			1,950			159			840			(609	)		2,340
	Interest expense			(137,190	)		(1,158	)		(1,939	)		—			(140,287	)
	Debt extinguishment loss			(42,347	)		—			—			—			(42,347	)
	Other income, net			3,051			699			557			609			4,916
	(Loss) income before income taxes			(89,687	)		25,876			2,150			—			(61,661	)
Provision (benefit) for income taxes			9,721			(3,094	)		5,346			—			11,973
Equity in earnings (losses) of subsidiaries			25,774			8,415			556			(34,745	)		—
Net (loss) income		$	(73,634	)	$	37,385		$	(2,640	)	$	(34,745	)	$	(73,634	)
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
For the Year Ended September 24, 2011
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
Revenues:
Product sales		$	411,309		$	964,584		$	376,575		$	(274,128	)	$	1,478,340
Service and other revenues			274,197			59,026			27,862			(50,076	)		311,009
			685,506			1,023,610			404,437			(324,204	)		1,789,349
Costs and expenses:
Cost of product sales			200,912			309,910			284,495			(274,128	)		521,189
Cost of product sales—amortization of intangible assets			5,224			167,341			4,891			—			177,456
Cost of service and other revenues			143,399			51,888			22,312			(50,076	)		167,523
Research and development			28,959			75,437			12,300			—			116,696
Selling and marketing			60,496			166,458			59,776			—			286,730
General and administrative			50,180			86,270			23,113			—			159,563
Amortization of intangible assets			2,709			54,851			774			—			58,334
Contingent consideration—compensation expense			20,002			—			—			—			20,002
Contingent consideration—fair value adjustments			(8,016	)		—			—			—			(8,016	)
Gain on sale of intellectual property			—			(84,502	)		—			—			(84,502	)
Restructuring and divestiture charges			(353	)		—			282			—			(71	)
			503,512			827,653			407,943			(324,204	)		1,414,904
Income (loss) from operations			181,994			195,957			(3,506	)		—			374,445
Interest income			1,495			1			364			—			1,860
Interest expense			(111,583	)		(1,357	)		(1,906	)		—			(114,846	)
Debt extinguishment loss			(29,891	)		—			—			—			(29,891	)
Other (expense) income, net			(1,706	)		(2,661	)		185			—			(4,182	)
Income (loss) before income taxes			40,309			191,940			(4,863	)		—			227,386
Provision (benefit) for income taxes			10,976			60,163			(903	)		—			70,236
Equity in earnings (losses) of subsidiaries			127,817			8,699			319			(136,835	)		—
Net income (loss)		$	157,150		$	140,476		$	(3,641	)	$	(136,835	)	$	157,150
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
For the Year Ended September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
Net (loss) income		$	(1,172,838	)	$	(1,113,933	)	$	(13,063	)	$	1,126,996		$	(1,172,838	)
Foreign currency cumulative translation adjustment			—			658			715			—			1,373
Adjustment to minimum pension liability, net of taxes			—			—			134			—			134
Unrealized gain on available-for-sale securities			—			12,094			—			—			12,094
Comprehensive (loss) income		$	(1,172,838	)	$	(1,101,181	)	$	(12,214	)	$	1,126,996		$	(1,159,237	)
For the Year Ended September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
Net (loss) income		$	(73,634	)	$	37,385		$	(2,640	)	$	(34,745	)	$	(73,634	)
Foreign currency translation adjustment			836			(527	)		5,908			—			6,217
Adjustment to minimum pension liability, net of taxes			—			—			(1,484	)		—			(1,484	)
Unrealized gain on available-for-sale security, net of taxes			—			62			—			—			62
Other comprehensive income (loss)			836			(465	)		4,424			—			4,795
Comprehensive (loss) income		$	(72,798	)	$	36,920		$	1,784		$	(34,745	)	$	(68,839	)
For the Year Ended September 24, 2011
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
Net income (loss)		$	157,150		$	140,476		$	(3,641	)	$	(136,835	)	$	157,150
Foreign currency translation adjustment			(1,127	)		(121	)		2,336			—			1,088
Adjustment to minimum pension liability, net of taxes			—			—			764			—			764
Other comprehensive income (loss)			(1,127	)		(121	)		3,100			—			1,852
Comprehensive income (loss)		$	156,023		$	140,355		$	(541	)	$	(136,835	)	$	159,002
SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
ASSETS
Current assets:
Cash and cash equivalents		$	321,523		$	387,422		$	113,545		$	—		$	822,490
Restricted cash			—			—			6,914			—			6,914
Accounts receivable, net			126,036			174,433			108,804			—			409,273
Inventories			81,924			146,678			60,761			—			289,363
Deferred income tax assets			—			19,042			494			(19,536	)		—
Prepaid income taxes			47,131			2,303			—			(4,689	)		44,745
Prepaid expenses and other current assets			16,246			21,112			11,003			—			48,361
Other current assets—assets held for sale			—			—			2,997			—			2,997
Intercompany receivables			—			2,442,502			31,949			(2,474,451	)		—
Total current assets			592,860			3,193,492			336,467			(2,498,676	)		1,624,143
Property, plant and equipment, net			29,313			356,736			105,479			—			491,528
Intangible assets, net			19,925			3,784,987			101,810			—			3,906,722
Goodwill			283,038			2,390,939			140,551			—			2,814,528
Other assets			103,548			58,446			1,908			—			163,902
Investment in subsidiaries			8,667,620			129,016			2,296			(8,798,932	)		—
Total assets		$	9,696,304		$	9,913,616		$	688,511		$	(11,297,608	)	$	9,000,823
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt		$	563,812		$	—		$	—		$	—		$	563,812
Accounts payable			27,865			42,661			10,008			—			80,534
Accrued expenses			152,950			79,629			44,319			(4,967	)		271,931
Deferred revenue			93,306			7,958			31,055			—			132,319
Deferred income tax liabilities			59,346			—			—			(19,536	)		39,810
Intercompany payables			2,418,089			—			64,411			(2,482,500	)		—
Total current liabilities			3,315,368			130,248			149,793			(2,507,003	)		1,088,406
Long-term debt, net of current portion			4,242,098			—			—			—			4,242,098
Deferred income tax liabilities			89,085			1,435,522			10,699			—			1,535,306
Deferred service obligations—long-term			11,251			3,511			12,864			(2,170	)		25,456
Other long-term liabilities			96,990			37,598			33,456			—			168,044
Total stockholders’ equity			1,941,512			8,306,737			481,699			(8,788,435	)		1,941,513
Total liabilities and stockholders’ equity		$	9,696,304		$	9,913,616		$	688,511		$	(11,297,608	)	$	9,000,823
SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
ASSETS
Current assets:
Cash and cash equivalents		$	210,028		$	269,416		$	80,986		$	—		$	560,430
Restricted cash			—			—			5,696			—			5,696
Accounts receivable, net			101,538			192,349			115,522			(76	)		409,333
Inventories			74,500			223,043			70,180			(532	)		367,191
Deferred income tax assets			13,578			—			617			(2,480	)		11,715
Prepaid income taxes			20,805			48,429			611			—			69,845
Prepaid expenses and other current assets			18,817			12,816			12,668			—			44,301
Intercompany receivables			—			2,094,017			55,761			(2,149,778	)		—
Other current assets—assets held-for-sale			—			67,878			26,625			—			94,503
Total current assets			439,266			2,907,948			368,666			(2,152,866	)		1,563,014
Property, plant and equipment, net			26,928			379,702			101,368			—			507,998
Intangible assets, net			24,034			4,162,930			114,286			—			4,301,250
Goodwill			279,956			3,522,474			140,349			—			3,942,779
Other assets			112,339			49,036			2,406			(1,714	)		162,067
Investments in subsidiaries			9,782,940			101,615			2,296			(9,886,851	)		—
Total assets		$	10,665,463		$	11,123,705		$	729,371		$	(12,041,431	)	$	10,477,108
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt		$	64,435		$	—		$	—		$	—		$	64,435
Accounts payable			29,847			43,339			14,037			—			87,223
Accrued expenses			238,387			86,566			50,052			(2,624	)		372,381
Deferred revenue			92,234			10,307			27,147			—			129,688
Intercompany payables			2,085,339			6,655			66,335			(2,158,329	)		—
Other current liabilities—assets held-for-sale			—			5,520			2,102			—			7,622
Total current liabilities			2,510,242			152,387			159,673			(2,160,953	)		661,349
Long-term debt, net of current portion			4,971,179			—			—			—			4,971,179
Deferred income tax liabilities			180,916			1,581,833			8,836			—			1,771,585
Deferred service obligations—long-term			7,536			1,160			7,601			(2,583	)		13,714
Other long-term liabilities			34,559			30,587			34,504			(1,400	)		98,250
Total stockholders’ equity			2,961,031			9,357,738			518,757			(9,876,495	)		2,961,031
Total liabilities and stockholders’ equity		$	10,665,463		$	11,123,705		$	729,371		$	(12,041,431	)	$	10,477,108
CONSOLIDATING STATEMENT OF CASH FLOWS
For the Year Ended September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by operating activities		$	237,354		$	205,034		$	51,434		$	—		$	493,822
INVESTING ACTIVITIES
Acquisition of businesses			(6,053	)		—			(220	)		—			(6,273	)
Payment of additional acquisition consideration			(16,808	)		—			—			—			(16,808	)
Proceeds from sale of business, net of cash transferred			—			83,646			1,488			—			85,134
Purchase of property and equipment			(15,480	)		(23,345	)		(10,129	)		—			(48,954	)
Increase in equipment under customer usage agreements			(464	)		(24,443	)		(16,269	)		—			(41,176	)
Purchase of insurance contracts			(4,000	)		—			—			—			(4,000	)
Proceeds from sale of intellectual property			—			60,000			—			—			60,000
Purchase of cost-method investments			(3,500	)		(225	)		—			—			(3,725	)
Sale of cost-method investments			2,104			—			—			—			2,104
Investment in subsdiaries			—			1,812			(1,812	)		—			—
Increase in other assets			(2,097	)		(4,209	)		(1,242	)		—			(7,548	)
Net cash provided by (used in) investing activities			(46,298	)		93,236			(28,184	)		—			18,754
FINANCING ACTIVITIES
Repayment of long-term debt			(265,000	)		—			—			—			(265,000	)
Payment of debt issuance cost			(9,440	)											(9,440	)
Payment of contingent consideration			(42,958	)		—			—			—			(42,958	)
Deferred acquisition consideration			(1,655	)		—			—			—			(1,655	)
Net proceeds from issuance of common stock pursuant to employee stock plans			75,100			—			—			—			75,100
Excess tax benefit related to equity awards			7,439			—			—			—			7,439
Payment of employee restricted stock minimum tax withholdings			(12,256	)		—			—			—			(12,256	)
Intercompany dividend			169,209			(175,000	)		5,791			—			—
Net cash used in (provided by) financing activities			(79,561	)		(175,000	)		5,791			—			(248,770	)
Effect of exchange rate changes on cash and cash equivalents			—			(5,264	)		3,518			—			(1,746	)
Net increase in cash and cash equivalents			111,495			118,006			32,559			—			262,060
Cash and cash equivalents, beginning of period			210,028			269,416			80,986			—			560,430
Cash and cash equivalents, end of period		$	321,523		$	387,422		$	113,545		$	—		$	822,490
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
For the Year Ended September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by operating activities		$	236,063		$	104,167		$	29,992		$	—		$	370,222
INVESTING ACTIVITIES
Acquisition of business, net of cash acquired			(3,971,970	)		196,771			12,796			—			(3,762,403	)
Payment of additional acquisition consideration			(8,858	)		—			(926	)		—			(9,784	)
Proceeds from sale of intellectual property			—			12,500			—			—			12,500
Purchase of property and equipment			(13,247	)		(12,444	)		(7,458	)		—			(33,149	)
Increase in equipment under customer usage agreements			—			(30,735	)		(14,889	)		—			(45,624	)
Acquisition of in-process research and development assets			(4,500	)		—			—			—			(4,500	)
Purchase of cost-method investment			—			(250	)		—			—			(250	)
Increase in other assets			(558	)		(2,230	)		(4,786	)		—			(7,574	)
Net cash (used in) provided by investing activities			(3,999,133	)		163,612			(15,263	)		—			(3,850,784	)
FINANCING ACTIVITIES
Proceeds from long-term debt			3,476,320			—			—			—			3,476,320
Payment of debt issuance costs			(81,408	)		—			—			—			(81,408	)
Payment of contingent consideration			(51,680	)		—			—			—			(51,680	)
Payment of deferred acquisition consideration			(44,223	)		—			—			—			(44,223	)
Net proceeds from issuance of common stock pursuant to employee stock plans			28,594			—			—			—			28,594
Excess tax benefit related to equity awards			6,206			—			—			—			6,206
Payment of employee restricted stock minimum tax withholdings			(5,710	)		—			—			—			(5,710	)
Net cash provided by financing activities			3,328,099			—			—			—			3,328,099
Effect of exchange rate changes on cash and cash equivalents			302			1,637			(1,378	)		—			561
Net (decrease) increase in cash and cash equivalents			(434,669	)		269,416			13,351			—			(151,902	)
Cash and cash equivalents, beginning of period			644,697			—			67,635			—			712,332
Cash and cash equivalents, end of period		$	210,028		$	269,416		$	80,986		$	—		$	560,430
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
For the Year Ended September 24, 2011
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by operating activities		$	431,353		$	9,040		$	15,631		$	—		$	456,024
INVESTING ACTIVITIES
Acquisition of business, net of cash acquired			(240,917	)		9,070			33,103			—			(198,744	)
Payment of additional acquisition consideration			(19,660	)		—			—			—			(19,660	)
Divestiture activities, net of cash transferred			1,138			—			1,129			—			2,267
Proceeds from sale of intellectual property			750			12,500			—			—			13,250
Purchase of property and equipment			(11,512	)		(8,646	)		(7,627	)		—			(27,785	)
Increase in equipment under customer usage agreements			(1,121	)		(17,361	)		(9,396	)		—			(27,878	)
Purchase of licensed technology and other intangible assets			—			(3,021	)		—			—			(3,021	)
Purchase of insurance contracts			(5,322	)		—			—			—			(5,322	)
Purchase of cost-method investment			—			(99	)		—			—			(99	)
Increase in restricted cash			—			—			405			—			405
Net cash (used in) provided by investing activities			(276,644	)		(7,557	)		17,614			—			(266,587	)
FINANCING ACTIVITIES
Repayment of long-term debt and notes payable			—			(1,362	)		—			—			(1,362	)
Payment of debt issuance costs			(5,327	)		—			—			—			(5,327	)
Payment of contingent consideration			(4,294	)		—			—			—			(4,294	)
Net proceeds from issuance of common stock pursuant to employee stock plans			25,404			—			—			—			25,404
Excess tax benefit related to equity awards			3,652			—			—			—			3,652
Payment of employee restricted stock minimum tax withholdings			(10,399	)		—			—			—			(10,399	)
Net cash provided by (used in) financing activities			9,036			(1,362	)		—			—			7,674
Effect of exchange rate changes on cash and cash equivalents			48			(121	)		(331	)		—			(404	)
Net increase in cash and cash equivalents			163,793			—			32,914			—			196,707
Cash and cash equivalents, beginning of period			480,904			—			34,721			—			515,625
Cash and cash equivalents, end of period		$	644,697		$	—		$	67,635		$	—		$	712,332

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 28, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on the last Saturday in September. Fiscal 2013, 2012 and 2011 ended on September 28, 2013, September 29, 2012 and September 24, 2011, respectively. Fiscal 2013 and 2011 were 52 week fiscal periods and fiscal 2012 was a 53 week fiscal period.
Management's Estimates and Uncertainties	'
	Management’s Estimates and Uncertainties
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple element arrangements, allowance for doubtful accounts, the net realizable value of inventory, estimated fair value of cost-method equity investments, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, stock-based compensation, contingent liabilities, tax reserves, deferred tax rates and recoverability of the Company’s net deferred tax assets and related valuation allowance.
	Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
	The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, dependence on third-party reimbursements to support the markets of the Company’s products, early stage of development of certain products, rapid technological changes, recoverability of long-lived assets (including intangible assets and goodwill), competition, stability of world financial markets, ability to obtain regulatory approvals, changes in the regulatory environment, limited number of suppliers, customer concentration, integration of acquisitions, substantial indebtedness, government regulations, future sales or issuances of its common stock, management of international activities, protection of proprietary rights, patent and other litigation and dependence on key individuals.
Cash Equivalents	'
	Cash Equivalents
	Cash equivalents are highly liquid investments with insignificant interest rate risk and maturities of three months or less at the time of acquisition. At September 28, 2013 and September 29, 2012, the Company’s cash equivalents consisted of money market accounts.
Marketable Securities	'
	Marketable Securities
	The Company’s marketable securities are comprised of an equity security and mutual funds. The equity security is an investment in the common stock of a publicly traded company, and the mutual funds are used to fund the deferred compensation plan the Company assumed in its Gen-Probe acquisition. The equity security is classified as available-for-sale and is recorded at fair value with the unrealized gains or losses, net of tax, within accumulated other comprehensive income (loss), which is a component of stockholders’ equity. The mutual funds are classified as trading and are recorded at fair value with unrealized gains and losses recorded in other income (expense), net in the Consolidated Statements of Operations.
	The Company periodically reviews its marketable equity securities classified as available-for-sale for other-than-temporary declines in fair value below cost basis, or whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The determination that a decline is other-than-temporary is, in part, subjective and influenced by many factors. When assessing marketable equity securities for other-than-temporary declines in value, the Company considers factors including: the significance of the decline in value compared to the cost basis; the underlying factors contributing to a decline in the prices of the security; how long the market value of the investment has been less than its cost basis; any market conditions that impact liquidity; the views of external investment analysts; the financial condition and near-term prospects of the investee; any news or financial information that has been released specific to the investee; and the outlook for the overall industry in which the investee operates. No such other-than-temporary impairment appeared to exist at September 28, 2013.
	The Company has one investment in a publicly traded security and the following reconciles its cost basis to its fair market value as of September 28, 2013 and September 29, 2012. There were no marketable securities at September 24, 2011.
		Cost			Gross Unrealized			Gross Unrealized			Fair Value
					Gains			Losses
	Equity security as of September 28, 2013	$	5,931		$	12,156		$	—		$	18,087
	Equity security as of September 29, 2012	$	5,931		$	98		$	—		$	6,029
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, cost-method equity investments, and trade accounts receivable. The Company invests its cash and cash equivalents with high credit quality financial institutions.
	The Company’s customers are principally located in the United States, Europe and Asia. The Company performs ongoing credit evaluations of the financial condition of its customers and generally does not require collateral. Although the Company is directly affected by the overall financial condition of the healthcare industry, as well as global economic conditions, management does not believe significant credit risk exists as of September 28, 2013. The Company generally has not experienced any material losses related to receivables from individual customers or groups of customers in the healthcare industry. The Company maintains an allowance for doubtful accounts based on accounts past due and historical collection experience.
	There were no customers with balances greater than 10% of accounts receivable as of September 28, 2013 and September 29, 2012, or any customers that represented greater than 10% of consolidated revenues for fiscal years 2013, 2012 and 2011.
Supplemental Cash Flow Statement Information	'
	Supplemental Cash Flow Statement Information
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Cash paid during the period for income taxes	$	79,893		$	166,565		$	118,850
	Cash paid during the period for interest	$	192,794		$	55,045		$	36,268
	Non-Cash Investing Activities:
	Fair value of stock options assumed in the Gen-Probe acquisition	$	—		$	2,655		$	—
	Additional acquisition contingent consideration accrued	$	—		$	—		$	18,924
	Non-Cash Financing Activities:
	Fair value of contingent consideration at acquisition	$	525		$	—		$	86,600
	Deferred payments for acquisitions	$	—		$	1,655		$	47,258
Inventories	'
	Inventories
	Inventories are valued at the lower of cost or market on a first in, first out basis. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The valuation of inventory requires management to estimate excess and obsolete inventory. The Company employs a variety of methodologies to determine the net realizable value of its inventory. Provisions for excess and obsolete inventory are primarily based on management’s estimates of forecasted sales, usage levels and expiration dates as applicable for disposable products. A significant change in the timing or level of demand for the Company’s products as compared to forecasted amounts may result in recording additional provisions for excess and obsolete inventory in the future. The Company records provisions for excess and obsolete inventory as cost of product sales.
	Inventories consisted of the following:
		September 28,			September 29,
		2013			2012
	Raw materials	$	115,575		$	134,983
	Work-in-process		51,171			93,218
	Finished goods		122,617			138,990
		$	289,363		$	367,191
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment is recorded at cost less allowances for depreciation. The straight-line method of depreciation is used for all property and equipment. Repair and maintenance costs are expensed as incurred. Property, plant and equipment are depreciated over the following estimated useful lives:
	Asset Classification	Estimated Useful Life
	Building and improvements	35–40 years
	Equipment and software	3–10 years
	Equipment under customer usage agreements	3–8 years
	Furniture and fixtures	5–7 years
	Leasehold improvements	Shorter of the Original Term of Lease
		or Estimated Useful Life
	Equipment under customer usage agreements primarily consists of diagnostic instrumentation and medical imaging equipment located at customer sites but owned by the Company. Generally, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of disposables. The depreciation costs associated with equipment under customer usage agreements are charged to cost of product sales over the estimated useful life of the equipment. The costs to maintain the equipment in the field are charged to cost of product sales as incurred.
Long-Lived Assets	'
	Long-Lived Assets
	The Company reviews its long-lived assets, which includes property and equipment and identifiable intangible assets (see below for discussion of intangible assets), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with ASC 360-10-35-15, Property, Plant and Equipment—Impairment or Disposal of Long-Lived Assets (ASC 360). Recoverability of these assets is evaluated by comparing the carrying value of the assets to the undiscounted cash flows estimated to be generated by those assets over their remaining economic life. If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are considered impaired. The impairment loss is measured by comparing the fair value of the assets to their carrying value. Fair value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique. At the end of the fourth quarter of fiscal 2013, the Company decided to transition certain of its placed equipment at customer sites to its Panther instrument, and as a result, the Company recorded a charge of $6.3 million to cost of product sales of which $3.7 million related to recording certain equipment at its fair value. At the end of the second quarter of fiscal 2012, the Company decided to cease manufacturing, marketing and selling its Adiana system, which was a product line within the Company’s GYN Surgical reporting segment, determining that the product was not financially viable and would not become so in the foreseeable future. As a result, in fiscal 2012, the Company recorded charges of $19.5 million of which $6.5 million was recorded within cost of product sales to write down certain manufacturing equipment and equipment placed at customer sites to its fair value that had no further utility. There were no significant impairment charges related to property and equipment in fiscal 2011.
Business Combinations and Acquisition of Intangible Assets	'
	Business Combinations and Acquisition of Intangible Assets
	The Company records tangible and intangible assets acquired in business combinations under the purchase method of accounting. The Company accounts for acquisitions in accordance with ASC 805, Business Combinations (ASC 805). Amounts paid for each acquisition are allocated to the assets acquired and liabilities assumed based on their fair values at the dates of acquisition. The Company allocates the purchase price in excess of the fair value of the net tangible assets acquired to identifiable intangible assets, including purchased research and development, based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. The use of alternative valuation assumptions, including estimated cash flows and discount rates, and alternative useful life assumptions could result in different purchase price allocations and intangible asset amortization expense in current and future periods.
	The valuation of purchased in-process research and development (“IPR&D”) as part of a business combination represents the estimated fair value at the dates of acquisition related to in-process projects. The Company’s IPR&D represents the value of in-process projects that have not yet reached technological feasibility and have no alternative future uses as of the date of acquisition. As required by ASC 805, the Company capitalizes the value attributable to these in-process projects at the time of the acquisition. Subsequent to acquisition, IPR&D assets are evaluated as an indefinite-lived intangible asset, consistent with the accounting treatment of goodwill. No additional amounts are capitalized and once the project is completed the asset is amortized over its estimated useful life. If the projects are not successful or completed in a timely manner, the Company may not realize the financial benefits expected for these projects or for the acquisitions as a whole and impairments may result.
	The Company uses the income approach to determine the fair value of its developed technology and IPR&D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. Regarding the value of the in-process projects, the Company considers, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of core technologies and other acquired assets, the expected introduction date and the estimated useful life of the technology. The Company bases the discount rate used to arrive at a present value as of the date of acquisition on the time value of money and medical technology investment risk factors. The Company believes that the estimated developed technology and IPR&D amounts represent the fair value at the date of acquisition and do not exceed the amount a third-party would pay for the assets.
	The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.
Intangible Assets and Goodwill	'
	Intangible Assets and Goodwill
	Intangible Assets
	Intangible assets are initially recorded at fair value and stated net of accumulated amortization and impairments. The Company amortizes its intangible assets that have finite lives using either the straight-line method, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized. Amortization is recorded over the estimated useful lives ranging from 2 to 30 years. The Company evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, the Company estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, the Company uses market participant assumptions pursuant to ASC 820, Fair Value Measurements.
	Indefinite lived intangible assets, such as IPR&D assets, are required to be tested for impairment annually, or more frequently if indicators of impairment are present. The Company’s annual impairment test date is as of the first day of its fourth quarter. The Company tested its IPR&D assets utilizing the DCF model and determined they were not impaired.
	During the fourth quarter of fiscal 2013, as a result of the Company’s conclusion that its Molecular Diagnostics reporting unit was impaired (as discussed below), the Company performed an impairment test of this reporting unit’s long-lived assets as of the first day of the fourth quarter. The impairment evaluation was based on expectations of future undiscounted cash flows compared to the carrying value of the long-lived assets. The Company’s cash flow estimates were based upon future projected net cash flows derived from the Company-wide annual planning process, which were used for the annual goodwill impairment test discussed below. Based on this analysis, the Molecular Diagnostics long-lived assets were deemed to not be impaired. The Company believes its procedures for estimating future cash flows were reasonable and consistent with market conditions at the time of estimation.
	During the third quarter of fiscal 2013, the Company determined that a certain developed technology asset was impaired and recorded a $1.7 million charge to cost of product sales to record the asset at its estimated fair value.
	During the fourth quarter of fiscal 2012 in connection with the company-wide annual budgeting and strategic planning process, the Company determined that indicators of impairment existed in its MammoSite reporting unit, which is included in the Breast Health reportable segment. The impairment indicators were due to a reduction in the Company’s revenue projections and long-term growth rates as a result of the continuing deterioration of the brachytherapy market and competition from existing technologies. The Company’s cash flow estimates were based upon future projected net cash flows derived from the company-wide annual planning process. The analysis indicated that MammoSite’s long-lived assets were recoverable based on the undiscounted cash flows over the remaining life of the predominant long-lived asset. The Company believes that its procedures for estimating future cash flows were reasonable and consistent with market conditions at the measurement date.
	During the fourth quarter of fiscal 2012, the Company acquired certain in-process research and development assets that were not part of a business acquisition. Since these assets had no alternative future use, the Company recorded in-process research and development charges of $4.5 million in fiscal 2012.
	Intangible assets consist of the following:
		September 28, 2013						September 29, 2012
	Description	Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Value						Value
	Developed technology	$	4,008,947		$	1,094,435		$	3,784,689		$	788,274
	In-process research and development		24,000			—			227,000			—
	Customer relationships and contracts		1,101,870			296,481			1,097,842			205,612
	Trade names		238,103			81,844			240,092			60,318
	Patents		13,026			8,495			11,417			7,906
	Business licenses		2,647			616			2,577			344
	Non-compete agreements		296			296			310			223
		$	5,388,889		$	1,482,167		$	5,363,927		$	1,062,677
	In fiscal 2012, as a result of its acquisition of Gen-Probe, the Company recorded $1.57 billion of developed technology assets and $227.0 million of IPR&D assets related to six projects. In fiscal 2013, management revised its valuation analysis for a correction of projected revenues expected from certain of the development projects which increased the value of the developed technology assets to $1.7 billion and reduced the IPR&D assets to $117.0 million. The Company recorded this adjustment in fiscal 2013 and determined it was immaterial to its financial statements.
	Subsequent to the acquisition and through September 2013, the Company has received FDA approval for three projects with an aggregate value of $93.0 million. Amortization of these assets begins once FDA approval is received. The other projects are expected to be completed over the next four years with a total cost of approximately $49.0 million to complete such projects. Given the uncertainties inherent with product development and commercial introduction, there can be no assurance that any of the Company’s product development efforts will be successful, completed on a timely basis or within budget, if at all.
	During 2012, the in-process research and development project from the Healthcome acquisition was completed and transferred to developed technology.
	Amortization expense related to developed technology and patents is classified as a component of cost of product sales—amortization of intangible assets in the Consolidated Statements of Operations. Amortization expense related to customer relationships and contracts, trade names, business licenses and non-competes is classified as a component of amortization of intangible assets in the Consolidated Statements of Operations.
	The estimated amortization expense at September 28, 2013 for each of the five succeeding fiscal years is as follows:
	Fiscal 2014	$	417,053
	Fiscal 2015		402,177
	Fiscal 2016		388,370
	Fiscal 2017		379,260
	Fiscal 2018		368,505
	Goodwill
	In accordance with ASC 350, Intangibles—Goodwill and Other (ASC 350), the Company tests goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that could indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate, operational performance of the business or key personnel, and an adverse action or assessment by a regulator.
	In performing the impairment test, the Company utilizes the two-step approach prescribed under ASC 350. The first step requires a comparison of the carrying value of each reporting unit to its estimated fair value. To estimate the fair value of its reporting units for Step 1, the Company primarily utilizes the income approach. The income approach is based on a discounted cash flow analysis (“DCF”) and calculates the fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting the after-tax cash flows to a present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company’s most recent budget and for years beyond the budget, the Company’s estimates are based on assumed growth rates. The Company believes its assumptions are consistent with the plans and estimates used to manage the underlying businesses. The discount rates, which are intended to reflect the risks inherent in future cash flow projections, used in the DCF are based on estimates of the weighted-average cost of capital (“WACC”) of market participants relative to each respective reporting unit. The market approach considers comparable market data based on multiples of revenue or earnings before interest, taxes, depreciation and amortization (“EBITDA”) and is primarily used as a corroborative analysis to the results of the DCF. The Company believes its assumptions used to determine the fair value of its respective reporting units are reasonable. If different assumptions were used, particularly with respect to forecasted cash flows, terminal values, WACCs, or market multiples, different estimates of fair value may result and there could be the potential that an impairment charge could result. Actual operating results and the related cash flows of the reporting units could differ from the estimated operating results and related cash flows.
	If the carrying value of a reporting unit exceeds its estimated fair value, the Company is required to perform the second step of the goodwill impairment test to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of a reporting unit’s goodwill to its carrying value. The implied fair value of goodwill is derived by performing a hypothetical purchase price allocation for each reporting unit as of the measurement date and allocating the reporting unit’s estimated fair value to its assets and liabilities. The residual amount from performing this allocation represents the implied fair value of goodwill. To the extent this amount is below the carrying value of goodwill, an impairment charge is recorded.
	The Company conducted its fiscal 2013 annual impairment test on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 30, 2013, and ultimately used the fair value determined by the DCF in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, market multiples and discount rates as of the measurement date. As a result of completing Step 1, all of the Company’s reporting units, except for its Molecular Diagnostics reporting unit, which is within the Company’s Diagnostics segment, had fair values exceeding their carrying values, and as such, Step 2 of the impairment test was not required for those reporting units. For illustrative purposes, had the fair value of each of the reporting units that passed Step 1 been lower by 10%, all of the remaining reporting units would have still passed Step 1 of the goodwill impairment test. Since, the fair value of the reporting units was determined by use of the DCF, and the key assumptions that drive the fair value in this model are the WACC, terminal values, growth rates, and the amount and timing of expected future cash flows, significant judgment is applied in determining fair value. If the current economic environment were to deteriorate, this would likely result in a higher WACC because market participants would require a higher rate of return. In the DCF as the WACC increases, the fair value decreases. The other significant factor in the DCF is the Company’s projected financial information (i.e., amount and timing of expected future cash flows and growth rates) and if these assumptions were to be adversely impacted; this could result in a reduction of the fair values of these reporting units.
	In connection with its company-wide annual budgeting and strategic planning process performed in the fourth quarter of fiscal 2013, the Company performed a full re-evaluation of its existing product development efforts and cost structure. As a result, the Company reduced its short term and long term revenue forecasts and determined that indicators of impairment existed in its Molecular Diagnostics reporting unit. The Molecular Diagnostics reporting unit is primarily comprised of the Company’s Aptima business acquired in the Gen-Probe acquisition and the molecular diagnostics business acquired in the Third Wave acquisition. The updated forecast, which reflects recent pricing pressures, is now lower, and the current projections for revenue and profitability are lower than those expected at the time of the Gen-Probe acquisition. As a result, the fair value of this reporting unit was below its carrying value. The Company performed Step 2 of the impairment test, consistent with the procedures described above, and recorded a goodwill impairment charge of $1.1 billion. The basis of fair value for Molecular Diagnostics assumed the reporting unit would be purchased or sold in a taxable transaction, and the discount rate of 10% applied to the after-tax cash flows was relatively consistent with that used in the Company’s purchase accounting for the Gen-Probe acquisition. For illustrative purposes, had the fair value of Molecular Diagnostics been lower by 10%, the Company would have recorded an additional impairment charge of $195.4 million.
	At September 28, 2013, the Company believes that its other reporting units, with goodwill aggregating $2.5 billion were not at risk of failing Step 1 of the goodwill impairment test based on the current forecasts.
	The Company conducted its fiscal 2012 annual impairment test on the first day of the fourth quarter. The Company utilized DCF and market approaches to estimate the fair value of its reporting units as of June 24, 2012, and ultimately used the fair value determined by the DCF in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, market multiples and discount rates as of the measurement date. As a result of completing Step 1, all of the Company’s reporting units, except MammoSite, which is within the Company’s Breast Health segment, had fair values exceeding their carrying values, and as such, Step 2 of the impairment test was not required. MammoSite’s fair value declined from fiscal 2011 primarily due to a reduction in the Company’s revenue projections and long-term growth rates. The changes in MammoSite’s financial projections were a result of the continuing deterioration of the brachytherapy market, and competition from existing technologies. The Company performed the Step 2 analysis for MammoSite, consistent with the procedures described above, and recorded a $5.8 million goodwill impairment charge, resulting in no remaining goodwill for this reporting unit. For the Company’s other reporting units, if their respective fair values had been lower by 10%, each reporting unit would have still passed Step 1 of the goodwill impairment test.
	The Company previously had ongoing litigation with Conceptus regarding potential patent infringement of a Conceptus patent by the Company’s Adiana system. In the first quarter of fiscal 2012, the jury returned a verdict in favor of Conceptus and awarded Conceptus $18.8 million in damages. Post-trial motions were filed, and Conceptus sought to enjoin the Company from further sales of the Adiana system. At the time, the Company was appealing the jury verdict. The jury verdict in the first quarter of fiscal 2012 and related subsequent litigation status was an indicator of impairment for the Company’s GYN Surgical reporting unit, and a reduction in the anticipated future cash flows of the GYN Surgical reporting unit could result in a material impairment charge. Accordingly, the Company performed an interim goodwill impairment analysis of the GYN Surgical reporting unit as of December 24, 2011, updating its cash flow projections and related assumptions from its fiscal 2011 annual impairment test, including the WACC, under various potential scenarios. The Company applied the weighted average probability approach to these scenarios to estimate the fair value of the GYN Surgical reporting unit. As a result of completing Step 1, GYN Surgical’s fair value exceeded its carrying value. Therefore, Step 2 of the impairment test was not required as of December 24, 2011. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, probabilities of cash flow scenarios, and market multiples as of that measurement date.
	In connection with the Company’s decision to discontinue the Adiana product line in the second quarter of fiscal 2012 and the Company’s updated lower forecast for the GYN Surgical reporting unit, the Company concluded that potential goodwill impairment indicators existed as of March 24, 2012. As such, the Company performed another interim goodwill impairment test of the GYN Surgical reporting unit as of March 24, 2012, updating its cash flow projections and related assumptions from the analysis performed as of December 24, 2011. As a result of completing Step 1, GYN Surgical’s fair value exceeded its carrying value. Therefore, Step 2 of the impairment test was not required as of March 24, 2012. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows, probabilities of cash flow scenarios, and market multiples as of that measurement date.
	The Company conducted its fiscal 2011 annual impairment test on the first day of the fourth quarter, and as noted above used DCF and market approaches to estimate the fair value of its reporting units as of June 26, 2011, and ultimately used the fair value determined by the DCF in making its impairment test conclusions. The Company believes it used reasonable estimates and assumptions about future revenue, cost projections, cash flows and market multiples as of the measurement date. As a result of completing Step 1, all of the Company’s reporting units had fair values exceeding their carrying values, and as such, Step 2 of the impairment test was not required. For illustrative purposes, had the fair value of each reporting unit been lower by 10%, each reporting unit would have still passed Step 1 of the goodwill impairment test.
	The Company believes that the procedures performed and the estimates and assumptions used in the Step 1 and Step 2 analyses for each reporting unit are reasonable and in accordance with U.S. generally accepted accounting principles. The estimate of fair value requires significant judgment. The impairment testing process is subjective and requires judgment at many points throughout the analysis. If these estimates or their related assumptions change in the future, the Company may be required to record impairment charges for these assets not previously recorded.
	A rollforward of goodwill activity by reportable segment from September 29, 2012 to September 28, 2013 is as follows:
		Breast Health			Diagnostics			GYN Surgical			Skeletal Health			Total
	Balance at September 29, 2012	$	635,741		$	2,283,447		$	1,015,466		$	8,125		$	3,942,779
	Impairment charge		—			(1,117,369	)		—			—			(1,117,369	)
	Disposition of portion of a reporting unit		—			(1,257	)		—			—			(1,257	)
	Gen-Probe acquisition adjustments		—			4,226			—			—			4,226
	Gen-Probe valuation revision adjustment		—			(15,750	)		—			—			(15,750	)
	Chindex acquisition		1,798			—			—			—			1,798
	SenoRx acquisition		692			—			—			—			692
	Tax adjustments		—			(868	)		12			—			(856	)
	Foreign currency		(1,866	)		1,125			978			28			265
	Balance at September 28, 2013	$	636,365		$	1,153,554		$	1,016,456		$	8,153		$	2,814,528
	A rollforward of accumulated goodwill impairment losses by reportable segment from September 29, 2012 to September 28, 2013 is as follows:
		Breast Health			Diagnostics			GYN Surgical			Total
	Balance at September 29, 2012	$	348,419		$	908,349		$	1,165,804		$	2,422,572
	Impairment charge		—			1,117,369			—			1,117,369
	Balance at September 28, 2013	$	348,419		$	2,025,718		$	1,165,804		$	3,539,941
Other Assets	'
	Other Assets
	Other assets consist of the following:
		September 28,			September 29,
		2013			2012
	Other Assets
	Deferred financing costs	$	60,620		$	82,760
	Life insurance contracts		33,864			25,978
	Mutual funds		6,861			6,995
	Marketable security		18,087			6,029
	Manufacturing access fees		15,971			18,323
	Cost-method equity investments		12,558			15,976
	Other		15,941			6,006
		$	163,902		$	162,067
	Deferred financing costs are related to the Company’s convertible notes, Credit Agreement and Senior Notes (see Note 5 for further discussion). The Company amortizes amounts related to each debt issuance using the effective interest rate method over the period of earliest redemption or the term of such debt. Life insurance contracts were purchased in connection with the Company’s Nonqualified Deferred Compensation Plan (“DCP”) and are recorded at their cash surrender value (see Note 11 for further discussion). The marketable security represents a publicly traded equity security, and the mutual funds are the underlying investments related to the deferred compensation liabilities the Company assumed in connection with the Gen-Probe acquisition. The manufacturing access fees are related to a manufacturing supply and purchase agreement for our HPV products acquired in the Gen-Probe acquisition, and these fees are being amortized over the term of the agreement.
	The Company’s cost-method equity investments are generally carried at cost as the Company owns less than 20% of the voting equity and does not have the ability to exercise significant influence over these companies. The Company regularly evaluates the carrying value of its cost-method equity investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income (expense), net in the Consolidated Statements of Operations. During fiscal 2013 and 2011, the Company recorded other-than-temporary impairment charges of $6.4 million and $2.4 million, respectively, related to certain of its cost-method equity investments to adjust their carrying amounts to fair value. No such charges were recorded in fiscal 2012. In the third quarter of fiscal 2013, the Company sold one of its investments and recorded a gain of $2.0 million.
Research and Software Development Costs	'
	Research and Software Development Costs
	Costs incurred for the research and development of the Company’s products are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future by the Company for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. If the Company’s expectations change such that it does not expect it will need the goods to be delivered or the services to be rendered, capitalized nonrefundable advance payments are recorded to expense in that period.
	The Company accounts for the development costs of software embedded in the Company’s products in accordance with ASC 985, Software. Costs incurred in the research, design and development of software embedded in products to be sold to customers are charged to expense until technological feasibility of the ultimate product to be sold is established. The Company’s policy is that technological feasibility is achieved when a working model, with the key features and functions of the product, is available for customer testing. Software development costs incurred after the establishment of technological feasibility and until the product is available for general release are capitalized, provided recoverability is reasonably assured. Software development costs eligible for capitalization have not been significant to date.
Foreign Currency Translation	'
	Foreign Currency Translation
	The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, Foreign Currency Matters. The reporting currency for the Company is the U.S. dollar. With the exception of its Costa Rica subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in other income (expense), net in the Consolidated Statement of Operations. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in other income (expense), net in the Consolidated Statements of Operations and to date have not been material.
Accumulated Other Comprehensive Income	'
	Accumulated Other Comprehensive Income
	Other comprehensive income (loss) includes certain transactions that have generally been reported in the statement of stockholders’ equity. The components of accumulated other comprehensive income consisted of the following:
		September 28,			September 29,
		2013			2012
	Foreign currency translation adjustment	$	8,584		$	7,211
	Unrealized gains on available-for-sale securities		12,156			62
	Minimum pension liability, net of tax of $150 and $207, respectively		(349	)		(483	)
		$	20,391		$	6,790
Revenue Recognition	'
	Revenue Recognition
	The Company generates revenue from the sale of its products, primarily medical imaging systems and diagnostic and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems.
	The Company recognizes product revenue upon shipment provided that there is persuasive evidence of an arrangement, there are no uncertainties regarding acceptance, the sales price is fixed or determinable, no right of return exists and collection of the resulting receivable is reasonably assured. Generally, the Company’s product arrangements for capital equipment sales, primarily in its Breast Health and Skeletal Health reporting segments, are multiple-element arrangements, including services, such as installation and training, and multiple products. Based on the terms and conditions of the product arrangements, the Company believes that these services and undelivered products can be accounted for separately from the delivered product element as the Company’s delivered products have value to its customers on a stand-alone basis. Accordingly, revenue for services not yet performed at the time of product shipment are deferred and recognized as such services are performed. The relative selling price of any undelivered products is also deferred at the time of shipment and recognized as revenue when these products are delivered. There is no customer right of return in the Company’s sales agreements.
	Service revenues primarily consist of amounts recorded under service and maintenance contracts and repairs not covered under warranty, installation and training, and shipping and handling costs billed to customers. Service and maintenance contract revenues are recognized ratably over the term of the contract. Other service revenues are recognized as the services are performed.
	For revenue arrangements with multiple deliverables, the Company records revenue as separate units of accounting if the delivered items have value to the customer on a stand-alone basis, and if the arrangement includes a general right of return relative to the delivered items, the delivery or performance of the undelivered items is considered probable and substantially within the Company’s control. Some of the Company’s products have both software and non-software components that function together to deliver the product’s essential functionality. The Company determined that except for its computer-aided detection (“CAD”) products and C-View product, the software element in its other products is incidental in accordance with the software revenue recognition rules and are not within the scope of the software revenue recognition rules, ASC 985-605, Software—Revenue Recognition. The Company determined that given the significance of the software component’s functionality to its CAD and C-View systems, which are sold by its Breast Health segment, these products are within the scope of the software revenue recognition rules. The Company evaluated the appropriate revenue recognition treatment of its other hardware products, including its Dimensions digital mammography systems, which have both software and non-software components that function together to deliver the products’ essential functionality (i.e., it is a tangible product), and determined they are not within the scope of ASC 985-605.
	The Company is required to allocate revenue to its multiple element arrangements based on the relative fair value of each element’s selling price. The Company typically determines the selling price of its products based on its best estimate of selling prices (“ESP”) and services based on vendor-specific objective evidence of selling price (“VSOE”). The Company determines VSOE based on its normal pricing and discounting practices for the specific product or service when sold on a stand-alone basis. In determining VSOE, the Company’s policy requires a substantial majority of selling prices for a product or service to be within a reasonably narrow range. The Company also considers the class of customer, method of distribution, and the geographies into which its products and services are sold when determining VSOE. If VSOE cannot be established, which may occur in instances when a product or service has not been sold separately, stand-alone sales are too infrequent, or product pricing is not within a narrow range, the Company attempts to establish the selling price based on third-party evidence of selling price (“TPE”). TPE is determined based on competitor prices for similar deliverables when sold separately. When the Company cannot determine VSOE or TPE, it uses ESP in its allocation of arrangement consideration. The objective of ESP is to determine the price at which the Company would typically transact a stand-alone sale of the product or service. ESP is determined by considering a number of factors including Company pricing policies, internal costs and gross margin objectives, method of distribution, information gathered from experience in customer negotiations, market research and information, recent technological trends, competitive landscape and geographies.
	For those arrangements accounted for under the software revenue recognition rules, ASC 985-605 generally requires revenue earned on software arrangements involving multiple elements to be allocated to each element based on their relative VSOE of fair value. If VSOE does not exist for a delivered element, the residual method is applied in which the arrangement consideration is allocated to the undelivered elements based on their VSOE with the remaining consideration recognized as revenue for the delivered elements. For multiple-element software arrangements where VSOE of fair value of Post-Contract Customer Support (“PCS”) has been established, the Company recognizes revenue using the residual method at the time all other revenue recognition criteria have been met.
	As part of the Diagnostics segment and as a result of the Gen-Probe acquisition, the Company manufactures blood screening products according to demand schedules provided by its collaboration partner, Novartis Vaccines and Diagnostics, Inc. (“Novartis”). The Company’s agreement provides that it shares a portion of Novartis’s revenue from screening blood donations. Upon shipment to Novartis, the Company recognizes blood screening product sales at an agreed upon fixed transfer price, which is not refundable, and records the related cost of products sold. Based on the terms of the Company’s collaboration agreement with Novartis, the Company’s ultimate share of the net revenue from sales to the end user in excess of the transfer price revenues recognized is not known until it is reported to the Company by Novartis. On a monthly basis, Novartis reports net revenue generated during the prior month and remits an additional corresponding net payment to the Company, which is recorded as revenue at that time. This payment combined with the transfer price revenues previously recognized represents the Company’s ultimate share of net revenue under the agreement.
	The Company sells its instruments to Novartis for use in blood screening and records these instrument sales upon delivery since Novartis is responsible for the placement, maintenance and repair of the units with its customers. The Company also sells instruments to its clinical diagnostics customers and records sales of these instruments upon delivery and customer acceptance. For certain customers with non-standard payment terms, instrument sales are recorded based upon expected cash collection. Prior to delivery, each instrument is tested to meet the Company’s specifications and the specifications of the United States Food and Drug Administration (“FDA”), and is shipped fully assembled. Customer acceptance of the Company’s clinical diagnostic instrument systems requires installation and training by the Company’s technical service personnel. Installation is a standard process consisting principally of uncrating, calibrating and testing the instrumentation.
	Within its Diagnostics business, and to a lesser extent, its GYN Surgical business, the Company provides its instrumentation (for example, the ThinPrep Processor, ThinPrep Imaging System, and the Panther and Tigris systems) and certain other hardware to customers without requiring them to purchase the equipment or enter into a lease. The Company installs the instrumentation or equipment at the customer’s site and recovers the cost of providing the instrumentation or equipment in the amount it charges for its diagnostic tests, assays and other disposables. Customers enter into a customer usage agreement and typically commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is typically between three and five years. Revenue is recognized over the term of the customer usage agreement as tests, assays and other disposable products are shipped, either origin or destination. The depreciation costs associated with the instruments and equipment are charged to cost of product sales on a straight-line basis over the estimated life of the instrument or equipment. The costs to maintain instruments and equipment in the field are charged to cost of product sales as incurred.
Accounts Receivable and Reserves	'
	Accounts Receivable and Reserves
	The Company records reserves for doubtful accounts based upon a specific review of all outstanding invoices, known collection issues and historical experience. The Company regularly evaluates the collectability of its trade accounts receivables and performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and its assessment of the customer’s current credit worthiness.
	Accounts receivable reserve activity for fiscal 2013, 2012 and 2011 is as follows:
		Balance at			Charged to			Write-			Balance at
		Beginning			Costs and			offs and			End of
		of Period			Expenses			Payments			Period
	Period Ended:
	September 28, 2013	$	6,396		$	4,296		$	(1,894	)	$	8,798
	September 29, 2012	$	6,516		$	3,270		$	(3,390	)	$	6,396
	September 24, 2011	$	7,769		$	1,614		$	(2,867	)	$	6,516
Cost of Service and Other Revenues	'
	Cost of Service and Other Revenues
	Cost of service and other revenues primarily represents payroll and related costs associated with the Company’s professional services’ employees, consultants, infrastructure costs and overhead allocations, including depreciation and rent and materials consumed in providing the service.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for share-based payments in accordance with ASC 718, Stock Compensation (ASC 718). As such, all share-based payments to employees, including grants of stock options and restricted stock units and shares issued under the Company’s employee stock purchase plan, are recognized in the Consolidated Statements of Operations based on their fair values on the date of grant.
Net Income (Loss) Per Share	'
	Net Income (Loss) Per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares and the dilutive effect of potential future issuances of common stock from outstanding stock options, restricted stock units and convertible debt determined by applying the treasury stock method. In accordance with ASC 718, the assumed proceeds under the treasury stock method include the average unrecognized compensation expense of in-the-money stock options and restricted stock units. This results in the assumed buyback of additional shares, thereby reducing the dilutive impact of stock options.
	The Company applies the provisions of ASC 260, Earnings Per Share, Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it relates to its convertible notes, and due to the type of debt instrument issued and its accounting policy, the Company applies the treasury stock method and not the if-converted method. The dilutive impact of the Company’s convertible notes is based on the difference between the Company’s current period average stock price and the conversion price of the convertible notes, provided there is a premium. Pursuant to this accounting standard, there is no dilution from the accreted principal of the convertible notes.
	A reconciliation of basic and diluted share amounts for fiscal 2013, 2012, and 2011 is as follows:
		September 28,			September 29,			September 24,
		2013			2012			2011
	Basic weighted average common shares outstanding		268,704			264,041			261,099
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units		—			—			3,206
	Diluted weighted average common shares outstanding		268,704			264,041			264,305
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options		8,445			10,491			7,747
	Restricted stock units		1,109			1,378			—
	In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock options’ combined exercise price, average unrecognized stock compensation expense and assumed tax benefits upon exercise is greater than the average stock price for the period. In those reporting periods in which the Company has a net loss, anti-dilutive shares are comprised of the impact of those number of shares that would have been dilutive had the Company had net income plus the number of common stock equivalents that would be anti-dilutive had the company had net income.
Product Warranties	'
	Product Warranties
	The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
	Product warranty activity for fiscal 2013 and 2012 is as follows:
		Balance at			Provisions			Acquired			Settlements/			Balance at End
		Beginning of									Adjustments			of Period
		Period
	Period ended:
	September 28, 2013	$	6,179		$	12,827		$	—		$	(9,748	)	$	9,258
	September 29, 2012	$	4,448		$	9,535		$	230		$	(8,034	)	$	6,179
Advertising Costs	'
	Advertising Costs
	Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising costs, which include trade shows and conventions, were approximately $14.1 million, $29.8 million and $29.0 million for fiscal 2013, 2012 and 2011, respectively, and were included in selling and marketing expense in the Consolidated Statements of Operations.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist. ASU 2013-11 amends the presentation requirements of ASC 740, Income Taxes, and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The Company is currently evaluating the impact of the adoption of ASU 2013-11 on its consolidated financial statements.
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. Under ASU 2013-02, an entity is required to provide information about the amounts reclassified out of Accumulated Other Comprehensive Income (AOCI) by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. The ASU is effective prospectively for reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 is not expected to have a significant impact on the Company’s results of operations or financial position.
	In December 2011, the FASB issued ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 amended ASC 210, Balance Sheet, to converge the presentation of offsetting assets and liabilities between U.S. GAAP and IFRS. ASU 2011-11 requires that entities disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. ASU 2011-11 is effective for fiscal years, and interim periods within those years, beginning after January 1, 2013, which is the Company’s fiscal year 2014. The Company is currently evaluating the impact of the adoption of ASU 2011-11 on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 28, 2013
Accounting Policies [Abstract]	'
Summary of Marketable Securities	'
	The Company has one investment in a publicly traded security and the following reconciles its cost basis to its fair market value as of September 28, 2013 and September 29, 2012. There were no marketable securities at September 24, 2011.
		Cost			Gross Unrealized			Gross Unrealized			Fair Value
					Gains			Losses
	Equity security as of September 28, 2013	$	5,931		$	12,156		$	—		$	18,087
	Equity security as of September 29, 2012	$	5,931		$	98		$	—		$	6,029
Supplemental Cash Flow Statement Information	'
	Supplemental Cash Flow Statement Information
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Cash paid during the period for income taxes	$	79,893		$	166,565		$	118,850
	Cash paid during the period for interest	$	192,794		$	55,045		$	36,268
	Non-Cash Investing Activities:
	Fair value of stock options assumed in the Gen-Probe acquisition	$	—		$	2,655		$	—
	Additional acquisition contingent consideration accrued	$	—		$	—		$	18,924
	Non-Cash Financing Activities:
	Fair value of contingent consideration at acquisition	$	525		$	—		$	86,600
	Deferred payments for acquisitions	$	—		$	1,655		$	47,258
Schedule of Inventories	'
	Inventories consisted of the following:
		September 28,			September 29,
		2013			2012
	Raw materials	$	115,575		$	134,983
	Work-in-process		51,171			93,218
	Finished goods		122,617			138,990
		$	289,363		$	367,191
Estimated Useful Lives of Property and Equipments	'
	Property, plant and equipment are depreciated over the following estimated useful lives:
	Asset Classification	Estimated Useful Life
	Building and improvements	35–40 years
	Equipment and software	3–10 years
	Equipment under customer usage agreements	3–8 years
	Furniture and fixtures	5–7 years
	Leasehold improvements	Shorter of the Original Term of Lease
		or Estimated Useful Life
Schedule of Intangible Assets	'
	Intangible assets consist of the following:
		September 28, 2013						September 29, 2012
	Description	Gross			Accumulated			Gross			Accumulated
		Carrying			Amortization			Carrying			Amortization
		Value						Value
	Developed technology	$	4,008,947		$	1,094,435		$	3,784,689		$	788,274
	In-process research and development		24,000			—			227,000			—
	Customer relationships and contracts		1,101,870			296,481			1,097,842			205,612
	Trade names		238,103			81,844			240,092			60,318
	Patents		13,026			8,495			11,417			7,906
	Business licenses		2,647			616			2,577			344
	Non-compete agreements		296			296			310			223
		$	5,388,889		$	1,482,167		$	5,363,927		$	1,062,677
Schedule of Estimated Amortization Expense	'
	The estimated amortization expense at September 28, 2013 for each of the five succeeding fiscal years is as follows:
	Fiscal 2014	$	417,053
	Fiscal 2015		402,177
	Fiscal 2016		388,370
	Fiscal 2017		379,260
	Fiscal 2018		368,505
Rollforward of Goodwill Activity by Reportable Segment	'
	A rollforward of goodwill activity by reportable segment from September 29, 2012 to September 28, 2013 is as follows:
		Breast Health			Diagnostics			GYN Surgical			Skeletal Health			Total
	Balance at September 29, 2012	$	635,741		$	2,283,447		$	1,015,466		$	8,125		$	3,942,779
	Impairment charge		—			(1,117,369	)		—			—			(1,117,369	)
	Disposition of portion of a reporting unit		—			(1,257	)		—			—			(1,257	)
	Gen-Probe acquisition adjustments		—			4,226			—			—			4,226
	Gen-Probe valuation revision adjustment		—			(15,750	)		—			—			(15,750	)
	Chindex acquisition		1,798			—			—			—			1,798
	SenoRx acquisition		692			—			—			—			692
	Tax adjustments		—			(868	)		12			—			(856	)
	Foreign currency		(1,866	)		1,125			978			28			265
	Balance at September 28, 2013	$	636,365		$	1,153,554		$	1,016,456		$	8,153		$	2,814,528
Rollforward of Accumulated Goodwill Impairment Losses by Reportable Segment	'
	A rollforward of accumulated goodwill impairment losses by reportable segment from September 29, 2012 to September 28, 2013 is as follows:
		Breast Health			Diagnostics			GYN Surgical			Total
	Balance at September 29, 2012	$	348,419		$	908,349		$	1,165,804		$	2,422,572
	Impairment charge		—			1,117,369			—			1,117,369
	Balance at September 28, 2013	$	348,419		$	2,025,718		$	1,165,804		$	3,539,941
Schedule of Other Assets	'
	Other assets consist of the following:
		September 28,			September 29,
		2013			2012
	Other Assets
	Deferred financing costs	$	60,620		$	82,760
	Life insurance contracts		33,864			25,978
	Mutual funds		6,861			6,995
	Marketable security		18,087			6,029
	Manufacturing access fees		15,971			18,323
	Cost-method equity investments		12,558			15,976
	Other		15,941			6,006
		$	163,902		$	162,067
Components of Accumulated Other Comprehensive Income	'
	The components of accumulated other comprehensive income consisted of the following:
		September 28,			September 29,
		2013			2012
	Foreign currency translation adjustment	$	8,584		$	7,211
	Unrealized gains on available-for-sale securities		12,156			62
	Minimum pension liability, net of tax of $150 and $207, respectively		(349	)		(483	)
		$	20,391		$	6,790
Accounts Receivable Reserve Activity	'
	Accounts receivable reserve activity for fiscal 2013, 2012 and 2011 is as follows:
		Balance at			Charged to			Write-			Balance at
		Beginning			Costs and			offs and			End of
		of Period			Expenses			Payments			Period
	Period Ended:
	September 28, 2013	$	6,396		$	4,296		$	(1,894	)	$	8,798
	September 29, 2012	$	6,516		$	3,270		$	(3,390	)	$	6,396
	September 24, 2011	$	7,769		$	1,614		$	(2,867	)	$	6,516
Schedule of Reconciliation of Basic and Diluted Share Amounts	'
	A reconciliation of basic and diluted share amounts for fiscal 2013, 2012, and 2011 is as follows:
		September 28,			September 29,			September 24,
		2013			2012			2011
	Basic weighted average common shares outstanding		268,704			264,041			261,099
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units		—			—			3,206
	Diluted weighted average common shares outstanding		268,704			264,041			264,305
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options		8,445			10,491			7,747
	Restricted stock units		1,109			1,378			—
Schedule of Product Warranty Activity	'
	Product warranty activity for fiscal 2013 and 2012 is as follows:
		Balance at			Provisions			Acquired			Settlements/			Balance at End
		Beginning of									Adjustments			of Period
		Period
	Period ended:
	September 28, 2013	$	6,179		$	12,827		$	—		$	(9,748	)	$	9,258
	September 29, 2012	$	4,448		$	9,535		$	230		$	(8,034	)	$	6,179

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Sep. 28, 2013
Gen-Probe Incorporated [Member]	'
Purchase Price Consideration	'
	The purchase price consideration was as follows:
	Cash paid	$	3,967,866
	Deferred payment		1,655
	Fair value of stock options exchanged		2,655
	Total purchase price	$	3,972,176
Components of Purchase Price Allocation	'
	The final, adjusted components of the purchase price allocation are as follows:
	Cash	$	205,463
	Accounts receivable		81,444
	Inventory		153,416
	Property, plant and equipment		274,095
	Other assets		191,971
	Assets held-for-sale, net		87,465
	Accounts payable		(19,671	)
	Accrued expenses		(131,623	)
	Other liabilities		(22,939	)
	Identifiable intangible assets:
	Developed technology		1,700,000
	In-process research and development		117,000
	Customer contract		585,000
	Trade names		95,000
	Deferred income taxes, net		(985,465	)
	Goodwill		1,641,020
	Purchase Price	$	3,972,176
Assets Groups Classified as Held for Sale	'
	The following represents the components of the asset groups classified as held-for-sale as of September 29, 2012:
	Assets:
	Cash	$	2,563
	Accounts receivable		8,520
	Inventory		15,680
	Property, plant and equipment		13,259
	Other assets		3,083
	Intangible assets and goodwill		51,398
	Total assets held-for-sale	$	94,503
	Liabilities:
	Accrued liabilities		(7,622	)
	Net assets held-for-sale	$	86,881
Schedule of Unaudited Pro Forma Information	'
	The following unaudited pro forma information presents the combined financial results for the Company and Gen-Probe as if the acquisition of Gen-Probe had been completed at the beginning of fiscal 2011:
		Year Ended			Year Ended
		September 29, 2012			September 24, 2011
	Revenue	$	2,526,336		$	2,310,384
	Net loss	$	(164,539	)	$	(127,240	)
	Basic and diluted net loss per common share	$	(0.62	)	$	(0.49	)
TCT International Co., Ltd. [Member]	'
Components of Purchase Price Allocation	'
	The components of the purchase price allocation consisted of the following:
	Cash	$	27,961
	Accounts receivable		17,811
	Inventory		5,301
	Property and equipment		4,710
	Other tangible assets		1,082
	Accrued taxes		(14,874	)
	Accounts payable and accrued expenses		(6,641	)
	Customer relationships		45,780
	Business licenses		2,500
	Trade names		2,110
	Deferred taxes, net		(12,473	)
	Goodwill		75,161
	Purchase Price	$	148,428
Interlace Medical, Inc [Member]	'
Purchase Price Consideration	'
	The purchase price consideration was as follows:
	Cash	$	126,798
	Contingent consideration		86,600
	Total purchase price	$	213,398
Components of Purchase Price Allocation	'
	The components of the purchase price allocation consisted of the following:
	Cash	$	9,070
	Inventory, including fair value adjustments		1,795
	Other tangible assets		1,291
	Accounts payable and accrued expenses		(1,988	)
	Developed technology		158,741
	Trade names		1,750
	Deferred taxes, net		(45,342	)
	Goodwill		88,081
	Purchase Price	$	213,398

Restructuring_and_Divestiture_1

Restructuring and Divestiture Charges (Tables)	12 Months Ended
	Sep. 28, 2013
Restructuring And Related Activities [Abstract]	'
Charges Taken Related to Restructuring Actions	'
	The following table displays charges taken related to restructuring actions in fiscal 2013 and 2012 and a rollforward of the charges to the accrued balances as of September 28, 2013. Such initiatives were not significant in fiscal 2011.
	Restructuring Charges	Abandonment of			Consolidation of			Closure of			Fiscal 2013			Other			Total
		Adiana Product			Diagnostics			Indianapolis			Actions			Operating
		Line			Operations			Facility						Cost
														Reductions
	Fiscal 2012 charges:
	Non-cash impairment charge	$	16,316		$	585		$	—		$	—		$	—		$	16,901
	Purchase orders and other contractual obligations		3,099			—			—			—			—			3,099
	Workforce reductions		128			14,202			879			—			40			15,249
	Facility closure costs		—			—			—			—			430			430
	Other		—			—			900			—			—			900
	Total fiscal 2012 charges	$	19,543		$	14,787		$	1,779		$	—		$	470		$	36,579
	Recorded to cost of product sales	$	19,064		$	—		$	—		$	—		$	—		$	19,064
	Recorded to restructuring	$	479		$	14,787		$	1,779		$	—		$	470		$	17,515
	Fiscal 2013 charges:
	Workforce reductions	$	—		$	13,950		$	4,805		$	11,332		$	1,127		$	31,214
	Facility closure costs		—			—			173			—			377			550
	Other		—			—			651			42			236			929
	Fiscal 2013 restructuring charges	$	—		$	13,950		$	5,629		$	11,374		$	1,740		$	32,693
	Divestiture net charges		—			—			—			—			—			112
	Fiscal 2013 restructuring and divestiture charges	$	—		$	13,950		$	5,629		$	11,374		$	1,740		$	32,805
Charges Taken Related to Accrued Restructuring Actions	'
	Rollforward of Accrued Restructuring
	Total fiscal 2012 charges	$	19,543		$	14,787		$	1,779		$	—		$	470		$	36,579
	Non-cash impairment charges		(16,316	)		(585	)		—			—			—			(16,901	)
	Stock compensation		—			(3,500	)		—			—			—			(3,500	)
	Severance payments		(128	)		(2,423	)		—			—			(78	)		(2,629	)
	Other payments		(2,572	)		—			—			—			(430	)		(3,002	)
	Acquired		—			83			—			—			—			83
	Foreign exchange and other adjustments		—			22			—			—			91			113
	Balance at September 29, 2012	$	527		$	8,384		$	1,779		$	—		$	53		$	10,743
	Fiscal 2013 restructuring charges	$	—		$	13,950		$	5,629		$	11,374		$	1,740		$	32,693
	Stock compensation		—			(6,322	)		—			(1,595	)		—			(7,917	)
	Non-cash impairment charges		—			—			—			—			(54	)		(54	)
	Severance payments		—			(13,068	)		(3,048	)		(4,425	)		(897	)		(21,438	)
	Other payments		(527	)		—			(566	)		(25	)		(560	)		(1,678	)
	Foreign exchange and other adjustments		—			(2	)		—			(14	)		6			(10	)
	Balance at September 28, 2013	$	—		$	2,942		$	3,794		$	5,315		$	288		$	12,339

Borrowings_and_Credit_Arrangem1

Borrowings and Credit Arrangements (Tables)	12 Months Ended
	Sep. 28, 2013
Debt Disclosure [Abstract]	'
Company's Borrowings	'
	Company’s borrowings consisted of the following:
			September 28,			September 29,
			2013			2012
	Current debt obligations, net of debt discount:
	Term Loan A		$	49,713		$	49,582
	Term Loan B			113,966			14,853
	Convertible Notes			400,133			—
	Total current debt obligations			563,812			64,435
	Long-term debt obligations, net of debt discount:
	Term Loan A			894,834			942,065
	Term Loan B			1,159,272			1,470,454
	Senior Notes			1,000,000			1,000,000
	Convertible Notes			1,187,992			1,558,660
	Total long-term debt obligations			4,242,098			4,971,179
	Total debt obligations		$	4,805,910		$	5,035,614
Debt Maturity Schedule for Components of Company's Obligations	'
	The debt maturity schedule for the Company’s obligations as of September 28, 2013 is as follows:
			2014			2015			2016		2017		2018		2019 and		Total
															Thereafter
	Term Loan A		$	50,000		$	100,000		$	200,000	$	600,000	$	—	$	—	$	950,000
	Term Loan B (1)			115,000			15,000			15,000		15,000		15,000		1,110,000		1,285,000
	Senior Notes			—			—			—		—		—		1,000,000		1,000,000
	Convertible Notes (2)			405,000			—			—		450,000		879,225		—		1,734,225
			$	570,000		$	115,000		$	215,000	$	1,065,000	$	894,225	$	2,110,000	$	4,969,225
	-1	Fiscal 2014 column reflects reclassifying the Company’s early pay-down of $100.0 million of Term Loan B on October 31, 2013 to current.
	-2	Classified based on the earliest date of redemption for each respective issuance and the balance in fiscal 2018 reflects accretion on the 2013 Notes through September 28, 2013 as described below.
Convertible Notes and Related Equity Components	'
	As of September 28, 2013 and September 29, 2012, the Convertible Notes and related equity components (recorded in additional paid-in-capital, net of deferred taxes) consisted of the following:
			2013			2012
	2007 Notes principal amount		$	405,000		$	775,000
	Unamortized discount			(4,867	)		(50,591	)
	Net carrying amount		$	400,133		$	724,409
	Equity component, net of taxes		$	121,496		$	233,353
	2010 Notes principal amount		$	450,000		$	450,000
	Unamortized discount			(58,310	)		(74,062	)
	Net carrying amount		$	391,690		$	375,938
	Equity component, net of taxes		$	60,054		$	60,054
	2012 Notes principal amount		$	500,000		$	500,000
	Unamortized discount			(34,630	)		(41,687	)
	Net carrying amount		$	465,370		$	458,313
	Equity component, net of taxes		$	49,195		$	49,195
	2013 Notes principal amount		$	370,000		$	—
	Principal accretion			9,225			—
	Unamortized discount			(48,293	)		—
	Net carrying amount		$	330,932		$	—
	Equity component, net of taxes		$	131,451		$	—
Interest Expense under Convertible Notes	'
	Interest expense under the Convertible Notes is as follows:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Amortization of debt discount		$	52,732		$	68,532		$	72,908
	Amortization of deferred financing costs			3,048			3,828			3,906
	Principal accretion			9,225			—			—
	Non-cash interest expense			65,005			72,360			76,814
	2.00% accrued interest			34,376			34,898			34,427
			$	99,381		$	107,258		$	111,241

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Sep. 28, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Assets and Liabilities Measured on Recurring Basis	'
	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following:
					Fair Value Measurements at September 28, 2013
		Carrying Value			Quoted Prices in			Significant			Significant
					Active Market for			Other			Unobservable
					Identical Assets			Observable			Inputs (Level 3)
					(Level 1)			Inputs (Level 2)
	Assets:
	Marketable securities:
	Equity security	$	18,087		$	18,087		$	—		$	—
	Mutual funds		6,861			6,861			—			—
	Total	$	24,948		$	24,948		$	—		$	—
	Liabilities:
	Deferred compensation liabilities	$	38,611		$	38,611		$	—		$	—
	Contingent consideration		3,780			—			—			3,780
	Total	$	42,391		$	38,611		$	—		$	3,780
					Fair Value Measurements at September 29, 2012
		Carrying Value			Quoted Prices in			Significant			Significant
					Active Market for			Other			Unobservable
					Identical Assets			Observable			Inputs (Level 3)
					(Level 1)			Inputs (Level 2)
	Assets:
	Money market funds	$	315		$	315		$	—		$	—
	Marketable securities:
	Equity security		6,029			6,029			—			—
	Mutual funds		6,995			6,995			—			—
	Total	$	13,339		$	13,339		$	—		$	—
	Liabilities:
	Deferred compensation liabilities	$	32,082		$	32,082		$	—		$	—
	Contingent consideration		86,368			—			—			86,368
	Total	$	118,450		$	32,082		$	—		$	86,368
Changes in Fair Value of Recurring Fair Value Measurements, Consisting of Contingent Consideration Liabilities, Using Significant Unobservable Inputs (Level 3)	'
	Changes in the fair value of recurring fair value measurements, which solely consisted of contingent consideration liabilities, using significant unobservable inputs (Level 3) during the years ended September 28, 2013 and September 29, 2012 were as follows:
		2013			2012			2011
	Beginning balance	$	86,368		$	103,790		$	29,500
	Contingent consideration liabilities recorded at fair value at acquisition		525			—			86,600
	Fair value adjustments		11,310			38,466			(8,016	)
	Payments made		(94,423	)		(55,888	)		(4,294	)
	Ending balance	$	3,780		$	86,368		$	103,790
Schedule of Estimated Fair Value of Intangible Assets, Goodwill and Cost-Method Equity Investment Measured on Nonrecurring Basis	'
	The following chart depicts the level of inputs within the fair value hierarchy used to estimate the fair value of equipment, intangible assets, goodwill and cost-method equity investments measured on a nonrecurring basis for which the Company recorded impairment charges:
					Fair Value Measurements Using
		Fair Value			Quoted Prices in		Significant	Significant			Total Gains
					Active Market for		Other	Unobservable			(Losses)
					Identical Assets		Observable	Inputs (Level 3)
					(Level 1)		Inputs (Level 2)
	Fiscal 2013:
	Goodwill	$	277,840					$	277,840		$	(1,117,369	)
	Equipment		1,363						1,363			(4,993	)
	Cost-method equity investments		1,483						1,483			(6,438	)
											$	(1,128,800	)
	Fiscal 2012:
	Equipment	$	—					$	—		$	(6,452	)
	Goodwill		—						—			(5,826	)
											$	(12,278	)
	Fiscal 2011:
	Cost-method equity investments	$	345					$	345		$	(2,445	)
Estimated Fair Values of Convertible Notes	'
	The estimated fair values of the Company’s Convertible Notes as of September 28, 2013 and September 29, 2012 are as follows:
		2013			2012
	2007 Notes	$	405,000		$	771,600
	2010 Notes		510,800			505,600
	2012 Notes		518,800			490,700
	2013 Notes		385,700			—
		$	1,820,300		$	1,767,900

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Sep. 28, 2013
Income Tax Disclosure [Abstract]	'
Income (Loss) Before Income Taxes	'
	The Company’s (loss) income before income taxes consisted of the following:
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Domestic	$	(1,184,603	)	$	(46,018	)	$	235,204
	Foreign		(8,358	)		(15,643	)		(7,818	)
		$	(1,192,961	)	$	(61,661	)	$	227,386
Provision for Income Taxes	'
	The (benefit) provision for income taxes contains the following components:
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Federal:
	Current	$	154,900		$	146,164		$	97,834
	Deferred		(182,739	)		(143,582	)		(33,808	)
			(27,839	)		2,582			64,026
	State:
	Current		15,305			15,348			15,739
	Deferred		(16,709	)		(10,186	)		(5,909	)
			(1,404	)		5,162			9,830
	Foreign:
	Current		7,655			5,653			4,770
	Deferred		1,465			(1,424	)		(8,390	)
			9,120			4,229			(3,620	)
		$	(20,123	)	$	11,973		$	70,236
Reconciliation of Income Tax (Benefit) at U.S. Federal Statutory Rate to Company's Effective Tax Rate	'
	The income tax (benefit) provision differs from the tax provision computed at the U.S. federal statutory rate due to the following:
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Income tax provision at federal statutory rate		(35.0	)%		(35.0	)%		35	%
	Increase (decrease) in tax resulting from:
	Goodwill impairment		32.8			3.3			—
	Domestic production activities deduction		(1.2	)		(20.3	)		(4.1	)
	State income taxes, net of federal benefit		(0.2	)		5.3			3.6
	Research and investment tax credits		(1.2	)		(1.6	)		(3.2	)
	Unrecognized tax benefits		0.3			13.5			(3.3	)
	Contingent consideration		2.6			59.8			1.5
	Nondeductible transaction expenses		—			7.5			—
	Cessation of Adiana		—			(28.6	)		—
	Executive compensation		0.2			2.3			(1.1	)
	Foreign rate differential		0.1			3.1			0.8
	Change in valuation allowance		(0.8	)		5.4			—
	Other		0.7			4.7			1.7
			(1.7	)%		19.4	%		30.9	%
Significant Components of the Company's Deferred Tax Assets and Liabilities	'
	The Company’s significant deferred tax assets and liabilities are as follows:
		September 28,			September 29,
		2013			2012
	Deferred tax assets
	Net operating loss carryforwards	$	49,277		$	47,472
	Capital losses		23,857			46,750
	Non-deductible accruals		21,527			22,198
	Non-deductible reserves		16,054			10,346
	Stock-based compensation		30,190			31,437
	Research and other credits		10,679			11,392
	Debt issuance costs		—			811
	Nonqualified deferred compensation plan		14,714			12,007
	Other temporary differences		6,960			3,000
			173,258			185,413
	Less: valuation allowance		(43,354	)		(64,337	)
		$	129,904		$	121,076
	Deferred tax liabilities
	Depreciation and amortization	$	(1,494,068	)	$	(1,635,043	)
	Debt discounts and deferrals		(189,298	)		(209,011	)
	Debt issuance costs		(10,941	)		—
	Fair value adjustments to current assets and liabilities		—			(28,413	)
	Investment in subsidiary		(10,713	)		(8,479	)
		$	(1,705,020	)	$	(1,880,946	)
		$	(1,575,116	)	$	(1,759,870	)
Activity of the Company's Unrecognized Income Tax Benefits	'
	The Company’s unrecognized income tax benefits activity for fiscal 2013 and 2012 are as follows:
		2013			2012
	Balance at beginning of fiscal year	$	53,148		$	31,026
	Tax positions related to current year:
	Additions		64,992			11,673
	Reductions		—			—
	Tax positions related to prior years:
	Additions related to change in estimate		3,317			1,327
	Reductions		(363	)		307
	Payments		(621	)		(197	)
	Lapses in statutes of limitations and settlements		(2,323	)		(4,144	)
	Acquired tax positions:
	Additions related to reserves acquired from acquisitions		3,676			13,156
	Balance as of the end of the fiscal year	$	121,826		$	53,148

Stockholders_Equity_and_StockB1

Stockholders' Equity and Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 28, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation Expense in Consolidated Statement of Operations	'
	The following presents stock-based compensation expense in the Company’s Consolidated Statement of Operations in fiscal 2013, 2012 and 2011:
			2013			2012			2011
	Cost of revenues		$	7,031		$	5,722		$	4,602
	Research and development			7,179			5,328			4,852
	Selling and marketing			8,915			7,355			5,954
	General and administrative			20,153			18,667			20,064
	Restructuring and divestiture			9,029			3,500			—
			$	52,307		$	40,572		$	35,472
Information Pertaining to Stock Options Granted and Related Assumptions	'
	Information pertaining to stock options granted during fiscal 2013, 2012 and 2011 and related assumptions are noted in the following table:
			Years ended
			September 28,			September 29,			September 24,
			2013			2012			2011
	Options granted			2,640			2,259			2,249
	Weighted-average exercise price		$	20.29		$	17.21		$	17.15
	Weighted-average grant date fair value		$	7.03		$	6.48		$	6.16
	Assumptions:
	Risk-free interest rates			0.5	%		0.7	%		1	%
	Expected life (in years)			4.4			4.3			4.2
	Expected volatility			44	%		47	%		45	%
	Dividend yield			—			—			—
Stock Option Activity	'
	The following table summarizes all stock option activity under the Company’s stock option plans for the year ended September 28, 2013:
			Number			Weighted-			Weighted-			Aggregate
			of Shares			Average			Average			Intrinsic
						Exercise Price			Remaining			Value
									Contractual Life
									in Years
	Options outstanding at September 29, 2012			18,039		$	17.4			4.4		$	78,962
	Granted			2,640			20.29
	Cancelled/forfeited			(1,021	)		20.04
	Exercised			(4,786	)		13.71					$	37,609
	Options outstanding at September 28, 2013			14,872		$	18.92			3.9		$	54,956
	Options exercisable at September 28, 2013			7,472		$	20.28			2.9		$	29,438
	Options vested and expected to vest at September 28, 2013 (1)			13,780		$	19			3.8		$	51,656
	-1	This represents the number of vested stock options as of September 28, 2013 plus the unvested outstanding options at September 28, 2013 expected to vest in the future, adjusted for estimated forfeitures.
Restricted Stock Unit Activity	'
	A summary of the Company’s RSU activity during the year ended September 28, 2013 is presented below:
	Non-vested Shares		Number of			Weighted-Average
			Shares			Grant-Date  Fair
						Value
	Non-vested at September 29, 2012			3,580		$	16.45
	Granted			1,995			19.94
	Vested			(1,711	)		15.98
	Forfeited			(405	)		18.11
	Non-vested at September 28, 2013			3,459		$	18.51
Black-Scholes Model Weighted Average Assumptions Used to Estimate Fair Value of Shares to Be Issued as of Grant Date	'
	The Company uses the Black-Scholes model to estimate the fair value of shares to be issued as of the grant date using the following weighted average assumptions:
			September 28,			September 29,
			2013			2012
	Assumptions:
	Risk-free interest rates			0.11	%		0.16	%
	Expected life (in years)			0.5			0.5
	Expected volatility			32	%		35	%
	Dividend yield			—			—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 28, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Contingent Consideration Charges Recorded to the Consolidated Statements of Operations	'
	A summary of amounts recorded to the Consolidated Statement of Operations is as follows:
	Statement of Operations Line Item – Fiscal 2013	Interlace			TCT		Total
	Contingent consideration—compensation expense	$	—		$	80,010	$	80,010
	Contingent consideration—fair value adjustments		11,310			—		11,310
		$	11,310		$	80,010	$	91,320
	Statement of Operations Line Item – Fiscal 2012	Sentinelle			Interlace		TCT		Healthcome		Total
		Medical
	Contingent consideration—compensation expense	$	—		$	—	$	75,459	$	5,572	$	81,031
	Contingent consideration—fair value adjustments		(3,364	)		41,830		—		—		38,466
		$	(3,364	)	$	41,830	$	75,459	$	5,572	$	119,497
	Statement of Operations Line Item – Fiscal 2011	Sentinelle			Interlace		TCT		Healthcome		Total
		Medical
	Contingent consideration—compensation expense	$	—		$	2,102	$	17,581	$	319	$	20,002
	Contingent consideration—fair value adjustments		(14,328	)		6,312		—		—		(8,016	)
		$	(14,328	)	$	8,414	$	17,581	$	319	$	11,986
Future Minimum Lease Payments, Including Principal and Interest	'
	Future minimum lease payments, including principal and interest, under these leases were as follows at September 28, 2013:
	Fiscal 2014	$	2,822
	Fiscal 2015		2,883
	Fiscal 2016		3,054
	Fiscal 2017		3,119
	Fiscal 2018		2,925
	Thereafter		300
	Total minimum payments		15,103
	Less-amount representing interest		(3,607	)
	Total	$	11,496
Summary of Purchase Commitments	'
	At September 28, 2013, purchase commitments were as follows:
	Fiscal 2014	$	55,935
	Fiscal 2015		12,684
	Fiscal 2016		3,000
	Fiscal 2017		3,000
	Fiscal 2018		750
	Thereafter		—
	Total	$	75,369
Summary of Minimum Royalty Commitments	'
	At September 28, 2013, minimum commitments for these agreements were as follows:
	Fiscal 2014	$	1,301
	Fiscal 2015		810
	Fiscal 2016		1,426
	Fiscal 2017		745
	Fiscal 2018		560
	Thereafter		4,450
	Total	$	9,292
Future Minimum Lease Payments under All Operating Leases	'
	Future minimum lease payments under all of the Company’s operating leases at September 28, 2013 are as follows:
	Fiscal 2014	$	20,689
	Fiscal 2015		16,192
	Fiscal 2016		13,600
	Fiscal 2017		12,249
	Fiscal 2018		10,830
	Thereafter		32,712
	Total	$	106,272
Future Minimum Annual Rental Income Payments under Sublease Agreements	'
	The future minimum annual rental income payments under these sublease agreements at September 28, 2013 are as follows:
	Fiscal 2014	$	1,551
	Fiscal 2015		913
	Fiscal 2016		20
	Fiscal 2017		15
	Total	$	2,499

Business_Segments_and_Geograph1

Business Segments and Geographic Information (Tables)	12 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	Segment information for fiscal 2013, 2012 and 2011 is as follows:
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Total revenues:
	Diagnostics	$	1,189,819		$	718,064		$	571,263
	Breast Health		905,076			875,771			825,551
	GYN Surgical		307,139			313,089			300,538
	Skeletal Health		90,245			95,728			91,997
		$	2,492,279		$	2,002,652		$	1,789,349
	Operating (loss) income:
	Diagnostics	$	(1,149,132	)	$	(32,787	)	$	170,693
	Breast Health		216,049			186,106			187,970
	GYN Surgical		19,664			(51,892	)		3,623
	Skeletal Health		7,137			12,290			12,159
		$	(906,282	)	$	113,717		$	374,445
	Depreciation and amortization:
	Diagnostics	$	369,818		$	197,274		$	165,065
	Breast Health		40,098			42,924			45,165
	GYN Surgical		105,233			103,781			92,587
	Skeletal Health		861			1,772			1,919
		$	516,010		$	345,751		$	304,736
	Capital expenditures:
	Diagnostics	$	51,653		$	44,939		$	23,128
	Breast Health		16,386			9,821			12,069
	GYN Surgical		9,145			12,233			11,467
	Skeletal Health		562			171			2,198
	Corporate		12,384			11,609			6,801
		$	90,130		$	78,773		$	55,663
	Identifiable assets:
	Diagnostics	$	4,667,942		$	6,170,553		$	1,770,107
	Breast Health		932,206			956,134			985,196
	GYN Surgical		1,849,518			1,944,386			2,049,682
	Skeletal Health		33,508			32,778			31,864
	Corporate		1,517,649			1,373,257			1,171,931
		$	9,000,823		$	10,477,108		$	6,008,780
Revenues by Geography	'
	Revenues by geography as a percentage of total revenues are as follows:
		Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	United States		75	%		74	%		77	%
	Europe		13	%		12	%		14	%
	Asia-Pacific		8	%		8	%		6	%
	All others		4	%		6	%		3	%
			100	%		100	%		100	%
Schedule of Geographically Located Property and Equipment, Net	'
	The Company’s property and equipment, net are geographically located as follows:
		September 28,			September 29,			September 24,
		2013			2012			2011
	United States	$	386,049		$	405,141		$	165,177
	Costa Rica		29,258			30,452			34,107
	Europe		61,472			59,927			29,591
	All other countries		14,749			12,478			9,791
		$	491,528		$	507,998		$	238,666

Accrued_Expenses_and_Other_Lon1

Accrued Expenses and Other Long-Term Liabilities (Tables)	12 Months Ended
	Sep. 28, 2013
Text Block [Abstract]	'
Schedule of Accrued Expenses	'
	Accrued expenses consist of the following:
		September 28,		September 29,
		2013		2012
	Accrued Expenses
	Compensation and employee benefits	$	127,464	$	143,673
	Contingent consideration		38,138		143,881
	Income and other taxes		17,369		12,424
	Interest		23,747		18,422
	Other		65,213		53,981
		$	271,931	$	372,381
Schedule of Other Long-Term Liabilities	'
		September 28,		September 29,
		2013		2012
	Other Long-Term Liabilities
	Accrued lease obligation—long-term	$	33,494	$	33,256
	Reserve for income tax uncertainties		115,395		38,518
	Pension liabilities		9,691		9,397
	Other		9,464		17,079
		$	168,044	$	98,250

Pension_and_Other_Employee_Ben1

Pension and Other Employee Benefits (Tables)	12 Months Ended
	Sep. 28, 2013
Compensation And Retirement Disclosure [Abstract]	'
Schedule of Reconciliation of Benefit Obligations, Plan Assets, Funded Status and Related Actuarial Assumptions	'
	The tables below provide a reconciliation of benefit obligations, plan assets, funded status, and related actuarial assumptions of the Company’s German Pension Benefits.
	Change in Benefit Obligation	Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Benefit obligation at beginning of year	$	(9,744	)	$	(8,064	)	$	(9,093	)
	Service cost		—			—			—
	Interest cost		(354	)		(391	)		(389	)
	Plan participants’ contributions		—			—			—
	Actuarial gain (loss)		188			(2,002	)		1,092
	Foreign exchange (loss) gain		(503	)		383			(5	)
	Benefits paid		348			330			331
	Benefit obligation at end of year		(10,065	)		(9,744	)		(8,064	)
	Plan assets		—			—			—
	Funded status	$	(10,065	)	$	(9,744	)	$	(8,064	)
Components of Net Periodic Benefit Cost and Related Actuarial Assumptions	'
	The tables below outline the components of the net periodic benefit cost and related actuarial assumptions of the Company’s German Pension Benefits plan.
	Components of Net Periodic Benefit Cost	Years ended
		September 28,			September 29,			September 24,
		2013			2012			2011
	Service cost	$	—		$	—		$	—
	Interest cost		354			391			389
	Expected return on plan assets		—			—			—
	Amortization of prior service cost		—			—			—
	Recognized net actuarial gain		—			(38	)		—
	Net periodic benefit cost	$	354		$	353		$	389
Schedule of Weighted-Average Net Periodic Benefit Cost Assumptions	'
	Weighted-Average Net Periodic Benefit Cost Assumptions	2013			2012			2011
	Discount rate		3.6	%		3.52	%		5.2	%
	Expected return on plan assets		0	%		0	%		0	%
	Rate of compensation increase		0	%		0	%		0	%
Schedule of Expected Pension Benefit	'
	The table below reflects the total Pension Benefits expected to be paid each fiscal year as of September 28, 2013:
	2014	$	374
	2015		399
	2016		415
	2017		428
	2018		441
	2019 to 2023		2,404

Quarterly_Statement_of_Operati1

Quarterly Statement of Operations Information (Unaudited) (Tables)	12 Months Ended
	Sep. 28, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Results of Operations	'
	The following table presents a summary of quarterly results of operations for fiscal 2013 and 2012:
			2013
			First		Second			Third			Fourth
			Quarter		Quarter			Quarter			Quarter
	Total revenue		$	631,362	$	612,663		$	626,136		$	622,118
	Gross profit			281,673		279,326			309,758			290,631
	Net income (loss) (1)			3,118		(51,104	)		(10,950	)		(1,113,902	)
	Diluted net income (loss) per common share		$	0.01	$	(0.19	)	$	(0.04	)	$	(4.11	)
			2012
			First		Second			Third			Fourth
			Quarter		Quarter			Quarter			Quarter(3)
	Total revenue		$	472,711	$	471,165		$	470,228		$	588,548
	Gross profit			249,370		226,110			244,640			274,317
	Net income (loss) (2)			20,812		(40,273	)		23,594			(77,767	)
	Diluted net income (loss) per common share		$	0.08	$	(0.15	)	$	0.09		$	(0.29	)
	-1	Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.
	-2	Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.
	-3	The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

Supplemental_Guarantor_Condens1

Supplemental Guarantor Condensed Consolidating Financials (Tables)	12 Months Ended
	Sep. 28, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Schedule of Supplemental Condensed Consolidating Statement of Operations	'
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Year Ended September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product sales	$	416,871		$	1,569,605		$	477,251		$	(362,836	)	$	2,100,891
	Service and other revenues		326,656			71,718			46,635			(53,621	)		391,388
			743,527			1,641,323			523,886			(416,457	)		2,492,279
	Costs and expenses:
	Cost of product sales		212,899			636,679			331,418			(362,836	)		818,160
	Cost of product sales—amortization of intangible assets		5,346			298,426			4,123			—			307,895
	Cost of product sales—impairment of intangible assets		—			—			1,714			—			1,714
	Cost of service and other revenues		157,391			59,943			39,409			(53,621	)		203,122
	Research and development		29,829			157,846			9,971			—			197,646
	Selling and marketing		77,982			176,041			88,114			—			342,137
	General and administrative		68,883			123,985			34,812			—			227,680
	Amortization of intangible assets		3,013			104,778			4,806			—			112,597
	Contingent consideration—compensation expense		80,010			—			—			—			80,010
	Contingent consideration—fair value adjustments		11,310			—			—			—			11,310
	Impairment of goodwill		—			1,117,369			—			—			1,117,369
	Gain on sale of intellectual property		—			(53,884	)		—			—			(53,884	)
	Restructuring and divestiture charges		4,889			21,647			6,269			—			32,805
			651,552			2,642,830			520,636			(416,457	)		3,398,561
	Income (loss) from operations		91,975			(1,001,507	)		3,250			—			(906,282	)
	Interest income		590			251			461			—			1,302
	Interest expense		(277,771	)		(1,260	)		(2,044	)		—			(281,075	)
	Debt extinguishment loss		(9,209	)		—									(9,209	)
	Other income (expense), net		193,254			(184,564	)		(6,387	)		—			2,303
	Loss before income taxes		(1,161	)		(1,187,080	)		(4,720	)		—			(1,192,961	)
	Provision (benefit) for income taxes		30,794			(59,260	)		8,343			—			(20,123	)
	Equity in earnings (losses) of subsidiaries		(1,140,883	)		13,887			—			1,126,996			—
	Net (loss) income	$	(1,172,838	)	$	(1,113,933	)	$	(13,063	)	$	1,126,996		$	(1,172,838	)
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Year Ended September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product sales	$	420,960		$	1,089,580		$	431,689		$	(284,501	)	$	1,657,728
	Service and other revenues		307,097			63,313			32,555			(58,041	)		344,924
			728,057			1,152,893			464,244			(342,542	)		2,002,652
	Costs and expenses:
	Cost of product sales		211,665			396,747			292,928			(284,501	)		616,839
	Cost of product sales—amortization of intangible assets		5,226			192,377			4,261			—			201,864
	Cost of service and other revenues		155,555			61,285			30,713			(58,041	)		189,512
	Research and development		28,065			91,199			11,698			—			130,962
	Selling and marketing		67,874			170,422			84,018			—			322,314
	General and administrative		52,568			136,243			31,683			—			220,494
	Amortization of intangible assets		2,709			64,357			4,970			—			72,036
	Contingent consideration—compensation expense		81,031			—			—			—			81,031
	Contingent consideration—fair value adjustments		38,466			—			—			—			38,466
	Impairment of goodwill		—			5,826			—			—			5,826
	Gain on sale of intellectual property		—			(12,424	)		—			—			(12,424	)
	Acquired in-process research and development		—			4,500			—			—			4,500
	Restructuring and divestiture charges		49			16,185			1,281			—			17,515
			643,208			1,126,717			461,552			(342,542	)		1,888,935
	Income from operations		84,849			26,176			2,692			—			113,717
	Interest income		1,950			159			840			(609	)		2,340
	Interest expense		(137,190	)		(1,158	)		(1,939	)		—			(140,287	)
	Debt extinguishment loss		(42,347	)		—			—			—			(42,347	)
	Other income, net		3,051			699			557			609			4,916
	(Loss) income before income taxes		(89,687	)		25,876			2,150			—			(61,661	)
	Provision (benefit) for income taxes		9,721			(3,094	)		5,346			—			11,973
	Equity in earnings (losses) of subsidiaries		25,774			8,415			556			(34,745	)		—
Net (loss) income	$	(73,634	)	$	37,385		$	(2,640	)	$	(34,745	)	$	(73,634	)
SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
For the Year Ended September 24, 2011
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Revenues:
Product sales	$	411,309		$	964,584		$	376,575		$	(274,128	)	$	1,478,340
Service and other revenues		274,197			59,026			27,862			(50,076	)		311,009
		685,506			1,023,610			404,437			(324,204	)		1,789,349
Costs and expenses:
Cost of product sales		200,912			309,910			284,495			(274,128	)		521,189
Cost of product sales—amortization of intangible assets		5,224			167,341			4,891			—			177,456
Cost of service and other revenues		143,399			51,888			22,312			(50,076	)		167,523
Research and development		28,959			75,437			12,300			—			116,696
Selling and marketing		60,496			166,458			59,776			—			286,730
General and administrative		50,180			86,270			23,113			—			159,563
Amortization of intangible assets		2,709			54,851			774			—			58,334
Contingent consideration—compensation expense		20,002			—			—			—			20,002
Contingent consideration—fair value adjustments		(8,016	)		—			—			—			(8,016	)
Gain on sale of intellectual property		—			(84,502	)		—			—			(84,502	)
Restructuring and divestiture charges		(353	)		—			282			—			(71	)
		503,512			827,653			407,943			(324,204	)		1,414,904
Income (loss) from operations		181,994			195,957			(3,506	)		—			374,445
Interest income		1,495			1			364			—			1,860
Interest expense		(111,583	)		(1,357	)		(1,906	)		—			(114,846	)
Debt extinguishment loss		(29,891	)		—			—			—			(29,891	)
Other (expense) income, net		(1,706	)		(2,661	)		185			—			(4,182	)
Income (loss) before income taxes		40,309			191,940			(4,863	)		—			227,386
Provision (benefit) for income taxes		10,976			60,163			(903	)		—			70,236
Equity in earnings (losses) of subsidiaries		127,817			8,699			319			(136,835	)		—
Net income (loss)	$	157,150		$	140,476		$	(3,641	)	$	(136,835	)	$	157,150
Schedule of Supplemental Condensed Consolidating Statements of Comprehensive (Loss) Income	'
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
	For the Year Ended September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net (loss) income	$	(1,172,838	)	$	(1,113,933	)	$	(13,063	)	$	1,126,996		$	(1,172,838	)
	Foreign currency cumulative translation adjustment		—			658			715			—			1,373
	Adjustment to minimum pension liability, net of taxes		—			—			134			—			134
	Unrealized gain on available-for-sale securities		—			12,094			—			—			12,094
	Comprehensive (loss) income	$	(1,172,838	)	$	(1,101,181	)	$	(12,214	)	$	1,126,996		$	(1,159,237	)
	For the Year Ended September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net (loss) income	$	(73,634	)	$	37,385		$	(2,640	)	$	(34,745	)	$	(73,634	)
	Foreign currency translation adjustment		836			(527	)		5,908			—			6,217
	Adjustment to minimum pension liability, net of taxes		—			—			(1,484	)		—			(1,484	)
	Unrealized gain on available-for-sale security, net of taxes		—			62			—			—			62
	Other comprehensive income (loss)		836			(465	)		4,424			—			4,795
	Comprehensive (loss) income	$	(72,798	)	$	36,920		$	1,784		$	(34,745	)	$	(68,839	)
	For the Year Ended September 24, 2011
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net income (loss)	$	157,150		$	140,476		$	(3,641	)	$	(136,835	)	$	157,150
	Foreign currency translation adjustment		(1,127	)		(121	)		2,336			—			1,088
	Adjustment to minimum pension liability, net of taxes		—			—			764			—			764
	Other comprehensive income (loss)		(1,127	)		(121	)		3,100			—			1,852
	Comprehensive income (loss)	$	156,023		$	140,355		$	(541	)	$	(136,835	)	$	159,002
Schedule of Supplemental Condensed Consolidating Balance Sheet	'
	SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
	September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	ASSETS
	Current assets:
	Cash and cash equivalents	$	321,523		$	387,422		$	113,545		$	—		$	822,490
	Restricted cash		—			—			6,914			—			6,914
	Accounts receivable, net		126,036			174,433			108,804			—			409,273
	Inventories		81,924			146,678			60,761			—			289,363
	Deferred income tax assets		—			19,042			494			(19,536	)		—
	Prepaid income taxes		47,131			2,303			—			(4,689	)		44,745
	Prepaid expenses and other current assets		16,246			21,112			11,003			—			48,361
	Other current assets—assets held for sale		—			—			2,997			—			2,997
	Intercompany receivables		—			2,442,502			31,949			(2,474,451	)		—
	Total current assets		592,860			3,193,492			336,467			(2,498,676	)		1,624,143
	Property, plant and equipment, net		29,313			356,736			105,479			—			491,528
	Intangible assets, net		19,925			3,784,987			101,810			—			3,906,722
	Goodwill		283,038			2,390,939			140,551			—			2,814,528
	Other assets		103,548			58,446			1,908			—			163,902
	Investment in subsidiaries		8,667,620			129,016			2,296			(8,798,932	)		—
	Total assets	$	9,696,304		$	9,913,616		$	688,511		$	(11,297,608	)	$	9,000,823
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Current portion of long-term debt	$	563,812		$	—		$	—		$	—		$	563,812
	Accounts payable		27,865			42,661			10,008			—			80,534
	Accrued expenses		152,950			79,629			44,319			(4,967	)		271,931
	Deferred revenue		93,306			7,958			31,055			—			132,319
	Deferred income tax liabilities		59,346			—			—			(19,536	)		39,810
	Intercompany payables		2,418,089			—			64,411			(2,482,500	)		—
	Total current liabilities		3,315,368			130,248			149,793			(2,507,003	)		1,088,406
	Long-term debt, net of current portion		4,242,098			—			—			—			4,242,098
	Deferred income tax liabilities		89,085			1,435,522			10,699			—			1,535,306
	Deferred service obligations—long-term		11,251			3,511			12,864			(2,170	)		25,456
	Other long-term liabilities		96,990			37,598			33,456			—			168,044
	Total stockholders’ equity		1,941,512			8,306,737			481,699			(8,788,435	)		1,941,513
	Total liabilities and stockholders’ equity	$	9,696,304		$	9,913,616		$	688,511		$	(11,297,608	)	$	9,000,823
	SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
	September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	ASSETS
	Current assets:
	Cash and cash equivalents	$	210,028		$	269,416		$	80,986		$	—		$	560,430
	Restricted cash		—			—			5,696			—			5,696
	Accounts receivable, net		101,538			192,349			115,522			(76	)		409,333
	Inventories		74,500			223,043			70,180			(532	)		367,191
	Deferred income tax assets		13,578			—			617			(2,480	)		11,715
	Prepaid income taxes		20,805			48,429			611			—			69,845
	Prepaid expenses and other current assets		18,817			12,816			12,668			—			44,301
	Intercompany receivables		—			2,094,017			55,761			(2,149,778	)		—
	Other current assets—assets held-for-sale		—			67,878			26,625			—			94,503
	Total current assets		439,266			2,907,948			368,666			(2,152,866	)		1,563,014
	Property, plant and equipment, net		26,928			379,702			101,368			—			507,998
	Intangible assets, net		24,034			4,162,930			114,286			—			4,301,250
	Goodwill		279,956			3,522,474			140,349			—			3,942,779
	Other assets		112,339			49,036			2,406			(1,714	)		162,067
	Investments in subsidiaries		9,782,940			101,615			2,296			(9,886,851	)		—
	Total assets	$	10,665,463		$	11,123,705		$	729,371		$	(12,041,431	)	$	10,477,108
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Current portion of long-term debt	$	64,435		$	—		$	—		$	—		$	64,435
	Accounts payable		29,847			43,339			14,037			—			87,223
Accrued expenses		238,387			86,566			50,052			(2,624	)		372,381
Deferred revenue		92,234			10,307			27,147			—			129,688
Intercompany payables		2,085,339			6,655			66,335			(2,158,329	)		—
Other current liabilities—assets held-for-sale		—			5,520			2,102			—			7,622
Total current liabilities		2,510,242			152,387			159,673			(2,160,953	)		661,349
Long-term debt, net of current portion		4,971,179			—			—			—			4,971,179
Deferred income tax liabilities		180,916			1,581,833			8,836			—			1,771,585
Deferred service obligations—long-term		7,536			1,160			7,601			(2,583	)		13,714
Other long-term liabilities		34,559			30,587			34,504			(1,400	)		98,250
Total stockholders’ equity		2,961,031			9,357,738			518,757			(9,876,495	)		2,961,031
Total liabilities and stockholders’ equity	$	10,665,463		$	11,123,705		$	729,371		$	(12,041,431	)	$	10,477,108
Schedule of Consolidating Statement of Cash Flows	'
	CONSOLIDATING STATEMENT OF CASH FLOWS
	For the Year Ended September 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	OPERATING ACTIVITIES
	Net cash provided by operating activities	$	237,354		$	205,034		$	51,434		$	—		$	493,822
	INVESTING ACTIVITIES
	Acquisition of businesses		(6,053	)		—			(220	)		—			(6,273	)
	Payment of additional acquisition consideration		(16,808	)		—			—			—			(16,808	)
	Proceeds from sale of business, net of cash transferred		—			83,646			1,488			—			85,134
	Purchase of property and equipment		(15,480	)		(23,345	)		(10,129	)		—			(48,954	)
	Increase in equipment under customer usage agreements		(464	)		(24,443	)		(16,269	)		—			(41,176	)
	Purchase of insurance contracts		(4,000	)		—			—			—			(4,000	)
	Proceeds from sale of intellectual property		—			60,000			—			—			60,000
	Purchase of cost-method investments		(3,500	)		(225	)		—			—			(3,725	)
	Sale of cost-method investments		2,104			—			—			—			2,104
	Investment in subsdiaries		—			1,812			(1,812	)		—			—
	Increase in other assets		(2,097	)		(4,209	)		(1,242	)		—			(7,548	)
	Net cash provided by (used in) investing activities		(46,298	)		93,236			(28,184	)		—			18,754
	FINANCING ACTIVITIES
	Repayment of long-term debt		(265,000	)		—			—			—			(265,000	)
	Payment of debt issuance cost		(9,440	)											(9,440	)
	Payment of contingent consideration		(42,958	)		—			—			—			(42,958	)
	Deferred acquisition consideration		(1,655	)		—			—			—			(1,655	)
	Net proceeds from issuance of common stock pursuant to employee stock plans		75,100			—			—			—			75,100
	Excess tax benefit related to equity awards		7,439			—			—			—			7,439
	Payment of employee restricted stock minimum tax withholdings		(12,256	)		—			—			—			(12,256	)
	Intercompany dividend		169,209			(175,000	)		5,791			—			—
	Net cash used in (provided by) financing activities		(79,561	)		(175,000	)		5,791			—			(248,770	)
	Effect of exchange rate changes on cash and cash equivalents		—			(5,264	)		3,518			—			(1,746	)
	Net increase in cash and cash equivalents		111,495			118,006			32,559			—			262,060
	Cash and cash equivalents, beginning of period		210,028			269,416			80,986			—			560,430
	Cash and cash equivalents, end of period	$	321,523		$	387,422		$	113,545		$	—		$	822,490
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
	For the Year Ended September 29, 2012
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	OPERATING ACTIVITIES
	Net cash provided by operating activities	$	236,063		$	104,167		$	29,992		$	—		$	370,222
	INVESTING ACTIVITIES
	Acquisition of business, net of cash acquired		(3,971,970	)		196,771			12,796			—			(3,762,403	)
	Payment of additional acquisition consideration		(8,858	)		—			(926	)		—			(9,784	)
	Proceeds from sale of intellectual property		—			12,500			—			—			12,500
	Purchase of property and equipment		(13,247	)		(12,444	)		(7,458	)		—			(33,149	)
	Increase in equipment under customer usage agreements		—			(30,735	)		(14,889	)		—			(45,624	)
	Acquisition of in-process research and development assets		(4,500	)		—			—			—			(4,500	)
	Purchase of cost-method investment		—			(250	)		—			—			(250	)
	Increase in other assets		(558	)		(2,230	)		(4,786	)		—			(7,574	)
	Net cash (used in) provided by investing activities		(3,999,133	)		163,612			(15,263	)		—			(3,850,784	)
	FINANCING ACTIVITIES
	Proceeds from long-term debt		3,476,320			—			—			—			3,476,320
	Payment of debt issuance costs		(81,408	)		—			—			—			(81,408	)
	Payment of contingent consideration		(51,680	)		—			—			—			(51,680	)
	Payment of deferred acquisition consideration		(44,223	)		—			—			—			(44,223	)
	Net proceeds from issuance of common stock pursuant to employee stock plans		28,594			—			—			—			28,594
	Excess tax benefit related to equity awards		6,206			—			—			—			6,206
	Payment of employee restricted stock minimum tax withholdings		(5,710	)		—			—			—			(5,710	)
	Net cash provided by financing activities		3,328,099			—			—			—			3,328,099
	Effect of exchange rate changes on cash and cash equivalents		302			1,637			(1,378	)		—			561
	Net (decrease) increase in cash and cash equivalents		(434,669	)		269,416			13,351			—			(151,902	)
	Cash and cash equivalents, beginning of period		644,697			—			67,635			—			712,332
	Cash and cash equivalents, end of period	$	210,028		$	269,416		$	80,986		$	—		$	560,430
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
For the Year Ended September 24, 2011
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by operating activities	$	431,353		$	9,040		$	15,631		$	—		$	456,024
INVESTING ACTIVITIES
Acquisition of business, net of cash acquired		(240,917	)		9,070			33,103			—			(198,744	)
Payment of additional acquisition consideration		(19,660	)		—			—			—			(19,660	)
Divestiture activities, net of cash transferred		1,138			—			1,129			—			2,267
Proceeds from sale of intellectual property		750			12,500			—			—			13,250
Purchase of property and equipment		(11,512	)		(8,646	)		(7,627	)		—			(27,785	)
Increase in equipment under customer usage agreements		(1,121	)		(17,361	)		(9,396	)		—			(27,878	)
Purchase of licensed technology and other intangible assets		—			(3,021	)		—			—			(3,021	)
Purchase of insurance contracts		(5,322	)		—			—			—			(5,322	)
Purchase of cost-method investment		—			(99	)		—			—			(99	)
Increase in restricted cash		—			—			405			—			405
Net cash (used in) provided by investing activities		(276,644	)		(7,557	)		17,614			—			(266,587	)
FINANCING ACTIVITIES
Repayment of long-term debt and notes payable		—			(1,362	)		—			—			(1,362	)
Payment of debt issuance costs		(5,327	)		—			—			—			(5,327	)
Payment of contingent consideration		(4,294	)		—			—			—			(4,294	)
Net proceeds from issuance of common stock pursuant to employee stock plans		25,404			—			—			—			25,404
Excess tax benefit related to equity awards		3,652			—			—			—			3,652
Payment of employee restricted stock minimum tax withholdings		(10,399	)		—			—			—			(10,399	)
Net cash provided by (used in) financing activities		9,036			(1,362	)		—			—			7,674
Effect of exchange rate changes on cash and cash equivalents		48			(121	)		(331	)		—			(404	)
Net increase in cash and cash equivalents		163,793			—			32,914			—			196,707
Cash and cash equivalents, beginning of period		480,904			—			34,721			—			515,625
Cash and cash equivalents, end of period	$	644,697		$	—		$	67,635		$	—		$	712,332

Operations_Additional_Informat

Operations - Additional Information (Detail) (Gen-Probe Incorporated [Member], USD $)	Aug. 01, 2012
In Billions, unless otherwise specified
Gen-Probe Incorporated [Member]	'
Nature Of Operations [Line Items]	'
Debt obtained by the Company to finance the acquisition	$3.50

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Sep. 28, 2013

Jun. 29, 2013

Sep. 29, 2012

Dec. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Aug. 01, 2012

Sep. 28, 2013

Sep. 28, 2013

Jun. 29, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Customer

Customer

Customer

Customer

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Molecular Diagnostics [Member]

Other reporting units [Member]

Technology-Based Intangible Assets [Member]

Technology-Based Intangible Assets [Member]

Technology-Based Intangible Assets [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Accounts receivable [Member]

Accounts receivable [Member]

Total revenues [Member]

Total revenues [Member]

Total revenues [Member]

Reclassifications [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash equivalent maturity period

'

'

'

'

'Three months or less

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of customers with balance greater than specified percentage

0

'

0

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

10.00%

10.00%

10.00%

'

Impairment charges on tangible assets

'

'

'

'

$6,300,000

$19,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges on long lived assets

700,000

'

'

'

3,700,000

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property plant and equipment not material charge

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets useful life, minimum

'

'

'

'

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets useful life, maximum

'

'

'

'

'30 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charge

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

Acquired In-process research and development charges

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets from business acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000,000

1,570,000,000

'

'

'

'

'

'

'

In-process research and development assets

'

'

'

'

'

'

'

117,000,000

227,000,000

117,000,000

'

'

'

'

'

'

'

'

'

'

'

'

In-process research and development, value

'

'

'

'

'

'

'

93,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total cost of completion of IPR&D projects

'

'

'

'

'

'

'

49,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected number of years for project completion

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate assumption for fair value measurement of reporting unit

'

'

'

'

10.00%

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

1,100,000,000

'

5,800,000

'

1,117,369,000

5,826,000

'

'

'

'

1,100,000,000

'

'

'

'

'

'

'

'

'

'

'

Percentage used to provide additional disclosure of potential goodwill impairment in the future

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional impairment charge

'

'

'

'

195,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reporting unit's goodwill

'

'

'

'

'

'

'

'

'

'

'

2,500,000,000

'

'

'

'

'

'

'

'

'

'

Damage awarded by jury

'

'

'

18,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of equity ownership at which cost-method investments would not qualify for cost-method accounting

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other-than-temporary impairment charges

'

'

'

'

6,400,000

0

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of investment

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Defined contract term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'5 years

Product Warranty Term

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advertising cost

'

'

'

'

$14,100,000

$29,800,000

$29,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail) (Equity Securities [Member], USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Equity Securities [Member]	'	'
Schedule Of Marketable Securities [Line Items]	'	'
Cost	$5,931	$5,931
Gross Unrealized Gains	12,156	98
Gross Unrealized Losses	'	'
Fair Value	$18,087	$6,029

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Supplemental Cash Flow Statement Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Accounting Policies [Abstract]	'	'	'
Cash paid during the period for income taxes	$79,893	$166,565	$118,850
Cash paid during the period for interest	192,794	55,045	36,268
Non-Cash Investing Activities:	'	'	'
Fair value of stock options assumed in the Gen-Probe acquisition	'	2,655	'
Additional acquisition contingent consideration accrued	'	'	18,924
Non-Cash Financing Activities:	'	'	'
Fair value of contingent consideration at acquisition	525	'	86,600
Deferred payments for acquisitions	'	$1,655	$47,258

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Schedule of Inventories (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Accounting Policies [Abstract]	'	'
Raw materials	$115,575	$134,983
Work-in-process	51,171	93,218
Finished goods	122,617	138,990
Inventory net total	$289,363	$367,191

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipments (Detail)	12 Months Ended
	Sep. 28, 2013
Building and Improvements [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'35 years
Building and Improvements [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'40 years
Equipment and Software [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Equipment and Software [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'10 years
Equipment Under Customer Usage Agreements [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Equipment Under Customer Usage Agreements [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'8 years
Furniture and Fixtures [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Furniture and Fixtures [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'7 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'Shorter of the Original Term of Lease or Estimated Useful Life

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	$5,388,889	$5,363,927
Accumulated Amortization	1,482,167	1,062,677
Developed Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	4,008,947	3,784,689
Accumulated Amortization	1,094,435	788,274
In-process Research and Development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	24,000	227,000
Customer Relationships and Contracts [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,101,870	1,097,842
Accumulated Amortization	296,481	205,612
Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	238,103	240,092
Accumulated Amortization	81,844	60,318
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	13,026	11,417
Accumulated Amortization	8,495	7,906
Business Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	2,647	2,577
Accumulated Amortization	616	344
Non-Competition Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	296	310
Accumulated Amortization	$296	$223

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Schedule of Estimated Amortization Expense (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Accounting Policies [Abstract]	'
Fiscal 2014	$417,053
Fiscal 2015	402,177
Fiscal 2016	388,370
Fiscal 2017	379,260
Fiscal 2018	$368,505

Recovered_Sheet1

Summary of Significant Accounting Policies - Rollforward of Goodwill Activity by Reportable Segments (Detail) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	$3,942,779	'
Impairment charge	-1,100,000	-5,800	-1,117,369	-5,826
Disposition of portion of a reporting unit	'	'	-1,257	'
Gen-Probe valuation revision adjustment	'	'	-15,750	'
Tax adjustments	'	'	-856	'
Foreign currency	'	'	265	'
Ending balance	2,814,528	3,942,779	2,814,528	3,942,779
Gen-Probe Incorporated [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Acquisition adjustments	'	'	4,226	'
Chindex Medical Limited [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Acquisition adjustments	'	'	1,798	'
SenoRx, Inc [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Acquisition adjustments	'	'	692	'
Breast Health [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	635,741	'
Impairment charge	'	'	'	'
Foreign currency	'	'	-1,866	'
Ending balance	636,365	'	636,365	'
Breast Health [Member] | Chindex Medical Limited [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Acquisition adjustments	'	'	1,798	'
Breast Health [Member] | SenoRx, Inc [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Acquisition adjustments	'	'	692	'
Diagnostics [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	2,283,447	'
Impairment charge	'	'	-1,117,369	'
Disposition of portion of a reporting unit	'	'	-1,257	'
Gen-Probe valuation revision adjustment	'	'	-15,750	'
Tax adjustments	'	'	-868	'
Foreign currency	'	'	1,125	'
Ending balance	1,153,554	'	1,153,554	'
Diagnostics [Member] | Gen-Probe Incorporated [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Acquisition adjustments	'	'	4,226	'
GYN Surgical [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	1,015,466	'
Impairment charge	'	'	'	'
Tax adjustments	'	'	12	'
Foreign currency	'	'	978	'
Ending balance	1,016,456	'	1,016,456	'
Skeletal Health [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning balance	'	'	8,125	'
Foreign currency	'	'	28	'
Ending balance	$8,153	'	$8,153	'

Recovered_Sheet2

Summary of Significant Accounting Policies - Rollforward of Accumulated Goodwill Impairment Losses by Reportable Segment (Detail) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Goodwill [Line Items]	'	'	'	'
Beginning Balance, Accumulated goodwill impairment losses	'	'	$2,422,572	'
Impairment charge	1,100,000	5,800	1,117,369	5,826
Ending Balance, Accumulated goodwill impairment losses	3,539,941	2,422,572	3,539,941	2,422,572
Breast Health [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning Balance, Accumulated goodwill impairment losses	'	'	348,419	'
Impairment charge	'	'	'	'
Ending Balance, Accumulated goodwill impairment losses	348,419	'	348,419	'
Diagnostics [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning Balance, Accumulated goodwill impairment losses	'	'	908,349	'
Impairment charge	'	'	1,117,369	'
Ending Balance, Accumulated goodwill impairment losses	2,025,718	'	2,025,718	'
GYN Surgical [Member]	'	'	'	'
Goodwill [Line Items]	'	'	'	'
Beginning Balance, Accumulated goodwill impairment losses	'	'	1,165,804	'
Impairment charge	'	'	'	'
Ending Balance, Accumulated goodwill impairment losses	$1,165,804	'	$1,165,804	'

Recovered_Sheet3

Summary of Significant Accounting Policies - Schedule of Other Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
Accounting Policies [Abstract]	'	'
Deferred financing costs	$60,620	$82,760
Life insurance contracts	33,864	25,978
Mutual funds	6,861	6,995
Marketable security	18,087	6,029
Manufacturing access fees	15,971	18,323
Cost-method equity investments	12,558	15,976
Other	15,941	6,006
Other assets	$163,902	$162,067

Recovered_Sheet4

Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Income (Loss) (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Accounting Policies [Abstract]	'	'
Foreign currency translation adjustment	$8,584	$7,211
Unrealized gains on available-for-sale securities	12,156	62
Minimum pension liability, net of tax of $150 and $207, respectively	-349	-483
Accumulated other comprehensive income	$20,391	$6,790

Recovered_Sheet5

Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Accounting Policies [Abstract]	'	'
Minimum pension liability, tax	$150	$207

Recovered_Sheet6

Summary of Significant Accounting Policies - Accounts Receivable Reserve Activity (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Accounting Policies [Abstract]	'	'	'
Balance at Beginning of Period	$6,396	$6,516	$7,769
Charged to Costs and Expenses	4,296	3,270	1,614
Write- offs and Payments	-1,894	-3,390	-2,867
Balance at End of Period	$8,798	$6,396	$6,516

Recovered_Sheet7

Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Share Amounts (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Earnings Per Share [Line Items]	'	'	'
Basic weighted average common shares outstanding	268,704	264,041	261,099
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units	'	'	3,206
Diluted weighted average common shares outstanding	268,704	264,041	264,305
Outstanding Stock Options [Member]	'	'	'
Weighted-average anti-dilutive shares related to:	'	'	'
Weighted-average anti-dilutive shares	8,445	10,491	7,747
Restricted Stock Units [Member]	'	'	'
Weighted-average anti-dilutive shares related to:	'	'	'
Weighted-average anti-dilutive shares	1,109	1,378	'

Recovered_Sheet8

Summary of Significant Accounting Policies - Product Warranty (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
Accounting Policies [Abstract]	'	'
Balance at Beginning of Period	$6,179	$4,448
Provisions	12,827	9,535
Acquired	'	230
Settlements/ Adjustments	-9,748	-8,034
Balance at End of Period	$9,258	$6,179

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Mar. 30, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Jan. 03, 2013

Sep. 28, 2013

Sep. 28, 2013

Dec. 31, 2012

31-May-13

Jun. 01, 2011

Sep. 28, 2013

Sep. 29, 2012

Dec. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Aug. 01, 2012

Jun. 29, 2013

Dec. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Jan. 06, 2011

Mar. 30, 2013

Mar. 24, 2012

Sep. 28, 2013

Sep. 24, 2011

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Mar. 30, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Jul. 19, 2011

Jul. 19, 2011

Jul. 19, 2011

Jul. 19, 2011

Jul. 19, 2011

Jul. 19, 2011

Property, Plant and Equipment [Member]

Land and Buildings [Member]

Chindex Medical Limited [Member]

SenoRx, Inc [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

Trade Names [Member]

Customer Relationships [Member]

Business Licenses [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Gen-Probe Incorporated [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Interlace Medical, Inc [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Beijing Healthcome Technology Company, Ltd. [Member]

Y

Y

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

Minimum [Member]

Maximum [Member]

Developed Technology [Member]

Customer Contract [Member]

Trade Names [Member]

First measurement period [Member]

First measurement period [Member]

Second measurement period [Member]

Developed Technology [Member]

Trade Names [Member]

Minimum [Member]

Maximum [Member]

Developed Technology [Member]

Trade Names [Member]

In-process Research and Development [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net purchase price

'

'

'

'

'

'

'

$4,400,000

$2,400,000

$148,400,000

'

'

'

'

'

'

'

'

'

$3,972,176,000

'

'

'

'

'

'

'

'

'

$213,398,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$82.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount paid to shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,800,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount paid to equity award holders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

169,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net debt obtained by the Company to finance the acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,480,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Direct transaction costs incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining fair value of stock options assumed to be recognized as compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate

'

0.50%

0.70%

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.41%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 7 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield, rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of stock options, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.07

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in developed technology

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in process research and development

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustment to valuation of intangibles

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement to sell LIFECODES business to Immucor

'

'

'

'

85,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payment of an additional amount based on future revenue results

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on the sale of LIFECODES business

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held-for-sale

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate used for cash flow projections

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.50%

'

'

'

'

'

'

10.00%

12.00%

'

'

'

15.60%

'

'

12.70%

'

'

'

'

'

'

'

'

'

'

27.00%

30.00%

'

'

'

In-process research and development

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

117,000,000

'

'

117,000,000

227,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

In-process research and development, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

93,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total cost of completion of IPR&D projects

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected number of years for project completion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, estimated useful life, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'13 years 4 months 24 days

'13 years

'11 years

'

'

'

'

'

'

'

'

'

'15 years

'13 years

'

'

'

'

'

'13 years

'7 years

'

Fair value adjustment to increase the carrying amount

'

'

'

'

'

107,900,000

70,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue earned by Gen-Probe post-acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

89,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax income (loss) from Gen-Probe post-acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition of equity interest, percentage

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

Cash portion of purchase price

'

'

'

'

'

'

'

'

'

135,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid

'

6,273,000

'

'

'

'

'

'

'

100,000,000

'

'

900,000

'

'

'

'

'

'

3,967,866,000

'

'

'

'

'

'

'

'

'

126,798,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred payment

'

'

1,655,000

47,258,000

'

'

'

'

'

35,000,000

'

47,500,000

'

'

47,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated working capital adjustment

'

'

'

'

'

'

'

'

'

13,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred payment, period deferred (Years)

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Working Capital

'

'

'

'

'

'

'

'

'

'

'

8,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of annual contingent payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum contingent earn-out payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000,000

75,500,000

17,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration payments

'

42,958,000

51,680,000

4,294,000

'

'

'

'

'

'

87,400,000

54,000,000

'

31,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

93,800,000

51,800,000

'

'

'

'

'

'

'

'

'

'

'

Accrued contingent consideration

'

'

'

'

'

'

'

'

'

'

31,700,000

'

'

31,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, weighted average useful life, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

'12 years 8 months 12 days

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum additional contingent payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

225,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,100,000

'

'

'

Contingent consideration arrangements recorded as compensation expense

'

80,010,000

81,031,000

20,002,000

'

'

'

'

'

'

'

'

'

80,010,000

75,459,000

17,581,000

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

5,600,000

300,000

'

'

'

'

'

'

Contingent consideration liability, fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

86,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration obligation, fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,300,000

'

41,800,000

'

'

86,900,000

'

'

'

'

'

'

'

'

'

'

Contingent consideration - fair value adjustments

'

11,310,000

38,466,000

-8,016,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of contingent consideration classified in the financing section of the statement of cash flows

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39,000,000

47,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash portion of purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,800,000

'

'

'

'

'

Finite-lived intangible assets, weighted average useful life, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

200,000

900,000

The excess of the purchase price over the fair value recorded to goodwill

'

$2,814,528,000

$3,942,779,000

'

'

'

'

'

'

$75,161,000

'

'

'

'

'

'

'

'

'

$1,641,020,000

'

'

'

'

'

'

'

'

'

$88,081,000

'

'

'

'

'

'

'

'

'

'

'

'

$6,400,000

'

'

'

'

'

Business_Combinations_Purchase

Business Combinations - Purchase Price Allocation (Detail) (USD $)	12 Months Ended			1 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011	Aug. 01, 2012	Jan. 06, 2011
				Gen-Probe Incorporated [Member]	Interlace Medical, Inc [Member]
Schedule Of Business Acquisitions Purchase Price Allocation [Line Items]	'	'	'	'	'
Cash	$6,273	'	'	$3,967,866	$126,798
Deferred payment	'	'	'	1,655	'
Contingent consideration	525	'	86,600	'	86,600
Fair value of stock options exchanged	'	2,655	'	2,655	'
Total purchase price	'	'	'	$3,972,176	$213,398

Business_Combinations_Componen

Business Combinations - Components of Purchase Price Allocation (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012	Jan. 06, 2011	Sep. 28, 2013	Sep. 29, 2012	Aug. 01, 2012	Jun. 01, 2011
In Thousands, unless otherwise specified			Interlace Medical, Inc [Member]	Gen-Probe Incorporated [Member]	Gen-Probe Incorporated [Member]	Gen-Probe Incorporated [Member]	TCT International Co., Ltd. [Member]
Schedule Of Business Acquisitions Purchase Price Allocation [Line Items]	'	'	'	'	'	'	'
Cash	'	'	$9,070	'	'	$205,463	$27,961
Accounts receivable	'	'	'	'	'	81,444	17,811
Inventory	'	'	1,795	'	'	153,416	5,301
Property, plant and equipment	'	'	'	'	'	274,095	4,710
Other assets	'	'	'	'	'	191,971	'
Other tangible assets	'	'	1,291	'	'	'	1,082
Assets held-for-sale, net	'	'	'	'	'	87,465	'
Accrued taxes	'	'	'	'	'	'	-14,874
Accounts payable	'	'	'	'	'	-19,671	'
Accounts payable and accrued expenses	'	'	-1,988	'	'	'	-6,641
Accrued expenses	'	'	'	'	'	-131,623	'
Developed technology	'	'	158,741	'	'	1,700,000	'
Customer relationships	'	'	'	'	'	585,000	45,780
Other liabilities	'	'	'	'	'	-22,939	'
Business licenses	'	'	'	'	'	'	2,500
Identifiable intangible assets:	'	'	'	'	'	'	'
Developed technology	'	'	158,741	'	'	1,700,000	'
In-process research and development	'	'	'	117,000	227,000	117,000	'
Customer contract	'	'	'	'	'	585,000	45,780
Trade names	'	'	1,750	'	'	95,000	2,110
Deferred income taxes, net	'	'	'	'	'	-985,465	'
Goodwill	2,814,528	3,942,779	88,081	'	'	1,641,020	75,161
Trade names	'	'	1,750	'	'	95,000	2,110
Deferred taxes, net	'	'	-45,342	'	'	'	-12,473
Goodwill	2,814,528	3,942,779	88,081	'	'	1,641,020	75,161
Purchase Price	'	'	$213,398	'	'	$3,972,176	$148,428

Business_Combinations_Assets_G

Business Combinations - Assets Groups Classified as Held For Sale (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Assets:	'	'
Other assets	$2,997	$94,503
Gen-Probe Incorporated [Member]	'	'
Assets:	'	'
Cash	'	2,563
Accounts receivable	'	8,520
Inventory	'	15,680
Property, plant and equipment	'	13,259
Other assets	'	3,083
Intangible assets and goodwill	'	51,398
Total assets held-for-sale	'	94,503
Liabilities:	'	'
Accrued liabilities	'	-7,622
Net assets held-for-sale	'	$86,881

Business_Combinations_Schedule

Business Combinations - Schedule of Unaudited Pro Forma Information (Detail) (Gen-Probe Incorporated [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 29, 2012	Sep. 24, 2011
Gen-Probe Incorporated [Member]	'	'
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]	'	'
Revenue	$2,526,336	$2,310,384
Net loss	($164,539)	($127,240)
Basic and diluted net loss per common share	($0.62)	($0.49)

Restructuring_and_Divestiture_2

Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail) (USD $)	3 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Non-cash impairment charge	'	'	'	'	$7,667	$16,901	'
Fiscal 2013 restructuring and divestiture charges	9,700	6,700	12,500	16,700	32,805	17,515	-71
Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Non-cash impairment charge	'	'	'	'	'	16,901	'
Purchase orders and other contractual obligations	'	'	'	'	'	3,099	'
Workforce reductions	'	'	'	'	'	15,249	'
Facility closure costs	'	'	'	'	'	430	'
Other	'	'	'	'	'	900	'
Total fiscal charges	'	'	'	'	'	36,579	'
Recorded to cost of product sales	'	'	'	'	'	19,064	'
Recorded to restructuring	'	'	'	'	'	17,515	'
Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Non-cash impairment charge	'	'	'	'	54	'	'
Workforce reductions	'	'	'	'	31,214	'	'
Facility closure costs	'	'	'	'	550	'	'
Other	'	'	'	'	929	'	'
Total fiscal charges	'	'	'	'	32,693	'	'
Divestiture net charges	'	'	'	'	112	'	'
Fiscal 2013 restructuring and divestiture charges	'	'	'	'	32,805	'	'
Abandonment of Adiana Product Line [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Non-cash impairment charge	'	'	'	'	'	16,316	'
Purchase orders and other contractual obligations	'	'	'	'	'	3,099	'
Workforce reductions	'	'	'	'	'	128	'
Total fiscal charges	'	'	'	'	'	19,543	'
Recorded to cost of product sales	'	'	'	'	'	19,064	'
Recorded to restructuring	'	'	'	'	'	479	'
Consolidation of Diagnostics Operations [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Non-cash impairment charge	'	'	'	'	'	585	'
Workforce reductions	'	'	'	'	'	14,202	'
Total fiscal charges	'	'	'	'	'	14,787	'
Recorded to restructuring	'	'	'	'	'	14,787	'
Consolidation of Diagnostics Operations [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Workforce reductions	'	'	'	'	13,950	'	'
Total fiscal charges	'	'	'	'	13,950	'	'
Fiscal 2013 restructuring and divestiture charges	'	'	'	'	13,950	'	'
Closure of Indianapolis Facility [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Workforce reductions	'	'	'	'	'	879	'
Other	'	'	'	'	'	900	'
Total fiscal charges	'	'	'	'	'	1,779	'
Recorded to restructuring	'	'	'	'	'	1,779	'
Closure of Indianapolis Facility [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Workforce reductions	'	'	'	'	4,805	'	'
Facility closure costs	'	'	'	'	173	'	'
Other	'	'	'	'	651	'	'
Total fiscal charges	'	'	'	'	5,629	'	'
Fiscal 2013 restructuring and divestiture charges	'	'	'	'	5,629	'	'
Fiscal 2013 Actions [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Workforce reductions	'	'	'	'	11,332	'	'
Other	'	'	'	'	42	'	'
Total fiscal charges	'	'	'	'	11,374	'	'
Fiscal 2013 restructuring and divestiture charges	'	'	'	'	11,374	'	'
Other Operating Cost Reductions [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Workforce reductions	'	'	'	'	'	40	'
Facility closure costs	'	'	'	'	'	430	'
Total fiscal charges	'	'	'	'	'	470	'
Recorded to restructuring	'	'	'	'	'	470	'
Other Operating Cost Reductions [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Non-cash impairment charge	'	'	'	'	54	'	'
Workforce reductions	'	'	'	'	1,127	'	'
Facility closure costs	'	'	'	'	377	'	'
Other	'	'	'	'	236	'	'
Total fiscal charges	'	'	'	'	1,740	'	'
Fiscal 2013 restructuring and divestiture charges	'	'	'	'	$1,740	'	'

Restructuring_and_Divestiture_3

Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
Restructuring Cost and Reserve [Line Items]	'	'
Non-cash impairment charges	($7,667)	($16,901)
Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	'	36,579
Non-cash impairment charges	'	-16,901
Stock compensation	'	-3,500
Severance payments	'	-2,629
Other payments	'	-3,002
Acquired	'	83
Foreign exchange and other adjustments	'	113
Balance	'	10,743
Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	32,693	'
Non-cash impairment charges	-54	'
Stock compensation	-7,917	'
Severance payments	-21,438	'
Other payments	-1,678	'
Foreign exchange and other adjustments	-10	'
Balance	12,339	'
Abandonment of Adiana Product Line [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	'	19,543
Non-cash impairment charges	'	-16,316
Severance payments	'	-128
Other payments	'	-2,572
Balance	'	527
Abandonment of Adiana Product Line [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Other payments	-527	'
Consolidation of Diagnostics Operations [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	'	14,787
Non-cash impairment charges	'	-585
Stock compensation	'	-3,500
Severance payments	'	-2,423
Acquired	'	83
Foreign exchange and other adjustments	'	22
Balance	'	8,384
Consolidation of Diagnostics Operations [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	13,950	'
Stock compensation	-6,322	'
Severance payments	-13,068	'
Foreign exchange and other adjustments	-2	'
Balance	2,942	'
Closure of Indianapolis Facility [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	'	1,779
Balance	'	1,779
Closure of Indianapolis Facility [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	5,629	'
Severance payments	-3,048	'
Other payments	-566	'
Balance	3,794	'
Fiscal 2013 Actions [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	11,374	'
Stock compensation	-1,595	'
Severance payments	-4,425	'
Other payments	-25	'
Foreign exchange and other adjustments	-14	'
Balance	5,315	'
Other Operating Cost Reductions [Member] | Fiscal 2012 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	'	470
Severance payments	'	-78
Other payments	'	-430
Foreign exchange and other adjustments	'	91
Balance	'	53
Other Operating Cost Reductions [Member] | Fiscal 2013 Charges [Member] | Restructuring [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total fiscal charges	1,740	'
Non-cash impairment charges	-54	'
Severance payments	-897	'
Other payments	-560	'
Foreign exchange and other adjustments	6	'
Balance	$288	'

Restructuring_and_Divestiture_4

Restructuring and Divestiture Charges - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Mar. 24, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Mar. 24, 2012

Sep. 29, 2012

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Mar. 24, 2012

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Indiana [Member ]

Indiana [Member ]

Subsequent Event [Member]

Restructuring [Member]

Restructuring [Member]

Abandonment of Adiana Product Line [Member]

Abandonment of Adiana Product Line [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Consolidation of Diagnostics Operations [Member]

Site Closure Costs [Member]

One-time Termination Benefits [Member]

Other Operating Cost Reductions [Member]

Other Operating Cost Reductions [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Closure of Indianapolis Facility [Member]

Employee Severance [Member]

Restructuring [Member]

Employees

Restructuring [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Divestiture charges

'

'

'

$18,300,000

'

'

'

'

'

'

'

'

'

$18,300,000

$19,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges - cost of product sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,100,000

'

'

'

'

'

'

'

'

'

'

'

'

Other restructuring charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges related to inventory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,900,000

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges related to manufacturing equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Charges related to outstanding contractual obligations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

Severance charge

'

4,600,000

'

'

300,000

'

'

'

'

'

4,600,000

'

'

'

100,000

900,000

3,200,000

13,300,000

10,800,000

'

1,100,000

100,000

'

900,000

'

4,800,000

6,800,000

Restructuring charges not recorded in cost of product sales

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

52,307,000

40,572,000

35,472,000

'

'

'

9,029,000

3,500,000

'

'

'

'

3,500,000

6,300,000

'

'

'

'

'

'

'

'

Employee retention program, payments in cash

'

'

9,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated aggregate severance charges

'

5,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,400,000

'

'

'

'

'

'

'

6,000,000

'

'

Exiting charges

'

'

'

'

'

'

'

'

900,000

800,000

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

Compensation charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

Number of employees affected

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

Impairment charges

'

'

'

'

'

7,667,000

16,901,000

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

Lease obligation charge and write-off of related leaseholds

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charges related to termination of lease

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

Impairment charges for assets held for sale

700,000

'

'

'

'

3,700,000

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held for sale, sales value

3,000,000

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held-for-sale inventory and equipment

2,400,000

'

'

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assets held-for-sale Goodwill

600,000

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on the sale of LIFECODES business

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Disposition charges

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from sale of minor non-core product line

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net gain on sale of minor non-core product line

'

'

'

'

$400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings_and_Credit_Arrangem2

Borrowings and Credit Arrangements - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

Dec. 10, 2010

Sep. 28, 2013

Mar. 30, 2013

Mar. 24, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Aug. 01, 2012

Aug. 01, 2012

Sep. 28, 2013

Sep. 29, 2012

Dec. 10, 2007

Sep. 28, 2013

Dec. 10, 2007

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Aug. 02, 2013

Sep. 28, 2013

Aug. 02, 2013

Aug. 02, 2013

Aug. 02, 2013

Aug. 02, 2013

Dec. 24, 2011

Nov. 18, 2010

Nov. 18, 2010

Mar. 24, 2012

Feb. 29, 2012

Feb. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Dec. 10, 2010

Sep. 28, 2013

Sep. 28, 2013

Nov. 14, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Feb. 14, 2013

Feb. 14, 2013

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Term Loan A [Member]

Term Loan A [Member]

Term Loan A [Member]

Term Loan A [Member]

Term Loan A [Member]

Term Loan A [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

Term Loan B [Member]

November 18, 2010 [Member]

November 18, 2010 [Member]

November 18, 2010 [Member]

February 29, 2012 [Member]

February 29, 2012 [Member]

February 29, 2012 [Member]

2007 Notes [Member]

2007 Notes [Member]

2007 Notes [Member]

2007 Notes [Member]

2007 Notes [Member]

2007 Notes [Member]

2010 Notes [Member]

2010 Notes [Member]

2010 Notes [Member]

2010 Notes [Member]

2010 Notes [Member]

2010 Notes [Member]

2012 Notes [Member]

2012 Notes [Member]

2012 Notes [Member]

2012 Notes [Member]

2012 Notes [Member]

December 15, 2017 [Member]

Thereafter [Member]

2013 Notes [Member]

2013 Notes [Member]

2013 Notes [Member]

2013 Notes [Member]

Revolving Facility [Member]

February 14, 2013 [Member]

February 14, 2013 [Member]

2007 Notes [Member]

2013 Notes [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Revolving Credit Facility [Member]

Subsequent Event [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Credit Agreement [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Credit Agreement [Member]

Convertible Notes [Member]

Convertible Notes [Member]

Minimum [Member]

Maximum [Member]

Percentage Added to Base Rate [Member]

Percentage Added to Eurodollar Rate [Member]

Percentage Added to Base Rate [Member]

Percentage Added to Eurodollar Rate [Member]

Base Rate Floor [Member]

Eurodollar Rate Floor [Member]

2007 Notes [Member]

2007 Notes [Member]

Minimum [Member]

Maximum [Member]

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

2013 Notes [Member]

2013 Notes [Member]

Minimum [Member]

Maximum [Member]

2007 Notes [Member]

Schedule Of Borrowings [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Carrying value of debt

'

$4,805,910,000

'

'

$4,805,910,000

$5,035,614,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facilities maximum borrowings

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000,000

'

'

'

'

'

'

'

'

1,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000,000

'

'

Debt instrument maturity date

'

'

'

'

'

'

'

'

'

'

'

'

1-Aug-20

'

'

'

'

'

1-Aug-17

'

'

'

'

'

'

'

'

1-Aug-19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Aug-17

'

'

Financing in an aggregate amount

'

'

'

'

'

'

'

'

'

'

2,800,000,000

1,000,000,000

'

'

'

'

1,725,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

450,000,000

'

500,000,000

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

370,000,000

370,000,000

Borrowed principal under credit agreement

'

'

'

'

'

'

'

2,240,000,000

2,240,000,000

'

2,500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing in an aggregate amount

'

'

'

'

'

'

'

'

2,410,000,000

'

'

987,400,000

'

'

1,690,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Applicable margin on refinanced Term Loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

0.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Applicable margin on refinanced Revolving Facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument base rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

2.00%

'

'

'

'

'

1.75%

2.75%

2.00%

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt extinguishment gain loss

'

6,000,000

3,200,000

42,300,000

-9,209,000

-42,347,000

-29,891,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

29,900,000

'

'

42,300,000

'

'

'

'

'

'

'

'

'

'

29,900,000

'

'

'

'

42,300,000

'

'

'

'

'

'

'

'

'

'

0

'

Refinancing issuance costs

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Direct third-party costs

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepayment of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Guarantors capital stock

'

'

'

'

'

'

'

65.00%

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal payments under Term Loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,500,000

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal payments under Term Loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitment fee percentage

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average interest rates, Borrowings outstanding under the credit agreement

'

'

'

'

'

'

'

3.70%

3.70%

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rates under Term Loans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.20%

'

'

'

'

'

'

'

'

3.75%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense

'

'

'

'

'

'

'

'

107,600,000

18,400,000

'

'

63,900,000

10,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash interest expense amortization of debt discount and deferred financing costs

'

'

'

'

81,177,000

74,974,000

76,814,000

'

14,500,000

2,400,000

'

'

1,600,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum net leverage ratio

'

'

'

'

'

'

'

'

7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease in leverage ratio

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum interest coverage ratio

'

'

'

'

'

'

'

3.25

3.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in interest coverage ratio

'

'

'

'

'

'

'

'

3.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

6.25%

'

'

'

'

2.00%

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

2.00%

'

'

2.00%

'

'

'

'

'

'

'

2.00%

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

2.00%

'

Maturity period

'

'

'

'

'

'

'

'

'

'

'

'2020

'

'

'2037

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2037

'

'

'2042

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2043

'

Offering price of principal amount

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amounts redeemed, percentage

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price equal to the aggregate principal amount so redeemed plus accrued and unpaid interest, percentage

'

'

'

'

'

'

'

'

'

'

'

106.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price of notes on or after: August 1, 2015 through July 31, 2016 of par value , percentage

'

'

'

'

'

'

'

'

'

'

'

103.13%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price of notes on or after: August 1, 2016 through July 31, 2017 of par value, percentage

'

'

'

'

'

'

'

'

'

'

'

102.08%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption price of notes on or after: August 1, 2017 through July 31, 2018 of par value, percentage

'

'

'

'

'

'

'

'

'

'

'

101.04%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption Price of notes on or after: August 1, 2018 and thereafter of par value, percentage

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage price of principal amount for repurchase of Senior notes in a change-in-control

'

'

'

'

'

'

'

'

'

'

'

101.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption Price of Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal payable, beginning date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Dec-17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase of outstanding notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate principal accretion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

2.00%

'

'

'

'

2.00%

'

'

4.00%

2.00%

'

'

'

'

'

'

'

Percent by which trading price of notes exceeds accreted principal resulting in contingent interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

'

'

'

'

'

120.00%

'

'

'

'

120.00%

'

'

'

'

'

'

'

'

'

'

'

Conversion price common shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$38.59

'

'

'

'

'

$23.03

'

'

'

'

'

$31.18

'

'

'

'

'

'

$38.59

'

'

'

'

'

'

Sales price exceeds conversion price, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

130.00%

'

'

'

'

'

130.00%

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

Maximum number of days the sales price exceeds sales price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'30 days

'

'

'

'

'

'20 days

'30 days

'

'

'

'20 days

'30 days

'

'

'

'

'20 days

'30 days

'

'

'

Percent of trading price per note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

98.00%

'

'

'

'

'

'

'

98.00%

'

'

'

'

98.00%

'

'

'

'

'

98.00%

'

'

'

'

'

Conversion description of notes in to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'During the five business day period after any five consecutive trading day period

'

'

'

'

'

'

'

'During the five business day period after any five consecutive trading day period

'

'

'

'

'During the five business day period after any five consecutive trading day period

'

'

'

'

'

'During the five business day period after any five consecutive trading day period

'

'

'

'

'

Non convertible common stock in excess of principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid to satisfy conversion obligations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of liability component of convertible notes at issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,256,000,000

'

'

'

349,000,000

'

'

'

'

'

454,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated effective interest rate

7.62%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.25%

'

'

'

'

6.52%

'

'

'

'

'

3.72%

'

'

'

'

'

'

'

5.42%

'

'

'

'

'

Fair value of conversion option

'

'

'

'

20,045,000

23,012,000

34,699,000

'

'

'

'

'

'

'

'

32,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

468,900,000

'

'

'

'

'

97,300,000

'

'

'

'

'

79,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes exchange loss on debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,000,000

'

'

'

'

'

39,700,000

'

'

'

'

'

'

'

'

'

'

'

'

Write-off of debt issuance costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,900,000

'

'

'

'

'

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, effective interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.46%

'

'

'

'

'

2.89%

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocation to the reacquisition of the equity component

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39,900,000

'

'

'

'

'

41,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Cash flow present value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

Percent of change in the fair value of the conversion option

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

Gain or loss from exchange

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Direct cost incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of days to remedy of the convertible notes

'

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extension fee percentage

'

0.25%

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares to convertible note holders

'

75.6

'

'

75.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Borrowings_and_Credit_Arrangem3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Schedule Of Borrowings [Line Items]	'	'
Convertible Notes	$400,133	'
Current debt obligations, net of debt discount	563,812	64,435
Convertible Notes	1,187,992	1,558,660
Total long-term debt obligations	4,242,098	4,971,179
Total debt obligations	4,805,910	5,035,614
Term Loan A [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Current debt obligations, net of debt discount	49,713	49,582
Long-term debt obligations, net of debt discount	894,834	942,065
Term Loan B [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Current debt obligations, net of debt discount	113,966	14,853
Long-term debt obligations, net of debt discount	1,159,272	1,470,454
Senior Notes [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Long-term debt obligations, net of debt discount	$1,000,000	$1,000,000

Borrowings_and_Credit_Arrangem4

Borrowings and Credit Arrangements - Debt Maturity Schedule for Components of Company's Obligations (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Schedule Of Borrowings [Line Items]	'
2014	$570,000
2015	115,000
2016	215,000
2017	1,065,000
2018	894,225
2019 and Thereafter	2,110,000
Total	4,969,225
Term Loan A [Member]	'
Schedule Of Borrowings [Line Items]	'
2014	50,000
2015	100,000
2016	200,000
2017	600,000
Total	950,000
Term Loan B [Member]	'
Schedule Of Borrowings [Line Items]	'
2014	115,000
2015	15,000
2016	15,000
2017	15,000
2018	15,000
2019 and Thereafter	1,110,000
Total	1,285,000
Senior Notes [Member]	'
Schedule Of Borrowings [Line Items]	'
2019 and Thereafter	1,000,000
Total	1,000,000
Convertible Notes [Member]	'
Schedule Of Borrowings [Line Items]	'
2014	405,000
2017	450,000
2018	879,225
Total	$1,734,225

Borrowings_and_Credit_Arrangem5

Borrowings and Credit Arrangements - Debt Maturity Schedule for Components of Company's Obligations (Parenthetical) (Detail) (Term Loan B [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013
Term Loan B [Member]	'
Schedule Of Borrowings [Line Items]	'
Debt Early Pay down	$100

Borrowings_and_Credit_Arrangem6

Borrowings and Credit Arrangements - Convertible Notes and Related Equity Components (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
2007 Notes [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Notes principal amount	$405,000	$775,000
Unamortized discount	-4,867	-50,591
Net carrying amount	400,133	724,409
Equity component, net of taxes	121,496	233,353
2010 Notes [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Notes principal amount	450,000	450,000
Unamortized discount	-58,310	-74,062
Net carrying amount	391,690	375,938
Equity component, net of taxes	60,054	60,054
2012 Notes [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Notes principal amount	500,000	500,000
Unamortized discount	-34,630	-41,687
Net carrying amount	465,370	458,313
Equity component, net of taxes	49,195	49,195
2013 Notes [Member]	'	'
Schedule Of Borrowings [Line Items]	'	'
Notes principal amount	370,000	'
Principal accretion	9,225	'
Unamortized discount	-48,293	'
Net carrying amount	330,932	'
Equity component, net of taxes	$131,451	'

Borrowings_and_Credit_Arrangem7

Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Debt Conversion [Line Items]	'	'	'
Non-cash interest expense	$81,177	$74,974	$76,814
Convertible Notes Payable [Member]	'	'	'
Debt Conversion [Line Items]	'	'	'
Amortization of debt discount	52,732	68,532	72,908
Amortization of deferred financing costs	3,048	3,828	3,906
Principal accretion	9,225	'	'
Non-cash interest expense	65,005	72,360	76,814
2.00% accrued interest	34,376	34,898	34,427
Interest expense, net	$99,381	$107,258	$111,241

Borrowings_and_Credit_Arrangem8

Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Parenthetical) (Detail) (Convertible Notes Payable [Member])	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Convertible Notes Payable [Member]	'	'	'
Debt Conversion [Line Items]	'	'	'
Percentage of accrued interest on Convertible Notes	2.00%	2.00%	2.00%

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Aug. 01, 2012
						Molecular Diagnostics [Member]	Mammosite [Member]	Credit Agreement [Member]	Credit Agreement [Member]
Fair Value Measurement [Line Items]	'	'	'	'	'	'	'	'	'
Cash and cash equivalents, fair value	'	$300,000	'	$300,000	'	'	'	'	'
Impairment of goodwill	1,100,000,000	5,800,000	1,117,369,000	5,826,000	'	1,100,000,000	5,800,000	'	'
Cost-method equity investments in non-publicly traded securities	12,600,000	16,000,000	12,600,000	16,000,000	'	'	'	'	'
Other-than-temporary impairment charge	'	'	6,400,000	'	2,400,000	'	'	'	'
Borrowed principal under credit agreement	'	'	'	'	'	'	'	2,240,000,000	2,500,000,000
Fair value of Senior Notes	$1,050,000,000	'	$1,050,000,000	'	'	'	'	'	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Assets:	'	'
Assets measured at fair value on a recurring basis	$24,948	$13,339
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	42,391	118,450
Money Market Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	315
Equity Securities [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	18,087	6,029
Mutual Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	6,861	6,995
Deferred Compensation Liabilities [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	38,611	32,082
Contingent Consideration [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	3,780	86,368
Quoted Prices in Active Market for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	24,948	13,339
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	38,611	32,082
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Money Market Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	315
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Equity Securities [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	18,087	6,029
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Mutual Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	6,861	6,995
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Deferred Compensation Liabilities [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	38,611	32,082
Quoted Prices in Active Market for Identical Assets (Level 1) [Member] | Contingent Consideration [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	'	'
Significant Other Observable Inputs (Level 2) [Member] | Money Market Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Significant Other Observable Inputs (Level 2) [Member] | Equity Securities [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Significant Other Observable Inputs (Level 2) [Member] | Mutual Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Significant Other Observable Inputs (Level 2) [Member] | Deferred Compensation Liabilities [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	'	'
Significant Other Observable Inputs (Level 2) [Member] | Contingent Consideration [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	3,780	86,368
Significant Unobservable Inputs (Level 3) [Member] | Money Market Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Significant Unobservable Inputs (Level 3) [Member] | Equity Securities [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Significant Unobservable Inputs (Level 3) [Member] | Mutual Funds [Member]	'	'
Assets:	'	'
Assets measured at fair value on a recurring basis	'	'
Significant Unobservable Inputs (Level 3) [Member] | Deferred Compensation Liabilities [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	'	'
Significant Unobservable Inputs (Level 3) [Member] | Contingent Consideration [Member]	'	'
Liabilities:	'	'
Liabilities measured at fair value on a recurring basis	$3,780	$86,368

Fair_Value_Measurements_Change

Fair Value Measurements - Changes in Fair Value of Recurring Fair Value Measurements Using Significant Unobservable Inputs (Level 3), Consisting of Contingent Consideration Liabilities (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Fair Value Disclosures [Abstract]	'	'	'
Beginning Balance	$86,368	$103,790	$29,500
Contingent consideration recorded at acquisition	525	'	86,600
Fair value adjustments	11,310	38,466	-8,016
Payments made	-94,423	-55,888	-4,294
Ending Balance	$3,780	$86,368	$103,790

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Estimated Fair Value of Intangible Assets, goodwill and Cost Method Equity Investment Measured on Nonrecurring Basis (Detail) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Fair Value Measurements Of Financial Instruments [Line Items]	'	'	'	'	'
Goodwill, Total Gains (Losses)	($1,100,000)	($5,800)	($1,117,369)	($5,826)	'
Equipment, Total Gains (Losses)	'	'	-4,993	-6,452	'
Cost-method equity investment, Total Gains (Losses)	'	'	-6,438	'	-2,445
Total Gains (Losses)	'	'	-1,128,800	-12,278	'
Goodwill	277,840	'	277,840	'	'
Equipment	1,363	'	1,363	'	'
Cost-method equity investments	1,483	'	1,483	'	345
Quoted Prices in Active Market for Identical Assets (Level 1) [Member]	'	'	'	'	'
Fair Value Measurements Of Financial Instruments [Line Items]	'	'	'	'	'
Goodwill	'	'	'	'	'
Equipment	'	'	'	'	'
Cost-method equity investments	'	'	'	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'	'	'	'
Fair Value Measurements Of Financial Instruments [Line Items]	'	'	'	'	'
Goodwill	'	'	'	'	'
Equipment	'	'	'	'	'
Cost-method equity investments	'	'	'	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'	'
Fair Value Measurements Of Financial Instruments [Line Items]	'	'	'	'	'
Goodwill	277,840	'	277,840	'	'
Equipment	1,363	'	1,363	'	'
Cost-method equity investments	$1,483	'	$1,483	'	$345

Fair_Value_Measurements_Estima

Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Estimated Fair Value Of Financial Instruments [Line Items]	'	'
Estimated fair values of debt instruments	$1,820,300	$1,767,900
2007 Notes [Member]	'	'
Estimated Fair Value Of Financial Instruments [Line Items]	'	'
Estimated fair values of debt instruments	405,000	771,600
2010 Notes [Member]	'	'
Estimated Fair Value Of Financial Instruments [Line Items]	'	'
Estimated fair values of debt instruments	510,800	505,600
2012 Notes [Member]	'	'
Estimated Fair Value Of Financial Instruments [Line Items]	'	'
Estimated fair values of debt instruments	518,800	490,700
2013 Notes [Member]	'	'
Estimated Fair Value Of Financial Instruments [Line Items]	'	'
Estimated fair values of debt instruments	$385,700	'

Sale_of_Makena_Additional_Info

Sale of Makena - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended			12 Months Ended
	Feb. 03, 2011	Jan. 16, 2008	Dec. 29, 2012	Mar. 24, 2012	Mar. 24, 2011	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Sale Of Intellectual Property [Line Items]	'	'	'	'	'	'	'	'
Transaction price of sale of intellectual property assets	'	$82,000,000	'	'	'	'	'	'
Amended transaction price as a result of executing amendment	'	'	'	'	'	199,500,000	'	'
Amount received upon FDA approval	12,500,000	'	'	'	'	'	'	'
Gain on net of certain contingent legal fees and amounts due to inventor	'	'	53,900,000	'	84,500,000	53,884,000	12,424,000	84,502,000
Scheduled amounts received	'	'	'	12,500,000	'	'	'	'
Additional amounts to be received under the amended agreement	'	'	'	'	'	95,000,000	'	'
Royalty on sales due	5.00%	'	'	'	'	'	'	'
Final payment received	'	'	'	'	'	60,000,000	'	'
Previously Received [Member] | Parent Company/Issuer [Member]	'	'	'	'	'	'	'	'
Sale Of Intellectual Property [Line Items]	'	'	'	'	'	'	'	'
Transaction price amounts received	$79,500,000	'	'	'	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'
Sale Of Intellectual Property [Line Items]	'	'	'	'	'	'	'	'
Period sales price is due from FDA approval, months	'	'	'	'	'	18	'	'
Maximum [Member]	'	'	'	'	'	'	'	'
Sale Of Intellectual Property [Line Items]	'	'	'	'	'	'	'	'
Period sales price is due from FDA approval, months	'	'	'	'	'	30	'	'

Income_Taxes_Income_Loss_Befor

Income Taxes - Income (Loss) Before Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Income Tax Disclosure [Abstract]	'	'	'
Domestic	($1,184,603)	($46,018)	$235,204
Foreign	-8,358	-15,643	-7,818
(Loss) income before income taxes	($1,192,961)	($61,661)	$227,386

Income_Taxes_Provision_for_Inc

Income Taxes - Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Federal:	'	'	'
Federal, Current	$154,900	$146,164	$97,834
Federal, Deferred	-182,739	-143,582	-33,808
Federal, Total	-27,839	2,582	64,026
State:	'	'	'
State, Current	15,305	15,348	15,739
State, Deferred	-16,709	-10,186	-5,909
State, Total	-1,404	5,162	9,830
Foreign:	'	'	'
Foreign, Current	7,655	5,653	4,770
Foreign, Deferred	1,465	-1,424	-8,390
Foreign, Total	9,120	4,229	-3,620
Provision for income taxes	($20,123)	$11,973	$70,236

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Income Tax (Benefit) at U.S. Federal Statutory Rate to Company's Effective Tax Rate (Detail)	12 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Income Tax Disclosure [Abstract]	'	'	'
Income tax provision at federal statutory rate	-35.00%	-35.00%	35.00%
Increase (decrease) in tax resulting from:	'	'	'
Goodwill impairment	32.80%	3.30%	'
Domestic production activities deduction	-1.20%	-20.30%	-4.10%
State income taxes, net of federal benefit	-0.20%	5.30%	3.60%
Research and investment tax credits	-1.20%	-1.60%	-3.20%
Unrecognized tax benefits	0.30%	13.50%	-3.30%
Contingent consideration	2.60%	59.80%	1.50%
Nondeductible transaction expenses	'	7.50%	'
Cessation of Adiana	'	-28.60%	'
Executive compensation	0.20%	2.30%	-1.10%
Foreign rate differential	0.10%	3.10%	0.80%
Change in valuation allowance	-0.80%	5.40%	'
Other	0.70%	4.70%	1.70%
Effective income tax rate	-1.70%	19.40%	30.90%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended
	Mar. 30, 2013	Sep. 28, 2013	Sep. 29, 2012
Income Taxes [Line Items]	'	'	'
Valuation allowance	'	$43,354,000	$64,337,000
Reversal of income tax reserves	'	9,100,000	'
Decrease in valuation allowance	'	21,000,000	'
Operating losses and credits expiration period	'	'Losses and credits expire between 2014 and 2033	'
Gross unrecognized tax benefits, excluding interest	'	121,800,000	53,100,000
Increase in gross unrecognized tax benefits	'	'	68,700,000
Increase in gross unrecognized tax benefits resulted from uncertain tax positions	58,400,000	'	'
Unrecognized tax benefit that would impact effective tax rate	'	61,000,000	'
Interest accrued on unrecognized tax benefits	'	3,600,000	2,600,000
Income tax penalty accrued	'	0	'
Income tax holiday expiration date	'	'2015	'
Unremitted foreign earnings	'	33,400,000	'
Net Operating Losses Carryforwards [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Amount with unlimited carry forward periods	'	55,200,000	'
Tax Credit Carryforward [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Amount with unlimited carry forward periods	'	9,000,000	'
Federal net operating loss expected to be expired unutilized	'	4,500,000	'
State net operating loss expected to be expired unutilized	'	69,300,000	'
Foreign net operating loss expected to be expired unutilized	'	67,500,000	'
Minimum [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Amount of unrecognized tax benefits that are reasonably possible of being reduced in the next twelve months	'	2,000,000	'
Maximum [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Amount of unrecognized tax benefits that are reasonably possible of being reduced in the next twelve months	'	4,000,000	'
Domestic Tax Authority [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Federal net operating losses	'	24,400,000	'
Federal credit carry forwards	'	900,000	'
State and Local Jurisdiction [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Federal net operating losses	'	41,200,000	'
Federal credit carry forwards	'	12,800,000	'
Foreign Tax Authority [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Federal net operating losses	'	55,200,000	'
Federal credit carry forwards	'	$1,900,000	'

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Deferred tax assets	'	'
Net operating loss carryforwards	$49,277	$47,472
Capital losses	23,857	46,750
Non-deductible accruals	21,527	22,198
Non-deductible reserves	16,054	10,346
Stock-based compensation	30,190	31,437
Research and other credits	10,679	11,392
Debt issuance costs	'	811
Nonqualified deferred compensation plan	14,714	12,007
Other temporary differences	6,960	3,000
Deferred tax assets, gross	173,258	185,413
Less: valuation allowance	-43,354	-64,337
Deferred tax assets, net	129,904	121,076
Deferred tax liabilities	'	'
Depreciation and amortization	-1,494,068	-1,635,043
Debt discounts and deferrals	-189,298	-209,011
Debt issuance costs	-10,941	'
Fair value adjustments to current assets and liabilities	'	-28,413
Investment in subsidiary	-10,713	-8,479
Deferred tax liabilities, net	-1,705,020	-1,880,946
Net deferred tax liabilities	($1,575,116)	($1,759,870)

Income_Taxes_Activity_of_Compa

Income Taxes - Activity of Company's Unrecognized Income Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
Income Tax Disclosure [Abstract]	'	'
Balance at beginning of fiscal year	$53,148	$31,026
Tax positions related to current year:	'	'
Additions	64,992	11,673
Reductions	'	'
Tax positions related to prior years:	'	'
Additions related to change in estimate	3,317	1,327
Reductions	-363	307
Payments	-621	-197
Lapses in statutes of limitations and settlements	-2,323	-4,144
Acquired tax positions:	'	'
Additions related to reserves acquired from acquisitions	3,676	13,156
Balance as of the end of the fiscal year	$121,826	$53,148

Stockholders_Equity_and_StockB2

Stockholders' Equity and Stock-Based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

Dec. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Mar. 31, 2012

Sep. 29, 2012

Sep. 28, 2013

Sep. 29, 2012

Series A Preferred Stock [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

2008 Equity Plan [Member]

2012 Employee Stock Purchase Plan [Member]

2008 Employee Stock Purchase Plan [Member]

2012 Employee Stock Purchase Plan [Member]

2012 Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share portion entitled to purchase by right

'

'

'

'

'One ten-thousandth

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

$0.01

$0.01

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price of each right

'

$107

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend record date

'

2-Dec-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized value of common shares to be repurchased

'

$250,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period available for common stock to be repurchased

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

'

'

'

'

'

'

'

'

31.5

'

0.4

'

'

Shares available for grant

'

'

'

'

'

'

'

'

'

'

'

13.6

'

'

'

'

Market stock units granted during the period

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Valuation of MSUs using Monte Carlo simulation model

$18.49

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum eligible percentage to receive target number of shares of company's common stock

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum eligible percentage to receive target number of shares of company's common stock

'

200.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation, period of vest term granted to employees, years

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

Percentage of vesting for stock granted to employees

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

Percentage of vesting for stock granted to employees

'

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

RSU, period of vest term granted to employees, years

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

Percentage of forfeiture rates, minimum

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of forfeiture rates, maximum

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

23,700,000

18,700,000

15,200,000

26,000,000

21,400,000

20,300,000

'

'

'

'

'

Tax benefit related to stock based compensation

'

17,200,000

12,200,000

14,800,000

'

'

'

'

'

'

'

'

'

'

'

'

Expense related to the acceleration of vesting for certain options assumed in acquisition

'

7,900,000

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation expense

'

'

'

'

'

30,000,000

'

'

41,600,000

'

'

'

'

'

'

'

Weighted average period of unrecognized stock-based compensation, years

'

'

'

'

'

'2 years 8 months 12 days

'

'

'2 years 7 months 6 days

'

'

'

'

'

'

'

Intrinsic value of option exercised

'

37,609,000

20,400,000

12,300,000

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of RSUs vested

'

'

'

'

'

'

'

'

27,300,000

15,700,000

43,200,000

'

'

'

'

'

Number of shares that may be issued under Employee Stock Purchase Plan

'

'

'

'

'

'

'

'

'

'

'

'

2.5

'

'

'

Percentage of common stock price for ESPP

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

Percent of exercise price to last reported closing price

'

'

'

'

'

'

'

'

'

'

'

'

'

95.00%

'

'

Stock-based compensation expense

'

$52,307,000

$40,572,000

$35,472,000

'

'

'

'

'

'

'

'

'

'

$2,700,000

$400,000

Stockholders_Equity_and_StockB3

Stockholders' Equity and Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statement of Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	$52,307	$40,572	$35,472
Cost of Revenues [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	7,031	5,722	4,602
Research and Development [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	7,179	5,328	4,852
Selling and Marketing [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	8,915	7,355	5,954
General and Administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	20,153	18,667	20,064
Restructuring [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based compensation expense	$9,029	$3,500	'

Stockholders_Equity_and_StockB4

Stockholders' Equity and Stock-Based Compensation - Information Pertaining to Stock Options Granted and Related Assumptions (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Options granted	2,640	2,259	2,249
Weighted-average exercise price	$20.29	$17.21	$17.15
Weighted-average grant date fair value	$7.03	$6.48	$6.16
Assumptions:	'	'	'
Risk-free interest rates	0.50%	0.70%	1.00%
Expected life (in years)	'4 years 4 months 24 days	'4 years 3 months 18 days	'4 years 2 months 12 days
Expected volatility	44.00%	47.00%	45.00%
Dividend yield	'	'	'

Stockholders_Equity_and_StockB5

Stockholders' Equity and Stock-Based Compensation - Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013		Sep. 29, 2012	Sep. 24, 2011
	Y		Y
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'		'	'
Options outstanding at September 29, 2012	18,039		'	'
Granted	2,640		'	'
Cancelled/forfeited	-1,021		'	'
Exercised	-4,786		'	'
Options outstanding at September 28, 2013	14,872		18,039	'
Number of Shares, Options exercisable at September 28, 2013	7,472		'	'
Number of Shares, Options vested and expected to vest at September 28, 2013	13,780	[1]	'	'
Weighted-Average Exercise Price, Options outstanding	$17.40		'	'
Weighted-Average Exercise Price, Granted	$20.29		$17.21	$17.15
Weighted-Average Exercise Price, Cancelled/Forfeited	$20.04		'	'
Weighted-Average Exercise Price, Exercised	$13.71		'	'
Weighted-Average Exercise Price, Options outstanding	$18.92		$17.40	'
Weighted-Average Exercise Price, Options exercisable at September 28, 2013	$20.28		'	'
Weighted-Average Exercise Price, Options vested and expected to vest at September 28, 2013	$19	[1]	'	'
Weighted-Average Remaining Contractual Life in Years, Options outstanding	4.4		'	'
Weighted-Average Remaining Contractual Life in Years, Options outstanding	3.9		4.4	'
Weighted-Average Remaining Contractual Life in Years, Options exercisable at September 29, 2013	'2 years 10 months 24 days		'	'
Weighted-Average Remaining Contractual Life in Years, Options vested and expected to vest at September 29, 2013	3.8	[1]	'	'
Aggregate Intrinsic Value, Options outstanding, Beginning balance	$78,962		'	'
Aggregate Intrinsic Value, Exercised	37,609		20,400	12,300
Aggregate Intrinsic Value, Options outstanding, Ending balance	54,956		78,962	'
Aggregate Intrinsic Value, Options exercisable at September 29, 2013	29,438		'	'
Aggregate Intrinsic Value, Options vested and expected to vest at September 29, 2013	$51,656	[1]	'	'
[1]	This represents the number of vested stock options as of September 28, 2013 plus the unvested outstanding options at September 28, 2013 expected to vest in the future, adjusted for estimated forfeitures.

Stockholders_Equity_and_StockB6

Stockholders' Equity and Stock-Based Compensation - Restricted Stock Unit Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Number of Shares, Non-vested, Beginning balance	3,580
Number of Shares, Granted	1,995
Number of Shares, Vested	-1,711
Number of Shares, Forfeited	-405
Number of Shares, Non-vested, Ending balance	3,459
Weighted-Average Grant-Date Fair Value, Non-vested, Beginning balance	$16.45
Weighted-Average Grant-Date Fair Value, Granted	$19.94
Weighted-Average Grant-Date Fair Value, Vested	$15.98
Weighted-Average Grant-Date Fair Value, Forfeited	$18.11
Weighted-Average Grant-Date Fair Value, Non-vested, Ending balance	$18.51

Stockholders_Equity_and_StockB7

Stockholders' Equity and Stock-Based Compensation - Assumptions to Value Stock Options (Detail) (USD $)	12 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Assumptions:	'	'	'
Risk-free interest rates	0.50%	0.70%	1.00%
Expected life (in years)	'4 years 4 months 24 days	'4 years 3 months 18 days	'4 years 2 months 12 days
Expected volatility	44.00%	47.00%	45.00%
Dividend yield	'	'	'
Employee stock purchase plan [Member]	'	'	'
Assumptions:	'	'	'
Risk-free interest rates	0.11%	0.16%	'
Expected life (in years)	'6 months	'6 months	'
Expected volatility	32.00%	35.00%	'
Dividend yield	'	'	'

Profit_Sharing_401k_Plan_Addit

Profit Sharing 401(k) Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Defined Contribution Plan [Abstract]	'	'	'
Contributions made by company	$13.40	$9.40	$6.40

Nonqualified_Deferred_Compensa1

Nonqualified Deferred Compensation Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
	Y
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]	'	'	'
Discretionary contribution, net of forfeitures	$38.60	$32.10	'
Gen-Probe Incorporated [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]	'	'	'
Deferred compensation plan investments	6.9	7	'
Nonqualified Deferred Compensation Plan [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]	'	'	'
Maximum employee contributions from base salary, percentage	75.00%	'	'
Maximum employee contributions from annual bonus, percentage	100.00%	'	'
Employee contributions vested, percentage	100.00%	'	'
Contributions, vesting period, years	3	'	'
Compensation expense for the DCP discretionary contributions	2.7	2.6	2.6
Investment in group life insurance contracts	$33.90	$26	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

Apr. 29, 2012

Oct. 17, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 28, 2013

Sep. 28, 2013

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Employees

Finance Leases [Member]

Alajuela, Costa Rica [Member]

Alajuela, Costa Rica [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

TCT International Co., Ltd. [Member]

Healthcome [Member]

Adiana, Inc [Member]

Adiana, Inc [Member]

Adiana, Inc [Member]

Times

Y

Leasehold Improvements [Member]

Alajuela, Costa Rica [Member]

Alajuela, Costa Rica [Member]

Lease

Y

Y

Contingent Consideration Earn-Out Payments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential contingent payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$155,000,000

'

'

Payment of contingent consideration

'

'

42,958,000

51,680,000

4,294,000

'

'

'

'

'

'

87,400,000

54,000,000

31,700,000

'

16,800,000

8,800,000

19,700,000

Damages awarded by jury

'

18,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Damages foregone by Conceptus

18,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued contingent consideration obligation

'

'

'

'

'

'

'

'

'

'

'

31,700,000

'

31,700,000

3,400,000

'

'

'

Number of lease agreements

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Fair market value of building and land

'

'

1,363,000

'

'

'

28,300,000

'

'

'

'

'

'

'

'

'

'

'

Accrued expenses

'

'

271,931,000

372,381,000

'

'

2,800,000

'

'

'

'

'

'

'

'

'

'

'

Other long-term liabilities

'

'

168,044,000

98,250,000

'

'

33,500,000

'

'

'

'

'

'

'

'

'

'

'

Optional lease extension period

'

'

'

'

'

'

'

'

'

12

10

'

'

'

'

'

'

'

Lease extension terms

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

Consecutive lease extension terms

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful lives of building in years

'

'

'

'

'

'

'

'35 years

'

'

'

'

'

'

'

'

'

'

Royalties to be paid on future sales on products lower range limit

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

Royalties to be paid on future sales on products upper range limit

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

Operating lease agreements, expiration year

'

'

'2035

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent expense, net of sublease income

'

'

19,900,000

18,300,000

19,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Rental income from subleases

'

'

$1,900,000

$3,200,000

$3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Employees subject to collective bargaining agreements

'

'

164

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Contingent Consideration Charges Recorded to the Consolidated Statement of Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Other Contingencies And Commitments [Line Items]	'	'	'
Contingent consideration-compensation expense	$80,010	$81,031	$20,002
Contingent consideration-fair value adjustments	11,310	38,466	-8,016
Contingent consideration total	91,320	119,497	11,986
Sentinelle Medical Inc. [Member]	'	'	'
Other Contingencies And Commitments [Line Items]	'	'	'
Contingent consideration-fair value adjustments	'	-3,364	-14,328
Contingent consideration total	'	-3,364	-14,328
Interlace Medical, Inc [Member]	'	'	'
Other Contingencies And Commitments [Line Items]	'	'	'
Contingent consideration-compensation expense	'	'	2,102
Contingent consideration-fair value adjustments	11,310	41,830	6,312
Contingent consideration total	11,310	41,830	8,414
TCT International Co., Ltd. [Member]	'	'	'
Other Contingencies And Commitments [Line Items]	'	'	'
Contingent consideration-compensation expense	80,010	75,459	17,581
Contingent consideration total	80,010	75,459	17,581
Healthcome [Member]	'	'	'
Other Contingencies And Commitments [Line Items]	'	'	'
Contingent consideration-compensation expense	'	5,572	319
Contingent consideration total	'	$5,572	$319

Commitments_and_Contingencies_3

Commitments and Contingencies - Future Minimum Lease Payments, Including Principal and Interest (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Fiscal 2014	$2,822
Fiscal 2015	2,883
Fiscal 2016	3,054
Fiscal 2017	3,119
Fiscal 2018	2,925
Thereafter	300
Total minimum payments	15,103
Less-amount representing interest	-3,607
Total	$11,496

Commitments_and_Contingencies_4

Commitments and Contingencies - Summary of Purchase Commitments (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Fiscal 2014	$55,935
Fiscal 2015	12,684
Fiscal 2016	3,000
Fiscal 2017	3,000
Fiscal 2018	750
Thereafter	'
Total	$75,369

Commitments_and_Contingencies_5

Commitments and Contingencies - Summary of Minimum Royalty Commitments (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Fiscal 2014	$1,301
Fiscal 2015	810
Fiscal 2016	1,426
Fiscal 2017	745
Fiscal 2018	560
Thereafter	4,450
Total	$9,292

Recovered_Sheet9

Commitments And Contingencies - Future Minimum Lease Payments Under All Operating Leases (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Fiscal 2014	$20,689
Fiscal 2015	16,192
Fiscal 2016	13,600
Fiscal 2017	12,249
Fiscal 2018	10,830
Thereafter	32,712
Total	$106,272

Recovered_Sheet10

Commitments And Contingencies - Future Minimum Annual Rental Income Payments Under Sublease Agreements (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
Fiscal 2014	$1,551
Fiscal 2015	913
Fiscal 2016	20
Fiscal 2017	15
Total	$2,499

Litigation_and_Other_Matters_A

Litigation and Other Matters - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Oct. 29, 2013	Sep. 04, 2012
Commitments And Contingencies Disclosure [Abstract]	'	'
Assessed damages	'	$4
Additional Payment	$14.70	'

Novartis_Collaboration_Agreeme1

Novartis Collaboration Agreement - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2009	Sep. 28, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Collaboration agreements revenue	'	197.9
Novartis [Member] | Collaboration Agreement [Member] | 2012-2013 [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Share of revenue from assay that includes test for HCV	47.00%	'
Novartis [Member] | Collaboration Agreement [Member] | 2014 [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Share of revenue from assay that includes test for HCV	48.00%	'
Novartis [Member] | Collaboration Agreement [Member] | 2015 [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Share of revenue from assay that includes test for HCV	50.00%	'
Blood screening [Member] | Novartis [Member] | Collaboration Agreement [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Collaboration agreement maturity date	'	30-Jun-25
Manufacturing costs entitled to recover	50.00%	'
Share of revenue from assay that excludes test for HCV	50.00%	'

Business_Segments_and_Geograph2

Business Segments and Geographic Information - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 23, 2012

Mar. 24, 2012

Dec. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Segment

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Number of reportable segments

'

'

'

'

'

'

'

'

4

'

'

Revenues

$622,118

$626,136

$612,663

$631,362

$588,548

[1]

$470,228

$471,165

$472,711

$2,492,279

$2,002,652

$1,789,349

Impairment of goodwill

1,100,000

'

'

'

5,800

'

'

'

1,117,369

5,826

'

Diagnostics [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

1,189,819

718,064

571,263

Impairment of goodwill

'

'

'

'

'

'

'

'

1,117,369

'

'

Breast Health [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

905,076

875,771

825,551

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

'

Molecular Diagnostics [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

1,100,000

'

'

Molecular Diagnostics [Member] | Diagnostics [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

1,100,000

'

'

Mammosite [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

'

5,800

'

Intersegment Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

0

'

'

Operating Segments [Member] | Mammosite [Member] | Breast Health [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

'

5,800

'

Operating Segments [Member] | Foreign Countries [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

$621,700

$511,200

$414,400

[1]

The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

Business_Segments_and_Geograph3

Business Segments and Geographic Information - Segment Information (Detail) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 23, 2012

Mar. 24, 2012

Dec. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Operating Statistics [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Total revenues

$622,118

$626,136

$612,663

$631,362

$588,548

[1]

$470,228

$471,165

$472,711

$2,492,279

$2,002,652

$1,789,349

Operating (loss) income

'

'

'

'

'

'

'

'

-906,282

113,717

374,445

Depreciation and amortization

'

'

'

'

'

'

'

'

516,010

345,751

304,736

Capital expenditures

'

'

'

'

'

'

'

'

90,130

78,773

55,663

Identifiable assets

9,000,823

'

'

'

10,477,108

'

'

'

9,000,823

10,477,108

6,008,780

Diagnostics [Member]

'

'

'

'

'

'

'

'

'

'

'

Operating Statistics [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Total revenues

'

'

'

'

'

'

'

'

1,189,819

718,064

571,263

Operating (loss) income

'

'

'

'

'

'

'

'

-1,149,132

-32,787

170,693

Depreciation and amortization

'

'

'

'

'

'

'

'

369,818

197,274

165,065

Capital expenditures

'

'

'

'

'

'

'

'

51,653

44,939

23,128

Identifiable assets

4,667,942

'

'

'

6,170,553

'

'

'

4,667,942

6,170,553

1,770,107

Breast Health [Member]

'

'

'

'

'

'

'

'

'

'

'

Operating Statistics [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Total revenues

'

'

'

'

'

'

'

'

905,076

875,771

825,551

Operating (loss) income

'

'

'

'

'

'

'

'

216,049

186,106

187,970

Depreciation and amortization

'

'

'

'

'

'

'

'

40,098

42,924

45,165

Capital expenditures

'

'

'

'

'

'

'

'

16,386

9,821

12,069

Identifiable assets

932,206

'

'

'

956,134

'

'

'

932,206

956,134

985,196

GYN Surgical [Member]

'

'

'

'

'

'

'

'

'

'

'

Operating Statistics [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Total revenues

'

'

'

'

'

'

'

'

307,139

313,089

300,538

Operating (loss) income

'

'

'

'

'

'

'

'

19,664

-51,892

3,623

Depreciation and amortization

'

'

'

'

'

'

'

'

105,233

103,781

92,587

Capital expenditures

'

'

'

'

'

'

'

'

9,145

12,233

11,467

Identifiable assets

1,849,518

'

'

'

1,944,386

'

'

'

1,849,518

1,944,386

2,049,682

Skeletal Health [Member]

'

'

'

'

'

'

'

'

'

'

'

Operating Statistics [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Total revenues

'

'

'

'

'

'

'

'

90,245

95,728

91,997

Operating (loss) income

'

'

'

'

'

'

'

'

7,137

12,290

12,159

Depreciation and amortization

'

'

'

'

'

'

'

'

861

1,772

1,919

Capital expenditures

'

'

'

'

'

'

'

'

562

171

2,198

Identifiable assets

33,508

'

'

'

32,778

'

'

'

33,508

32,778

31,864

Corporate [Member]

'

'

'

'

'

'

'

'

'

'

'

Operating Statistics [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Capital expenditures

'

'

'

'

'

'

'

'

12,384

11,609

6,801

Identifiable assets

$1,517,649

'

'

'

$1,373,257

'

'

'

$1,517,649

$1,373,257

$1,171,931

[1]

The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

Business_Segments_and_Geograph4

Business Segments and Geographic Information - Revenues by Geography (Detail)	12 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Schedule Of Geographical Segments [Line Items]	'	'	'
Revenues	100.00%	100.00%	100.00%
United States [Member]	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'
Revenues	75.00%	74.00%	77.00%
Europe [Member]	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'
Revenues	13.00%	12.00%	14.00%
Asia [Member]	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'
Revenues	8.00%	8.00%	6.00%
All Others Countries [Member]	'	'	'
Schedule Of Geographical Segments [Line Items]	'	'	'
Revenues	4.00%	6.00%	3.00%

Business_Segments_and_Geograph5

Business Segments and Geographic Information - Schedule of Geographically Located Property and Equipment, Net (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
In Thousands, unless otherwise specified
Geographic Information For Property Plant And Equipment [Line Items]	'	'	'
Property and equipment	$491,528	$507,998	$238,666
United States [Member]	'	'	'
Geographic Information For Property Plant And Equipment [Line Items]	'	'	'
Property and equipment	386,049	405,141	165,177
Costa Rica [Member]	'	'	'
Geographic Information For Property Plant And Equipment [Line Items]	'	'	'
Property and equipment	29,258	30,452	34,107
Europe [Member]	'	'	'
Geographic Information For Property Plant And Equipment [Line Items]	'	'	'
Property and equipment	61,472	59,927	29,591
All Others Countries [Member]	'	'	'
Geographic Information For Property Plant And Equipment [Line Items]	'	'	'
Property and equipment	$14,749	$12,478	$9,791

Accrued_Expenses_and_Other_Lon2

Accrued Expenses and Other Long-Term Liabilities - Schedule of Accrued Expenses (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Accrued Expenses	'	'
Compensation and employee benefits	$127,464	$143,673
Contingent consideration	38,138	143,881
Income and other taxes	17,369	12,424
Interest	23,747	18,422
Other	65,213	53,981
Total	$271,931	$372,381

Accrued_Expenses_and_Other_Lon3

Accrued Expenses and Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Thousands, unless otherwise specified
Other Long-Term Liabilities	'	'
Accrued lease obligation-long-term	$33,494	$33,256
Reserve for income tax uncertainties	115,395	38,518
Pension liabilities	9,691	9,397
Other	9,464	17,079
Total	$168,044	$98,250

Pension_and_Other_Employee_Ben2

Pension and Other Employee Benefits - Additional Information (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012
In Millions, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Pension liability	$10.10	$9.70
Projected benefit obligations in excess of plan assets	10.1	9.7
Accumulated benefit obligation	10.1	9.7
Projected benefit obligation for long-term service awards	$0.60	$0.60

Pension_and_Other_Employee_Ben3

Pension and Other Employee Benefits - Schedule of Reconciliation of Benefit Obligations, Plan Assets Funded Status (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Other Liabilities Disclosure [Abstract]	'	'	'
Benefit obligation at beginning of year	($9,744)	($8,064)	($9,093)
Service cost	'	'	'
Interest cost	-354	-391	-389
Plan participants' contributions	'	'	'
Actuarial gain (loss)	188	-2,002	1,092
Foreign exchange (loss) gain	-503	383	-5
Benefits paid	348	330	331
Benefit obligation at end of year	-10,065	-9,744	-8,064
Plan assets	'	'	'
Funded status	($10,065)	($9,744)	($8,064)

Pension_and_Other_Employee_Ben4

Pension and Other Employee Benefits - Components of Net Periodic Benefit Cost and Related Actuarial Assumptions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Other Liabilities Disclosure [Abstract]	'	'	'
Service cost	'	'	'
Interest cost	354	391	389
Expected return on plan assets	'	'	'
Amortization of prior service cost	'	'	'
Recognized net actuarial gain	'	-38	'
Net periodic benefit cost	$354	$353	$389

Pension_and_Other_Employee_Ben5

Pension and Other Employee Benefits - Schedule of Weighted-Average Net Periodic Benefit Cost Assumptions (Detail)	12 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Defined Benefit Plan Assumptions Used In Calculations [Abstract]	'	'	'
Discount rate	3.60%	3.52%	5.20%
Expected return on plan assets	0.00%	0.00%	0.00%
Rate of compensation increase	0.00%	0.00%	0.00%

Pension_and_Other_Employee_Ben6

Pension and Other Employee Benefits - Schedule of Expected Pension Benefit (Detail) (USD $)	Sep. 28, 2013
In Thousands, unless otherwise specified
Defined Benefit Plan Estimated Future Benefit Payments [Abstract]	'
2014	$374
2015	399
2016	415
2017	428
2018	441
2019 to 2023	$2,404

Quarterly_Statement_of_Operati2

Quarterly Statement of Operations Information - Summary of Quarterly Results of Operations (Detail) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013		Jun. 29, 2013		Mar. 30, 2013		Dec. 29, 2012		Sep. 29, 2012		Jun. 23, 2012		Mar. 24, 2012		Dec. 24, 2011		Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Quarterly Financial Information Disclosure [Abstract]	'		'		'		'		'		'		'		'		'	'	'
Total revenue	$622,118		$626,136		$612,663		$631,362		$588,548	[1]	$470,228		$471,165		$472,711		$2,492,279	$2,002,652	$1,789,349
Gross profit	290,631		309,758		279,326		281,673		274,317	[1]	244,640		226,110		249,370		'	'	'
Net income (loss)	($1,113,902)	[2]	($10,950)	[2]	($51,104)	[2]	$3,118	[2]	($77,767)	[1],[3]	$23,594	[3]	($40,273)	[3]	$20,812	[3]	($1,172,838)	($73,634)	$157,150
Diluted net income (loss) per common share	($4.11)		($0.04)		($0.19)		$0.01		($0.29)	[1]	$0.09		($0.15)		$0.08		($4.36)	($0.28)	$0.59
[1]	The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.
[2]	Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.
[3]	Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.

Quarterly_Statement_of_Operati3

Quarterly Statement of Operations Information - Summary of Quarterly Results of Operations (Parenthetical) (Detail) (USD $)	3 Months Ended							12 Months Ended
	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Mar. 24, 2012	Mar. 24, 2011	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'
Gain on sale of intellectual property	'	'	'	$53,900,000	'	'	$84,500,000	$53,884,000	$12,424,000	$84,502,000
Loss on debt extinguishment	6,000,000	'	3,200,000	'	'	42,300,000	'	-9,209,000	-42,347,000	-29,891,000
Impairment of goodwill	1,100,000,000	'	'	'	5,800,000	'	'	1,117,369,000	5,826,000	'
Restructuring charges	9,700,000	6,700,000	12,500,000	'	16,700,000	'	'	32,805,000	17,515,000	-71,000
In-process research and development expense	'	'	'	'	4,500,000	'	'	'	4,500,000	'
Direct acquisition transaction costs	'	'	'	'	30,700,000	'	'	'	'	'
Divestiture charges	'	'	'	'	'	18,300,000	'	'	'	'
Amortization expense from the Gen-Probe acquisition	'	'	'	'	$29,700,000	'	'	'	'	'

Supplemental_Guarantor_Condens2

Supplemental Guarantor Condensed Consolidating Financials - Additional Information (Detail) (Parent Company/Issuer [Member])	1 Months Ended
	Aug. 31, 2012
Parent Company/Issuer [Member]	'
Condensed Balance Sheet Statements, Captions [Line Items]	'
Ownership Percentage	100.00%

Supplemental_Guarantor_Condens3

Supplemental Guarantor Condensed Consolidating Financial Statements - Schedule of Supplemental Condensed Consolidating Statement of Operations (Detail) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 23, 2012

Mar. 24, 2012

Dec. 24, 2011

Mar. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Revenues:

'

'

'

'

'

'

'

'

'

'

'

'

Product sales

'

'

'

'

'

'

'

'

'

$2,100,891

$1,657,728

$1,478,340

Service and other revenues

'

'

'

'

'

'

'

'

'

391,388

344,924

311,009

Total revenues

622,118

626,136

612,663

631,362

588,548

[1]

470,228

471,165

472,711

'

2,492,279

2,002,652

1,789,349

Costs and expenses:

'

'

'

'

'

'

'

'

'

'

'

'

Cost of product sales

'

'

'

'

'

'

'

'

'

818,160

616,839

521,189

Cost of product sales-amortization of intangible assets

'

'

'

'

'

'

'

'

'

307,895

201,864

177,456

Cost of product sales-impairment of intangible assets

'

'

'

'

'

'

'

'

'

1,714

'

'

Cost of service and other revenues

'

'

'

'

'

'

'

'

'

203,122

189,512

167,523

Research and development

'

'

'

'

'

'

'

'

'

197,646

130,962

116,696

Selling and marketing

'

'

'

'

'

'

'

'

'

342,137

322,314

286,730

General and administrative

'

'

'

'

'

'

'

'

'

227,680

220,494

159,563

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

112,597

72,036

58,334

Contingent consideration-compensation expense

'

'

'

'

'

'

'

'

'

80,010

81,031

20,002

Contingent consideration-fair value adjustments

'

'

'

'

'

'

'

'

'

11,310

38,466

-8,016

Impairment of goodwill

1,100,000

'

'

'

5,800

'

'

'

'

1,117,369

5,826

'

Gain on sale of intellectual property

'

'

'

-53,900

'

'

'

'

-84,500

-53,884

-12,424

-84,502

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

'

4,500

'

Restructuring and divestiture charges

9,700

6,700

12,500

'

16,700

'

'

'

'

32,805

17,515

-71

Costs and expenses, total

'

'

'

'

'

'

'

'

'

3,398,561

1,888,935

1,414,904

Income (loss) from operations

'

'

'

'

'

'

'

'

'

-906,282

113,717

374,445

Interest income

'

'

'

'

'

'

'

'

'

1,302

2,340

1,860

Interest expense

'

'

'

'

'

'

'

'

'

-281,075

-140,287

-114,846

Debt extinguishment loss

6,000

'

3,200

'

'

'

42,300

'

'

-9,209

-42,347

-29,891

Other (expense) income, net

'

'

'

'

'

'

'

'

'

2,303

4,916

-4,182

(Loss) income before income taxes

'

'

'

'

'

'

'

'

'

-1,192,961

-61,661

227,386

Provision (benefit) for income taxes

'

'

'

'

'

'

'

'

'

-20,123

11,973

70,236

Equity in earnings (losses) of subsidiaries

'

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

-1,113,902

[2]

-10,950

[2]

-51,104

[2]

3,118

[2]

-77,767

[1],[3]

23,594

[3]

-40,273

[3]

20,812

[3]

'

-1,172,838

-73,634

157,150

Parent Company/Issuer [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues:

'

'

'

'

'

'

'

'

'

'

'

'

Product sales

'

'

'

'

'

'

'

'

'

416,871

420,960

411,309

Service and other revenues

'

'

'

'

'

'

'

'

'

326,656

307,097

274,197

Total revenues

'

'

'

'

'

'

'

'

'

743,527

728,057

685,506

Costs and expenses:

'

'

'

'

'

'

'

'

'

'

'

'

Cost of product sales

'

'

'

'

'

'

'

'

'

212,899

211,665

200,912

Cost of product sales-amortization of intangible assets

'

'

'

'

'

'

'

'

'

5,346

5,226

5,224

Cost of product sales-impairment of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

Cost of service and other revenues

'

'

'

'

'

'

'

'

'

157,391

155,555

143,399

Research and development

'

'

'

'

'

'

'

'

'

29,829

28,065

28,959

Selling and marketing

'

'

'

'

'

'

'

'

'

77,982

67,874

60,496

General and administrative

'

'

'

'

'

'

'

'

'

68,883

52,568

50,180

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

3,013

2,709

2,709

Contingent consideration-compensation expense

'

'

'

'

'

'

'

'

'

80,010

81,031

20,002

Contingent consideration-fair value adjustments

'

'

'

'

'

'

'

'

'

11,310

38,466

-8,016

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and divestiture charges

'

'

'

'

'

'

'

'

'

4,889

49

-353

Costs and expenses, total

'

'

'

'

'

'

'

'

'

651,552

643,208

503,512

Income (loss) from operations

'

'

'

'

'

'

'

'

'

91,975

84,849

181,994

Interest income

'

'

'

'

'

'

'

'

'

590

1,950

1,495

Interest expense

'

'

'

'

'

'

'

'

'

-277,771

-137,190

-111,583

Debt extinguishment loss

'

'

'

'

'

'

'

'

'

-9,209

-42,347

-29,891

Other (expense) income, net

'

'

'

'

'

'

'

'

'

193,254

3,051

-1,706

(Loss) income before income taxes

'

'

'

'

'

'

'

'

'

-1,161

-89,687

40,309

Provision (benefit) for income taxes

'

'

'

'

'

'

'

'

'

30,794

9,721

10,976

Equity in earnings (losses) of subsidiaries

'

'

'

'

'

'

'

'

'

-1,140,883

25,774

127,817

Net (loss) income

'

'

'

'

'

'

'

'

'

-1,172,838

-73,634

157,150

Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues:

'

'

'

'

'

'

'

'

'

'

'

'

Product sales

'

'

'

'

'

'

'

'

'

1,569,605

1,089,580

964,584

Service and other revenues

'

'

'

'

'

'

'

'

'

71,718

63,313

59,026

Total revenues

'

'

'

'

'

'

'

'

'

1,641,323

1,152,893

1,023,610

Costs and expenses:

'

'

'

'

'

'

'

'

'

'

'

'

Cost of product sales

'

'

'

'

'

'

'

'

'

636,679

396,747

309,910

Cost of product sales-amortization of intangible assets

'

'

'

'

'

'

'

'

'

298,426

192,377

167,341

Cost of product sales-impairment of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

Cost of service and other revenues

'

'

'

'

'

'

'

'

'

59,943

61,285

51,888

Research and development

'

'

'

'

'

'

'

'

'

157,846

91,199

75,437

Selling and marketing

'

'

'

'

'

'

'

'

'

176,041

170,422

166,458

General and administrative

'

'

'

'

'

'

'

'

'

123,985

136,243

86,270

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

104,778

64,357

54,851

Contingent consideration-compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration-fair value adjustments

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

'

1,117,369

5,826

'

Gain on sale of intellectual property

'

'

'

'

'

'

'

'

'

-53,884

-12,424

-84,502

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

'

4,500

'

Restructuring and divestiture charges

'

'

'

'

'

'

'

'

'

21,647

16,185

'

Costs and expenses, total

'

'

'

'

'

'

'

'

'

2,642,830

1,126,717

827,653

Income (loss) from operations

'

'

'

'

'

'

'

'

'

-1,001,507

26,176

195,957

Interest income

'

'

'

'

'

'

'

'

'

251

159

1

Interest expense

'

'

'

'

'

'

'

'

'

-1,260

-1,158

-1,357

Debt extinguishment loss

'

'

'

'

'

'

'

'

'

'

'

'

Other (expense) income, net

'

'

'

'

'

'

'

'

'

-184,564

699

-2,661

(Loss) income before income taxes

'

'

'

'

'

'

'

'

'

-1,187,080

25,876

191,940

Provision (benefit) for income taxes

'

'

'

'

'

'

'

'

'

-59,260

-3,094

60,163

Equity in earnings (losses) of subsidiaries

'

'

'

'

'

'

'

'

'

13,887

8,415

8,699

Net (loss) income

'

'

'

'

'

'

'

'

'

-1,113,933

37,385

140,476

Non-Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues:

'

'

'

'

'

'

'

'

'

'

'

'

Product sales

'

'

'

'

'

'

'

'

'

477,251

431,689

376,575

Service and other revenues

'

'

'

'

'

'

'

'

'

46,635

32,555

27,862

Total revenues

'

'

'

'

'

'

'

'

'

523,886

464,244

404,437

Costs and expenses:

'

'

'

'

'

'

'

'

'

'

'

'

Cost of product sales

'

'

'

'

'

'

'

'

'

331,418

292,928

284,495

Cost of product sales-amortization of intangible assets

'

'

'

'

'

'

'

'

'

4,123

4,261

4,891

Cost of product sales-impairment of intangible assets

'

'

'

'

'

'

'

'

'

1,714

'

'

Cost of service and other revenues

'

'

'

'

'

'

'

'

'

39,409

30,713

22,312

Research and development

'

'

'

'

'

'

'

'

'

9,971

11,698

12,300

Selling and marketing

'

'

'

'

'

'

'

'

'

88,114

84,018

59,776

General and administrative

'

'

'

'

'

'

'

'

'

34,812

31,683

23,113

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

4,806

4,970

774

Contingent consideration-compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration-fair value adjustments

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of intellectual property

'

'

'

'

'

'

'

'

'

'

'

'

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and divestiture charges

'

'

'

'

'

'

'

'

'

6,269

1,281

282

Costs and expenses, total

'

'

'

'

'

'

'

'

'

520,636

461,552

407,943

Income (loss) from operations

'

'

'

'

'

'

'

'

'

3,250

2,692

-3,506

Interest income

'

'

'

'

'

'

'

'

'

461

840

364

Interest expense

'

'

'

'

'

'

'

'

'

-2,044

-1,939

-1,906

Debt extinguishment loss

'

'

'

'

'

'

'

'

'

'

'

'

Other (expense) income, net

'

'

'

'

'

'

'

'

'

-6,387

557

185

(Loss) income before income taxes

'

'

'

'

'

'

'

'

'

-4,720

2,150

-4,863

Provision (benefit) for income taxes

'

'

'

'

'

'

'

'

'

8,343

5,346

-903

Equity in earnings (losses) of subsidiaries

'

'

'

'

'

'

'

'

'

'

556

319

Net (loss) income

'

'

'

'

'

'

'

'

'

-13,063

-2,640

-3,641

Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues:

'

'

'

'

'

'

'

'

'

'

'

'

Product sales

'

'

'

'

'

'

'

'

'

-362,836

-284,501

-274,128

Service and other revenues

'

'

'

'

'

'

'

'

'

-53,621

-58,041

-50,076

Total revenues

'

'

'

'

'

'

'

'

'

-416,457

-342,542

-324,204

Costs and expenses:

'

'

'

'

'

'

'

'

'

'

'

'

Cost of product sales

'

'

'

'

'

'

'

'

'

-362,836

-284,501

-274,128

Cost of product sales-amortization of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

Cost of product sales-impairment of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

Cost of service and other revenues

'

'

'

'

'

'

'

'

'

-53,621

-58,041

-50,076

Research and development

'

'

'

'

'

'

'

'

'

'

'

'

Selling and marketing

'

'

'

'

'

'

'

'

'

'

'

'

General and administrative

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration-compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration-fair value adjustments

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of intellectual property

'

'

'

'

'

'

'

'

'

'

'

'

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and divestiture charges

'

'

'

'

'

'

'

'

'

'

'

'

Costs and expenses, total

'

'

'

'

'

'

'

'

'

-416,457

-342,542

-324,204

Income (loss) from operations

'

'

'

'

'

'

'

'

'

'

'

'

Interest income

'

'

'

'

'

'

'

'

'

'

-609

'

Interest expense

'

'

'

'

'

'

'

'

'

'

'

'

Debt extinguishment loss

'

'

'

'

'

'

'

'

'

'

'

'

Other (expense) income, net

'

'

'

'

'

'

'

'

'

'

609

'

(Loss) income before income taxes

'

'

'

'

'

'

'

'

'

'

'

'

Provision (benefit) for income taxes

'

'

'

'

'

'

'

'

'

'

'

'

Equity in earnings (losses) of subsidiaries

'

'

'

'

'

'

'

'

'

1,126,996

-34,745

-136,835

Net (loss) income

'

'

'

'

'

'

'

'

'

$1,126,996

($34,745)

($136,835)

[1]

The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

[2]

Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.

[3]

Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.

Supplemental_Guarantor_Condens4

Supplemental Guarantor Condensed Consolidating Financial Statements - Schedule of Supplemental Condensed Consolidating Statements of Comprehensive (Loss) Income (Detail) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2013

Jun. 29, 2013

Mar. 30, 2013

Dec. 29, 2012

Sep. 29, 2012

Jun. 23, 2012

Mar. 24, 2012

Dec. 24, 2011

Sep. 28, 2013

Sep. 29, 2012

Sep. 24, 2011

Schedule of Condensed Consolidating Statement of Comprehensive Income [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

($1,113,902)

[1]

($10,950)

[1]

($51,104)

[1]

$3,118

[1]

($77,767)

[2],[3]

$23,594

[2]

($40,273)

[2]

$20,812

[2]

($1,172,838)

($73,634)

$157,150

Foreign currency cumulative translation adjustment

'

'

'

'

'

'

'

'

1,373

6,217

1,088

Adjustment to minimum pension liability, net of taxes

'

'

'

'

'

'

'

'

134

-1,484

764

Unrealized gain on available-for-sale securities, net of tax

'

'

'

'

'

'

'

'

12,094

62

'

Other comprehensive income (loss)

'

'

'

'

'

'

'

'

13,601

4,795

1,852

Comprehensive (loss) income

'

'

'

'

'

'

'

'

-1,159,237

-68,839

159,002

Parent Company/Issuer [Member]

'

'

'

'

'

'

'

'

'

'

'

Schedule of Condensed Consolidating Statement of Comprehensive Income [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

'

-1,172,838

-73,634

157,150

Foreign currency cumulative translation adjustment

'

'

'

'

'

'

'

'

'

836

-1,127

Adjustment to minimum pension liability, net of taxes

'

'

'

'

'

'

'

'

'

'

'

Unrealized gain on available-for-sale securities, net of tax

'

'

'

'

'

'

'

'

'

'

'

Other comprehensive income (loss)

'

'

'

'

'

'

'

'

'

836

-1,127

Comprehensive (loss) income

'

'

'

'

'

'

'

'

-1,172,838

-72,798

156,023

Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

Schedule of Condensed Consolidating Statement of Comprehensive Income [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

'

-1,113,933

37,385

140,476

Foreign currency cumulative translation adjustment

'

'

'

'

'

'

'

'

658

-527

-121

Adjustment to minimum pension liability, net of taxes

'

'

'

'

'

'

'

'

'

'

'

Unrealized gain on available-for-sale securities, net of tax

'

'

'

'

'

'

'

'

12,094

62

'

Other comprehensive income (loss)

'

'

'

'

'

'

'

'

'

-465

-121

Comprehensive (loss) income

'

'

'

'

'

'

'

'

-1,101,181

36,920

140,355

Non-Guarantor Subsidiaries [Member]

'

'

'

'

'

'

'

'

'

'

'

Schedule of Condensed Consolidating Statement of Comprehensive Income [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

'

-13,063

-2,640

-3,641

Foreign currency cumulative translation adjustment

'

'

'

'

'

'

'

'

715

5,908

2,336

Adjustment to minimum pension liability, net of taxes

'

'

'

'

'

'

'

'

134

-1,484

764

Unrealized gain on available-for-sale securities, net of tax

'

'

'

'

'

'

'

'

'

'

'

Other comprehensive income (loss)

'

'

'

'

'

'

'

'

'

4,424

3,100

Comprehensive (loss) income

'

'

'

'

'

'

'

'

-12,214

1,784

-541

Eliminations [Member]

'

'

'

'

'

'

'

'

'

'

'

Schedule of Condensed Consolidating Statement of Comprehensive Income [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

'

'

'

'

'

'

'

'

1,126,996

-34,745

-136,835

Foreign currency cumulative translation adjustment

'

'

'

'

'

'

'

'

'

'

'

Adjustment to minimum pension liability, net of taxes

'

'

'

'

'

'

'

'

'

'

'

Unrealized gain on available-for-sale securities, net of tax

'

'

'

'

'

'

'

'

'

'

'

Other comprehensive income (loss)

'

'

'

'

'

'

'

'

'

'

'

Comprehensive (loss) income

'

'

'

'

'

'

'

'

$1,126,996

($34,745)

($136,835)

[1]

Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.

[2]

Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.

[3]

The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.

Supplemental_Guarantor_Condens5

Supplemental Guarantor Condensed Consolidating Financial Statements - Schedule of Supplemental Condensed Consolidating Balance Sheet (Detail) (USD $)	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011	Sep. 25, 2010
In Thousands, unless otherwise specified
Current assets:	'	'	'	'
Cash and cash equivalents	$822,490	$560,430	$712,332	$515,625
Restricted cash	6,914	5,696	'	'
Accounts receivable, net	409,273	409,333	'	'
Inventories	289,363	367,191	'	'
Deferred income tax assets	'	11,715	'	'
Prepaid income taxes	44,745	69,845	'	'
Prepaid expenses and other current assets	48,361	44,301	'	'
Other current assets-assets held for sale	2,997	94,503	'	'
Intercompany receivables	'	'	'	'
Total current assets	1,624,143	1,563,014	'	'
Property, plant and equipment, net	491,528	507,998	238,666	'
Intangible assets, net	3,906,722	4,301,250	'	'
Goodwill	2,814,528	3,942,779	'	'
Other assets	163,902	162,067	'	'
Investment in subsidiaries	'	'	'	'
Total assets	9,000,823	10,477,108	6,008,780	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	563,812	64,435	'	'
Accounts payable	80,534	87,223	'	'
Accrued expenses	271,931	372,381	'	'
Deferred revenue	132,319	129,688	'	'
Deferred income tax liabilities	39,810	'	'	'
Intercompany payables	'	'	'	'
Other current liabilities-assets held-for-sale	'	7,622	'	'
Total current liabilities	1,088,406	661,349	'	'
Long-term debt, net of current portion	4,242,098	4,971,179	'	'
Deferred income tax liabilities	1,535,306	1,771,585	'	'
Deferred service obligations-long-term	25,456	13,714	'	'
Other long-term liabilities	168,044	98,250	'	'
Total stockholders' equity	1,941,513	2,961,031	2,936,895	2,698,549
Total liabilities and stockholders' equity	9,000,823	10,477,108	'	'
Parent Company/Issuer [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	321,523	210,028	644,697	480,904
Restricted cash	'	'	'	'
Accounts receivable, net	126,036	101,538	'	'
Inventories	81,924	74,500	'	'
Deferred income tax assets	'	13,578	'	'
Prepaid income taxes	47,131	20,805	'	'
Prepaid expenses and other current assets	16,246	18,817	'	'
Other current assets-assets held for sale	'	'	'	'
Intercompany receivables	'	'	'	'
Total current assets	592,860	439,266	'	'
Property, plant and equipment, net	29,313	26,928	'	'
Intangible assets, net	19,925	24,034	'	'
Goodwill	283,038	279,956	'	'
Other assets	103,548	112,339	'	'
Investment in subsidiaries	8,667,620	9,782,940	'	'
Total assets	9,696,304	10,665,463	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	563,812	64,435	'	'
Accounts payable	27,865	29,847	'	'
Accrued expenses	152,950	238,387	'	'
Deferred revenue	93,306	92,234	'	'
Deferred income tax liabilities	59,346	'	'	'
Intercompany payables	2,418,089	2,085,339	'	'
Other current liabilities-assets held-for-sale	'	'	'	'
Total current liabilities	3,315,368	2,510,242	'	'
Long-term debt, net of current portion	4,242,098	4,971,179	'	'
Deferred income tax liabilities	89,085	180,916	'	'
Deferred service obligations-long-term	11,251	7,536	'	'
Other long-term liabilities	96,990	34,559	'	'
Total stockholders' equity	1,941,512	2,961,031	'	'
Total liabilities and stockholders' equity	9,696,304	10,665,463	'	'
Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	387,422	269,416	'	'
Restricted cash	'	'	'	'
Accounts receivable, net	174,433	192,349	'	'
Inventories	146,678	223,043	'	'
Deferred income tax assets	19,042	'	'	'
Prepaid income taxes	2,303	48,429	'	'
Prepaid expenses and other current assets	21,112	12,816	'	'
Other current assets-assets held for sale	'	67,878	'	'
Intercompany receivables	2,442,502	2,094,017	'	'
Total current assets	3,193,492	2,907,948	'	'
Property, plant and equipment, net	356,736	379,702	'	'
Intangible assets, net	3,784,987	4,162,930	'	'
Goodwill	2,390,939	3,522,474	'	'
Other assets	58,446	49,036	'	'
Investment in subsidiaries	129,016	101,615	'	'
Total assets	9,913,616	11,123,705	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	'	'	'	'
Accounts payable	42,661	43,339	'	'
Accrued expenses	79,629	86,566	'	'
Deferred revenue	7,958	10,307	'	'
Deferred income tax liabilities	'	'	'	'
Intercompany payables	'	6,655	'	'
Other current liabilities-assets held-for-sale	'	5,520	'	'
Total current liabilities	130,248	152,387	'	'
Long-term debt, net of current portion	'	'	'	'
Deferred income tax liabilities	1,435,522	1,581,833	'	'
Deferred service obligations-long-term	3,511	1,160	'	'
Other long-term liabilities	37,598	30,587	'	'
Total stockholders' equity	8,306,737	9,357,738	'	'
Total liabilities and stockholders' equity	9,913,616	11,123,705	'	'
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	113,545	80,986	67,635	34,721
Restricted cash	6,914	5,696	'	'
Accounts receivable, net	108,804	115,522	'	'
Inventories	60,761	70,180	'	'
Deferred income tax assets	494	617	'	'
Prepaid income taxes	'	611	'	'
Prepaid expenses and other current assets	11,003	12,668	'	'
Other current assets-assets held for sale	2,997	26,625	'	'
Intercompany receivables	31,949	55,761	'	'
Total current assets	336,467	368,666	'	'
Property, plant and equipment, net	105,479	101,368	'	'
Intangible assets, net	101,810	114,286	'	'
Goodwill	140,551	140,349	'	'
Other assets	1,908	2,406	'	'
Investment in subsidiaries	2,296	2,296	'	'
Total assets	688,511	729,371	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	'	'	'	'
Accounts payable	10,008	14,037	'	'
Accrued expenses	44,319	50,052	'	'
Deferred revenue	31,055	27,147	'	'
Deferred income tax liabilities	'	'	'	'
Intercompany payables	64,411	66,335	'	'
Other current liabilities-assets held-for-sale	'	2,102	'	'
Total current liabilities	149,793	159,673	'	'
Long-term debt, net of current portion	'	'	'	'
Deferred income tax liabilities	10,699	8,836	'	'
Deferred service obligations-long-term	12,864	7,601	'	'
Other long-term liabilities	33,456	34,504	'	'
Total stockholders' equity	481,699	518,757	'	'
Total liabilities and stockholders' equity	688,511	729,371	'	'
Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	'	'	'	'
Restricted cash	'	'	'	'
Accounts receivable, net	'	-76	'	'
Inventories	'	-532	'	'
Deferred income tax assets	-19,536	-2,480	'	'
Prepaid income taxes	-4,689	'	'	'
Prepaid expenses and other current assets	'	'	'	'
Other current assets-assets held for sale	'	'	'	'
Intercompany receivables	-2,474,451	-2,149,778	'	'
Total current assets	-2,498,676	-2,152,866	'	'
Property, plant and equipment, net	'	'	'	'
Intangible assets, net	'	'	'	'
Goodwill	'	'	'	'
Other assets	'	-1,714	'	'
Investment in subsidiaries	-8,798,932	-9,886,851	'	'
Total assets	-11,297,608	-12,041,431	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	'	'	'	'
Accounts payable	'	'	'	'
Accrued expenses	-4,967	-2,624	'	'
Deferred revenue	'	'	'	'
Deferred income tax liabilities	-19,536	'	'	'
Intercompany payables	-2,482,500	-2,158,329	'	'
Other current liabilities-assets held-for-sale	'	'	'	'
Total current liabilities	-2,507,003	-2,160,953	'	'
Long-term debt, net of current portion	'	'	'	'
Deferred income tax liabilities	'	'	'	'
Deferred service obligations-long-term	-2,170	-2,583	'	'
Other long-term liabilities	'	-1,400	'	'
Total stockholders' equity	-8,788,435	-9,876,495	'	'
Total liabilities and stockholders' equity	($11,297,608)	($12,041,431)	'	'

Supplemental_Guarantor_Condens6

Supplemental Guarantor Condensed Consolidating Financial Statements - Schedule of Consolidating Statement of Cash Flows (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 24, 2011
Operating activities	'	'	'
Net cash provided by operating activities	$493,822	$370,222	$456,024
Investing activities	'	'	'
Acquisition of businesses	-6,273	'	'
Acquisition of business, net of cash acquired	-6,273	-3,762,403	-198,744
Payment of additional acquisition consideration	-16,808	-9,784	-19,660
Divestiture activities, net of cash transferred	85,134	'	2,267
Purchase of property and equipment	-48,954	-33,149	-27,785
Increase in equipment under customer usage agreements	-41,176	-45,624	-27,878
Purchase of insurance contracts	-4,000	'	-5,322
Proceeds from sale of intellectual property	60,000	12,500	13,250
Purchase of licensed technology and other intangible assets	'	'	-3,021
Acquisition of in-process research and development assets	'	-4,500	'
Purchase of cost-method investment	-3,725	-250	-99
Sale of cost-method investments	2,104	'	'
Increase in restricted cash	'	'	405
Investment in subsdiaries	'	'	'
Increase in other assets	-7,548	-7,574	405
Net cash provided by (used in) investing activities	18,754	-3,850,784	-266,587
Financing activities	'	'	'
Repayment of long-term debt	-265,000	'	-1,362
Proceeds from long-term debt	'	3,476,320	'
Payment of debt issuance cost	-9,440	-81,408	-5,327
Payment of contingent consideration	-42,958	-51,680	-4,294
Deferred acquisition consideration	-1,655	'	'
Payment of deferred acquisition consideration	-1,655	-44,223	'
Net proceeds from issuance of common stock pursuant to employee stock plans	75,100	28,594	25,404
Excess tax benefit related to equity awards	7,439	6,206	3,652
Payment of employee restricted stock minimum tax withholdings	-12,256	-5,710	-10,399
Intercompany dividend	'	'	'
Net cash (used in) provided by financing activities	-248,770	3,328,099	7,674
Effect of exchange rate changes on cash and cash equivalents	-1,746	561	-404
Net (decrease) increase in cash and cash equivalents	262,060	-151,902	196,707
Cash and cash equivalents, beginning of period	560,430	712,332	515,625
Cash and cash equivalents, end of period	822,490	560,430	712,332
Parent Company/Issuer [Member]	'	'	'
Operating activities	'	'	'
Net cash provided by operating activities	237,354	236,063	431,353
Investing activities	'	'	'
Acquisition of businesses	-6,053	'	'
Acquisition of business, net of cash acquired	'	-3,971,970	-240,917
Payment of additional acquisition consideration	-16,808	-8,858	-19,660
Divestiture activities, net of cash transferred	'	'	1,138
Purchase of property and equipment	-15,480	-13,247	-11,512
Increase in equipment under customer usage agreements	-464	'	-1,121
Purchase of insurance contracts	-4,000	'	-5,322
Proceeds from sale of intellectual property	'	'	750
Purchase of licensed technology and other intangible assets	'	'	'
Acquisition of in-process research and development assets	'	-4,500	'
Purchase of cost-method investment	-3,500	'	'
Sale of cost-method investments	2,104	'	'
Increase in restricted cash	'	'	'
Investment in subsdiaries	'	'	'
Increase in other assets	-2,097	-558	'
Net cash provided by (used in) investing activities	-46,298	-3,999,133	-276,644
Financing activities	'	'	'
Repayment of long-term debt	-265,000	'	'
Proceeds from long-term debt	'	3,476,320	'
Payment of debt issuance cost	-9,440	-81,408	-5,327
Payment of contingent consideration	-42,958	-51,680	-4,294
Deferred acquisition consideration	-1,655	'	'
Payment of deferred acquisition consideration	'	-44,223	'
Net proceeds from issuance of common stock pursuant to employee stock plans	75,100	28,594	25,404
Excess tax benefit related to equity awards	7,439	6,206	3,652
Payment of employee restricted stock minimum tax withholdings	-12,256	-5,710	-10,399
Intercompany dividend	169,209	'	'
Net cash (used in) provided by financing activities	-79,561	3,328,099	9,036
Effect of exchange rate changes on cash and cash equivalents	'	302	48
Net (decrease) increase in cash and cash equivalents	111,495	-434,669	163,793
Cash and cash equivalents, beginning of period	210,028	644,697	480,904
Cash and cash equivalents, end of period	321,523	210,028	644,697
Guarantor Subsidiaries [Member]	'	'	'
Operating activities	'	'	'
Net cash provided by operating activities	205,034	104,167	9,040
Investing activities	'	'	'
Acquisition of businesses	'	'	'
Acquisition of business, net of cash acquired	'	196,771	9,070
Payment of additional acquisition consideration	'	'	'
Divestiture activities, net of cash transferred	83,646	'	'
Purchase of property and equipment	-23,345	-12,444	-8,646
Increase in equipment under customer usage agreements	-24,443	-30,735	-17,361
Purchase of insurance contracts	'	'	'
Proceeds from sale of intellectual property	60,000	12,500	12,500
Purchase of licensed technology and other intangible assets	'	'	-3,021
Acquisition of in-process research and development assets	'	'	'
Purchase of cost-method investment	-225	-250	-99
Sale of cost-method investments	'	'	'
Increase in restricted cash	'	'	'
Investment in subsdiaries	1,812	'	'
Increase in other assets	-4,209	-2,230	'
Net cash provided by (used in) investing activities	93,236	163,612	-7,557
Financing activities	'	'	'
Repayment of long-term debt	'	'	-1,362
Proceeds from long-term debt	'	'	'
Payment of debt issuance cost	'	'	'
Payment of contingent consideration	'	'	'
Deferred acquisition consideration	'	'	'
Payment of deferred acquisition consideration	'	'	'
Net proceeds from issuance of common stock pursuant to employee stock plans	'	'	'
Excess tax benefit related to equity awards	'	'	'
Payment of employee restricted stock minimum tax withholdings	'	'	'
Intercompany dividend	-175,000	'	'
Net cash (used in) provided by financing activities	-175,000	'	-1,362
Effect of exchange rate changes on cash and cash equivalents	-5,264	1,637	-121
Net (decrease) increase in cash and cash equivalents	118,006	269,416	'
Cash and cash equivalents, beginning of period	269,416	'	'
Cash and cash equivalents, end of period	387,422	269,416	'
Non-Guarantor Subsidiaries [Member]	'	'	'
Operating activities	'	'	'
Net cash provided by operating activities	51,434	29,992	15,631
Investing activities	'	'	'
Acquisition of businesses	-220	'	'
Acquisition of business, net of cash acquired	'	12,796	33,103
Payment of additional acquisition consideration	'	-926	'
Divestiture activities, net of cash transferred	1,488	'	1,129
Purchase of property and equipment	-10,129	-7,458	-7,627
Increase in equipment under customer usage agreements	-16,269	-14,889	-9,396
Purchase of insurance contracts	'	'	'
Proceeds from sale of intellectual property	'	'	'
Purchase of licensed technology and other intangible assets	'	'	'
Acquisition of in-process research and development assets	'	'	'
Purchase of cost-method investment	'	'	'
Sale of cost-method investments	'	'	'
Increase in restricted cash	'	'	405
Investment in subsdiaries	-1,812	'	'
Increase in other assets	-1,242	-4,786	'
Net cash provided by (used in) investing activities	-28,184	-15,263	17,614
Financing activities	'	'	'
Repayment of long-term debt	'	'	'
Proceeds from long-term debt	'	'	'
Payment of debt issuance cost	'	'	'
Payment of contingent consideration	'	'	'
Deferred acquisition consideration	'	'	'
Payment of deferred acquisition consideration	'	'	'
Net proceeds from issuance of common stock pursuant to employee stock plans	'	'	'
Excess tax benefit related to equity awards	'	'	'
Payment of employee restricted stock minimum tax withholdings	'	'	'
Intercompany dividend	5,791	'	'
Net cash (used in) provided by financing activities	5,791	'	'
Effect of exchange rate changes on cash and cash equivalents	3,518	-1,378	-331
Net (decrease) increase in cash and cash equivalents	32,559	13,351	32,914
Cash and cash equivalents, beginning of period	80,986	67,635	34,721
Cash and cash equivalents, end of period	113,545	80,986	67,635
Eliminations [Member]	'	'	'
Operating activities	'	'	'
Net cash provided by operating activities	'	'	'
Investing activities	'	'	'
Acquisition of businesses	'	'	'
Acquisition of business, net of cash acquired	'	'	'
Payment of additional acquisition consideration	'	'	'
Divestiture activities, net of cash transferred	'	'	'
Purchase of property and equipment	'	'	'
Increase in equipment under customer usage agreements	'	'	'
Purchase of insurance contracts	'	'	'
Proceeds from sale of intellectual property	'	'	'
Purchase of licensed technology and other intangible assets	'	'	'
Acquisition of in-process research and development assets	'	'	'
Purchase of cost-method investment	'	'	'
Sale of cost-method investments	'	'	'
Increase in restricted cash	'	'	'
Investment in subsdiaries	'	'	'
Increase in other assets	'	'	'
Net cash provided by (used in) investing activities	'	'	'
Financing activities	'	'	'
Repayment of long-term debt	'	'	'
Proceeds from long-term debt	'	'	'
Payment of debt issuance cost	'	'	'
Payment of contingent consideration	'	'	'
Deferred acquisition consideration	'	'	'
Payment of deferred acquisition consideration	'	'	'
Net proceeds from issuance of common stock pursuant to employee stock plans	'	'	'
Excess tax benefit related to equity awards	'	'	'
Payment of employee restricted stock minimum tax withholdings	'	'	'
Intercompany dividend	'	'	'
Net cash (used in) provided by financing activities	'	'	'
Effect of exchange rate changes on cash and cash equivalents	'	'	'
Net (decrease) increase in cash and cash equivalents	'	'	'
Cash and cash equivalents, beginning of period	'	'	'
Cash and cash equivalents, end of period	'	'	'